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General Introduction
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LONGEVITY
Longevity is usually defined as age at death or survival to an exceptional age, such as 90
years or older or even 100 years or older [1]. In the past century, most Western countries have
experienced substantial increases in life expectancy. This has been mostly due to a marked
reduction in early life mortality during the first half of the twentieth century, followed by an 
almost twofold reduction in mortality at ages above 70 years in the past 50 years [2] (Figure
1; source: CBS). Longevity is a complex phenotype to which both environmental factors
such as lifestyle and genetic factors are known to contribute [3]. The genetic contribution
to age at death has been estimated to range from 15 to 25%, and up to 40% for reaching 
longevity, suggesting a significant but relatively modest genetic contribution to the human 
lifespan [4-6]. However, the clustering of extreme ages in families and the increased relative 
risk of survival to old age amongst the siblings of nonagenarians [7] and of centenarians 
(100+) [8-13] suggest that the genetic factors play a much stronger role as the phenotype
becomes more extreme [3]. While environmental factors affecting longevity include
smoking, alcohol consumption, diastolic blood pressure and C-reactive protein [14], APOE
[3, 15-19] and FOXO3 [20, 21] remain the only genes consistently associated with longevity.
Figure 1 | Age at death in the previous century (Source: CBS 2013).
METHODS FOR GENE DISCOVERY IN COMPLEX TRAITS
Two basic gene finding methods are linkage analysis and association analysis. Linkage
analysis searches for regions of the genome with a higher-than-expected number of shared
alleles among affected individuals within a family [22]. These chromosomal regions are
expected to harbor mutation(s) that cause the disease. As this method involves segregation, 
it can only be applied in a family based setting. The method is powerful to discover loci 
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harboring mutations that might be rare and family specific and have large effects on 
the disease. To identify variants that are common in populations and have small effects
on the disease (as are expected in the case of a complex trait like longevity), association 
analysis is best performed. Association analysis tests whether a specific genetic variant is 
more frequent in cases than in controls in case of a disease. There are two ways in which 
association analysis can be performed; (1) direct association analysis and (2) indirect
association analysis. In direct association analysis functional/causal variants are tested for
association with the disease while in indirect association analysis common variant(s), that
are expected to tag the unknown functional/causal variant, are tested for association with 
the disease. The direct association analysis can be performed in a candidate gene approach 
where causal variants in genes that are known to have a biological impact on the disease
are directly genotyped; or on Next generation sequence (NGS) data, which captures most
variation in the genome [23] including the rare and causal variants. Indirect association is
generally performed as genome-wide association studies (GWAS) where studies use various
single nucleotide polymorphisms (SNPs) genotyping arrays (e.g., http://www.illumina.com/
applications/genotyping.ilmn) to perform genotyping of common SNPs ranging from a few
hundred thousand to millions across the genome, assuming that these will tag the actual
causal variant by means of proximity and correlation referred to as linkage disequilibrium
(LD). Since GWAS involve testing of all SNPs genome-wide regardless of any prior hypothesis,
unlike the candidate gene approach, GWAS are hypothesis free. As common variants are
likely to have small effects on the disease, large cohorts are needed to achieve sufficient 
statistical power for their discovery. Therefore, in genome wide association studies (GWAS),
the aim is to accumulate the highest achievable number of genotypes of as many subjects
as possible. This is achieved by pooling of GWAS in a meta-analysis. Pooling requires studies 
to perform genetic imputations to a common reference. Previously, for most GWAS HapMap
Central European (CEU) population was used as a reference, which enabled a meta-analysis
of ~ 2.5 million SNPs. More recently the 1000 Genomes (http://www.1000genomes.org/) 
and the Genome of the Netherlands (GoNL) (http://www.bbmri.nl/en-gb/activities/
projects/131-genome-of-the-netherlands) projects have provided reference populations 
enabling imputations of up to ~ 38 million genetic variants including single nucleotide 
variants (SNVs) and small insertions and deletions over the entire human genome. Thus the
coverage of the study is increased not only of the common genetic variants that exert small
effects on the disease but also of the rare variants that may have large effects on the disease.
Discovery of both rare and common variants require large samples in a population based 
setting. However, families with a few affected individuals may provide a powerful base to
detect large effect rare variants using linkage analysis (Figure 2).
Despite the growing popularity of GWAS at the cost of candidate gene research, the GWAS
technology has also opened the opportunity to study candidate genes at a larger scale. 
Using GWAS arrays it is now possible to study families of candidate genes simultaneously.
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Figure 2 | Low-frequency variants and disease susceptibility (Source: McCarthy et al. 2008)
GENETIC EPIDEMIOLOGY OF LONGEVITY
For longevity, only two candidate genes have been consistently identified by meta-analysis, 
namely APOE and FOXO3. The APOE ε4 isoform has also been linked to elevated cholesterol, 
cardiovascular disease, age-related cognitive decline and dementia [16]. Thus APOE may 
influence longevity through premature onset of age-related diseases. FOXO3 was first
associated with longevity in a candidate gene study conducted in male centenarians and 
subsequently replicated in various samples of centenarians and long-lived individuals 
[20, 21]. Large scale GWAS have not been very successful in identifying genetic variants 
associated with longevity [1]. To date, six GWAS on longevity have been performed [3, 17,
19, 24-26]. The only consistent association in these GWAS is the APOE locus. Increasing 
the sample size may improve power to detect associations, but the lack of successful 
identification of genetic variants associated with longevity may also be due to the fact that 
GWAS (at least with the HapMap imputed ~ 2.5 million genetic variants) are better powered
to detect only common variants that exert small effects on the trait. Although relatively
rare variants that may exert large effects on the trait may be studied by using the imputed
genetic variants from the 1000G or GoNL, the imputation of such variants is difficult and 
often unreliable. To date no GWAS on longevity has been performed using the imputed
genetic variants from the 1000G or GoNL. NGS technology offers an expensive but a better
alternate for studying rare genetic variants in relation to longevity. 
As to linkage analysis in families three studies have been conducted, leading to eight 
chromosomal regions that are linked to longevity with LOD > 3 [27-29]. Only the region
containing APOE has yielded the identification of genes associated with longevity. 
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MODEL ORGANISMS LEADING TO PATHWAYS IN LONGEVITY
Model organisms have been the major means of discovering the genetic pathways 
leading to longevity, providing candidate genes for further study in humans. The term
“model organism” has been applied to those species, that, because of their small size and
short generation times, facilitate experimental laboratory research [30]. Species such as 
Caenorhabditis elegans, Drosophila melanogaster and Mus musculus have become favorite
in experimental research as they combine the advantages of a relatively short life span,
low maintenance costs, and excellent background genetics [31]. Experiments in model
organisms have demonstrated that changes in genes can dramatically increase their 
lifespan. In some cases, mean and maximum lifespan is extended up to fivefold [32]. The 
equivalent life-extending effect in humans would result in an average lifespan of 400 years. 
Such large effects are not expected in humans, however genes and pathways identified
in model organisms can give hints about genetic processes involved in human longevity.
As the majority of candidate genes of longevity have been identified by studies with
mutants, they do not necessarily represent the effect of natural variation in the same genes
that determine human longevity [32]. Natural variation in these genes likely convey more 
moderate effects on longevity. The most well-known and studied pathways associated with
longevity in model organisms are the insulin/insulin-like growth factor signaling pathway, 
the stress response and senescence.
INSULIN/INSULIN-LIKE GROWTH FACTOR SIGNALING PATHWAY
The insulin/insulin-like growth factor (IGF) signalling (IIS) pathway was the first pathway
discovered for longevity. The first gene in the IIS pathway linked to longevity was daf-2 (worm
insulin receptor) in C. elegans [33, 34]. Long-lived daf-2 mutant worms show resistance to
oxidative stress and increased thermo-tolerance [35, 36]. The increase in stress resistance
of long-lived IIS mutant worms requires the presence of daf-16, although resistance to
heat stress has been uncoupled from the IIS pathway in most model organisms [37]. Stress 
resistance will be described in more detail below.
The first IIS mutation in fruit flies (D. melanogaster) that extends lifespan was identified in
2001 [38]. chico1 flies have a mutation in CHICO, the Drosophila orthologue of the insulin 
receptor substrate [39]. The homozygous mutant flies have low IGF-1 levels, are less than
half the size of wild-type flies and have an increased median lifespan of up to 48% [38, 
39]. A mutation in the Drosophila insulin receptor (dINR) also increases lifespan. Inrp5545/InrE19
dwarf females live 85% longer than controls and the dwarf males show reduced late-life,
age-specific mortality [40]. 
All known mutations in the IIS pathway in C. elegans and D. melanogaster lead to reduced 
levels of IGF-1. The association between low IGF-1 levels and longevity has also been
seen in mammals. Two separate dwarf mouse (M. musculus) mutants, the Snell and Ames
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mutants, are deficient in growth hormone (GH), thyroid hormone and prolactin due to 
underdeveloped pituitary cells and live 40 to 65% longer than non-mutant littermates [41, 
42]. Additionally, a GH receptor knock-out mouse model, whose only deficiency is a GH
resistance and subsequently lower IGF-1 levels, also has an increased lifespan [43]. 
Thanks to intensive selective breeding in the last 300 or 400 years an enormous diversification
of dog breeds has occurred. This diversification is largely due to human pressures leading
to unparalleled variations in body mass and lifespan within a single species. Body mass 
can vary from 1 kg in the Chihuahua to over 100 kg in the Great Dane. Lifespan also varies 
tremendously from 8 to 15+ years in pet dogs. This diversity poses a unique opportunity to
evaluate factors that contribute to lifespan. Lifespan in dogs has been shown to be inversely 
related to body size in multiple studies [44-47]. The finding that small dog breeds, that live 
longer, also have lower IGF-1 levels supports a role for the IIS pathway in this association 
[48].
In humans the IIS pathway (Figure 3) has been studied extensively for association with
longevity. The IIS pathway is involved in cell survival, cell growth and proliferation in humans.
The only replicated genetic variant associated with longevity that falls in the IIS pathway in
humans is FOXO3 [20, 21]. FOXO3 is the human homologue of daf-16, one of the known 
lifespan increasing genes in C. elegans. Additionally there is some evidence that long-lived
individuals have decreased plasma IGF-1 levels but replication are lacking [49]. Mutations
in the IGF-IR gene have been associated with low levels of plasma IGF-1 and longevity 
previously [50], but this gene did not surface in GWAS of longevity. The most compelling
evidence is perhaps that a composite score of IIS genes (GHRHR, GH1, IGF1, INS, IRS1) was 
found to be significantly associated with smaller body size (p-value = 0.004) and longevity
(p-value = 0.047) [51]. Despite the modest p-value, this gene based analysis parallels the
finding in animals, the increase in lifespan in most European countries is paralleled by an
increase in height, which makes it unlikely that this pathway drives human longevity.
Within the Rotterdam Study the IIS pathway has been studied extensively by Vaessen et al
[52-54] and will therefore not be covered in this thesis.
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Figure 3 | Graphical representation of the human insulin/insulin-like growth factor signalling pathway.
Genes are represented in their location within the pathway. In square fields additional pathways which 
are controlled downstream from IGF-1 signalling are depicted.
STRESS RESPONSE
The second pathway involved in longevity consistently in animal models is the response
to stress. Stress, or stressors, is used here to describe experiences that are challenging
emotionally and/or physiologically. Well known stressors include heat, reactive oxygen 
species, ischemia, inflammation and hormonal imbalance [55]. Stressors cause modifications
to the intracellular milieu that may damage deoxy ribonucleic acid (DNA) and protein
products. This can cause proteins to misfold, which disrupts the proteostasis. Proteostasis
refers to controlling the concentration, conformation, binding interactions and location
of individual proteins by readapting the innate biology of the cell [56]. Wrongly folded 
proteins have been associated to various age-related diseases, including Creutzfeldt-Jakob
disease (prion protein), Alzheimer’s disease (AD; β-amyloid) and Parkinson’s disease (PD;
α-Synuclein) among others [57]. 
Proteostasis is tightly regulated by a dedicated family of proteins known as Heat Shock 
Proteins (HSPs), also named stress proteins or molecular chaperones. HSPs ensure survival 
under stressful conditions that, if left unchecked, would lead to irreversible cell damage
and ultimately to cell death [56, 58]. Abnormal expression of these proteins has been 
widely observed in a number of disease states, including oxidant injury, ischemia, cardiac 
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hypertrophy, fever, inflammation, metabolic diseases, tissue trauma, neuronal injury and
cancer, as well as in experimental models of aging [59]. 
Thus variation in genes encoding HSPs are plausible risk factors for association with 
longevity, as well as genetic causes of protein folding disorders like AD and PD, yet they
were not systematically investigated primarily due to the great complexity and number of 
HSPs, which has only recently been resolved with a new and comprehensive nomenclature
[60].
SENESCENCE
A pathway involved in longevity is senescence that can now be translated to large-scale
population studies through telomere metabolism [61]. Telomeres are tandem repeats of 
long hexamers (TTAGGG) at the end of chromosomes [62, 63]. Their predominant function is
the protection of chromosome extremities from fusion and degradation [64]. The necessity
of telomeres was first recognized in the late 1930s and it was only in the early 1960s that
it was observed that normal human cells have a limited replicative capacity [65, 66]. The
concept of the ‘end replication problem’, stemming from the inability of DNA polymerase 
to completely replicate the DNA, provided the basis for the mitotic clock hypothesis which 
connects the natural shortening of telomeres with age to the limited replicative capacity of 
a cell [67-69]. This limit corresponds to a state of mitotic senescence triggered by telomeres
that have reached the shortest length compatible with stability [61]. Thus telomere length 
is often seen as a marker for biological age, rather than chronological age. Though telomere 
length can be restored by telomerase, this enzyme is not expressed at sufficient levels to
maintain telomere length in humans and most other long-lived mammals [70, 71]. Therefore,
telomere length shortening has been recognized as not only a marker of biological age but
also a mechanism of aging [72, 73].
Convincing evidence for a causative association between telomere length and longevity
stems from premature aging syndromes. Mutations in DKC1, a component of telomerase, 
are responsible for the X-linked form of Dyskeratosis congenita (DC), which has been 
associated with signs of premature aging [74-76]. Mutations in TERC, the RNA template
of telomerase, are responsible for the autosomal dominant form of DC [77]. DC patients 
have shortened telomeres and show reduced in vitro telomerase activity thus pointing to 
telomere-dependent replicative senescence as the driving force of the disease [78-80].
Genetic research on telomere length is perhaps more interesting than longevity itself as the
heritability is higher, ranging from 40 to 80% [81-83], compared to that of longevity (40%).
Despite the relatively small GWAS (N < 3500), three loci were identified, including 18q12.2, 
OBFC1 and TERC [84-86]. A recent GWAS including 37,684 participants identified seven 
loci for telomere length [87]. These include TERC, TERT, NAF1, OBFC1, ZNF208, RTEL1 and
ACYP2, confirming two of the previously identified loci. Additionally, in a gene set analysis 
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it was shown that genetic variation in the telomere maintenance pathway is associated to
longevity [88]. It is highly likely that further genetic research will discover more loci, which 
could also be potentially relevant to longevity. Further genetic research with larger samples
will likely discover more loci, which may serve as plausible candidates for association with
longevity.
METABOLOMICS
Pathways associated with longevity in animal models, in particular the IIS pathway, are
clearly linked to metabolism. Additionally, aging is often accompanied by disabilities and 
diseases such as cardiovascular diseases, AD, chronic joint symptoms, arthritis and diabetes, 
which are also known to have a strong metabolic component [89, 90]. In the Leiden
Longevity Study, LDL and triglycerides were associated with longevity [91]. Metabolomics
is a new technology that focuses on obtaining a more complete depiction of the metabolic 
status of an organism instead of single compounds [92]. Numerous small molecules are
measured that represent a whole range of intermediate metabolic pathways and may serve 
as biomarkers [93]. Previously, metabolic profiles have been associated with age and aging-
related diseases, such as type 2 diabetes, atherosclerosis, cancer and Alzheimer’s Disease
[94-99]. Metabolic profiles and biological age have been linked in mice [100], in humans
an age-related metabolic profile of 22 metabolites explained 5% of the total variance in
telomere length [96].
AIM OF THIS THESIS
The aim of this thesis is to find genetic markers associated with longevity in GWAS and
candidate gene studies, as well as to gain a better understanding of telomere length
metabolism.
Though in recent years great successes have been seen in complex trait genetics, for
longevity no major successes have been made. In Chapter 2 we performed a GWAS on the 
longevity phenotype. Longevity cases were defined as individuals of 90 years and over, 
while controls were defined as individuals who have died between 55 and 80 years of age 
(Chapter 2.1). In Chapter 2.2 we aimed to unravel the genetic architecture of longevity, that 
is, whether rare variants with large effects or rather multiple common variants across the
entire genome each exerting a small effect on longevity are predominantly determining
longevity in the general population.
Chapter 3 aims to elucidate the association of candidate genes from the stress response 
pathway (HSPs) with longevity, here defined as all-cause mortality, as well as the association
of HSPs with two age-related protein-folding disorders AD and PD. In contrast to the classical
indirect candidate gene studies we targeted complete gene families based on pathways 
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and animal models. In Chapter 3.1 we investigated the association of all SNPs genotyped or
imputed in the HSP70 genes and its main co-chaperones with AD. HSP70 has been shown
to co-localize with Aβ plaques and participates in the neuroprotective response to these
plaques [101-104]. Additionally we performed pathway analysis using the SNP Ratio Test
tool to identify if any HSP sub-family had more significant SNPs than would be expected by
chance [105]. In Chapter 3.2 we turned our focus to PD. This time we investigated previously
identified candidates HSP10, HSP60, HSP70, HSP90 and Heat Shock Factors (HSF). Finally,
in Chapter 3.3, we investigated the association of HSP70, small HSP and HSF families with
all-cause mortality.
In Chapter 4 we investigate telomere length as a measure of senescence. We first elucidated
the heritability as well as major familial effects in telomere length in Chapter 4.1. In Chapter 
4.2 we investigated a previously described survivor effect in telomere length reducing the 
variance over age and investigated whether there is evidence for selection against short
or long telomeres using a three-generation family-based approach. In Chapter 4.3 we
investigated the association between telomere length and height as observed previously
in two separate animal species bridging the IIS theory of body size and the senescence 
hypotheses. Finally, in Chapter 4.4 and 4.5 we investigated metabolites for their association
with telomere length. First we investigated adipokines, known to be associated with oxidative
stress, and their association with telomere length (Chapter 4.4). Next we investigated a wide
range of serum metabolites using targeted metabolite profiling by electrospray ionization
(ESI) tandem mass-spectrometry (BIOCRATES platform) (Chapter 4.5). The metabolites 
investigated ideally represent a wide range of biological processes therefore providing a
new opportunity to better understand the telomere length metabolism.
Chapter 5 includes the general discussion of the results of this thesis. Chapter 5.1 focuses 
on the difficulties of distinguishing true from false positives, a problem encountered 
in Chapters 3 and 4.5. Chapter 5.2 discusses findings of several chapters in a broader 
context and suggests future research. Chapter 6 includes a summary of the thesis. The
supplementary material for the publications in this thesis (chapters 2 to 5) can be found in
Chapter 7. Finally, the acknowledgements and a publication list can be found in Chapter 8.
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ABSTRACT
The genetic contribution to longevity in humans has been estimated to range from 15 to 
25%. Only two genes, APOE and FOXO3, have shown consistent results across studies. 
In this genome-wide association study we included 6,036 longevity cases that reached age 
90 years or older and 3,757 controls that died between ages 55 and 80 years. We additionally 
attempted to replicate previously identified SNP associations with longevity.
We found suggestive evidence for the association of SNPs near CADM2 and GRIK2 and 
longevity. We further confirmed the association of APOE and FOXO3 with longevity, but did
not replicate other previously identified associations.
An important conclusion of this study is the lack of finding new associations with longevity 
to age 90+. There are several potential reasons why we did not observe definitive new 
loci. Longevity may represent multiple complex traits with heterogeneous genetic
underpinnings. Alternatively, it could be that longevity is regulated by rare variants rather 
than common variants.
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INTRODUCTION
There is ample evidence that genetic factors are involved in extreme longevity both in
humans and in other organisms. In model organisms, ranging from C. elegans to mice, 
mutations in the insulin/IGF-1 signaling (IIS) pathway have been shown to substantially
increase lifespan [1-6]. Other suggested mechanisms involve stress resistance as mediated
by heat shock proteins [7, 8], cellular senescence as mediated by telomere length [9] and
inflammation/immune function [10]. The genetic contribution to lifespan in humans has
been estimated to range from 15 to 25% [11-13].
Though many human candidate longevity genes have been investigated, only two genes 
have shown consistent results across studies. The first consistent association found was APOE
[14]. It was subsequently replicated in both candidate gene and genome-wide association 
studies (GWAS) with genome-wide significant evidence [15-20]. The second longevity gene
identified was FOXO3 in male centenarians and replicated in other candidate gene studies 
that include both men and women across ethnicities, though FOXO3 was not identified in
GWAS [21-25].
Early GWAS have failed to identify new longevity genes as reviewed by Murabito et al [26]. In 
2010 the CHARGE consortium published a meta-analysis of 1,836 longevity (90+) cases and
a comparison group of 1,955 individuals whom died between 55 and 80 years [27]. A total
of 24 independent SNPs were identified, though none reached genome-wide significance.
The key to success to GWAS has proven to be large sample size and statistical power. Since the
original CHARGE GWAS [27] additional members of each cohort have reached or exceeded 
age 90 and additional studies have joined the consortium permitting an expanded meta-
analysis of longevity. Using the same study design as the original CHARGE longevity study, 
the sample size of the current study is 6,036 longevity cases and 3,757 controls.
METHODS 
Participants
The participants of this study are of European ancestry and include cohorts of the CHARGE
Consortium [28]. All cohorts periodically assess the vital status of their participants. 
Although some of the cohorts include multiple ethnic groups, only data from self-reported 
Caucasians were used. Informed written consent was obtained from all participants and 
appropriate institutional approvals were obtained. A brief description of each population is 
given in the Supplementary Material.
Longevity Phenotype
In the present study longevity was defined as reaching age 90 years or older. Genotyped
participants who died between the ages of 55 and 80 years were used as the control group.
The control group was limited to deceased participants to ensure that no one in the control
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group could subsequently achieve longevity. The minimum age at death was set to match
the minimum age at enrollment in the Rotterdam Study (RS). The maximal age at death 
was set arbitrarily at age 80 years to include the majority of deaths and to exclude those
participants who survived far beyond the average life expectancy for their respective birth 
cohort. Across the cohorts there were 6,036 participants who achieved longevity and the
control group had 3,757 participants.
Genotyping and imputation
As different genotyping platforms were used across studies, we imputed to 2.5 million 
SNPs using the HapMap 22 CEU (Build 36) genotyped samples as a reference. Details on the 
study-specific quality control procedures for genotyping and imputation can be found in
Supplementary Table 1.
Statistical analysis
We used logistic regression to test each SNP for association with longevity using an additive
model adjusting for sex. Fixed-effects inverse-variance meta-analysis was performed using
METAL. P-values were corrected for genomic control. Associations with a p-value < 5*10-8
were considered to be significant, while associations with a p-value < 1*10-5 were considered
to be suggestive and proceeded to replication.
Detailed analysis of replication cohorts and additional analyses can be found in the
Supplementary Material. Conditional analysis of the FOXO3 locus was performed using the 
GCTA tool without individual level data [29, 30]. We further attempted to replicate previously
identified SNP associations with longevity. Finally, we used gene networks available at www.
genenetworks.nl as a bioinformatics resource to further investigate significant findings.
RESULTS
General characteristics of discovery and replication cohorts can be found in Table 1 and 
Table 2 respectively. Between 0.0% and 70.3% of those achieving longevity were still alive at 
the time that longevity status was ascertained. Among those who had died, the distribution 
of causes of death differed between longevity cases and the comparison group. Whereas
1.0% to 17.3% of those achieving longevity died of cancer, 10.1% to 50.3% of deaths in the 
comparison group could be attributed to cancer.
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Table 1 | General characteristics of discovery cohorts.
N Women, % Alive, % Cause of death, %*
CVD Cancer Other Unknown
RS1 90+ cases 899 79.0 23.6 31.4 7.9 60.7 0.0
comparison 1192 41.3 0.0 32.2 40.1 27.7 0.0
RS2 90+ cases 69 60.9 69.6 33.3 14.3 52.4 0.0
comparison 161 37.3 0.0 23.6 50.3 26.1 0.0
SOF** 90+ cases 1720 100.0 54.4 16.8 3.6 21.5 0.0
comparison 124 100.0 0.0 37.9 28.2 33.9 0.0
CHS 90+ cases 791 62.3 41.7 51.5 17.3 30.6 0.6
comparison 560 53.2 0.0 33.6 39.3 27.0 0.2
MrOS*** 90+ cases 670 0.0 43.6 19.9 6.9 21.8 3.1
comparison 502 0.0 0.0 29.3 38.8 31.7 0.2
FHS 90+ cases 320 66.9 0.0 24.1 11.6 51.9 12.5
comparison 484 34.3 0.0 24.6 43.8 25.2 6.4
HRS 90+ cases 384 67.5 68.5 3.0 15.0 12.6 69.5
comparison 401 45.6 0.0 12.1 10.1 16.2 61.6
AGES 90+ cases 541 61.2 65.1 27.3 8.4 16.2 48.1
comparison 145 49.0 0.0 28.2 35.5 18.4 18.0
RADC 90+ cases 468 75.2 40.0 0.0 0.0 0.0 100.0
comparison 78 48.7 0.0 0.0 0.0 0.0 100.0
InCHIANTI 90+ cases 101 72.3 70.3 8.9 3.0 7.9 80.2
comparison 75 36.0 0.0 6.7 20.0 4.0 69.3
BLSA 90+ cases 128 49.2 50.0 4.7 1.0 3.0 91.4
comparison 42 26.2 0.0 9.5 19.0 2.3 69.1
RS1: Rotterdam Study 1; RS2: Rotterdam Study 2; SOF: Study of Osteoporotic Fractures; CHS: Cardiovascular Health Study;
MrOS: Osteoporotic Fractures in Men Study; FHS: Framingham Heart Study; HRS: Health and Retirement Study; AGES: Age, 
Gene/Environment Susceptibility -Reykjavik Study; RADC: Religious Orders Study and Rush Memory and Aging Project;
InCHIANTI: Invecchiare nel Chianti; BLSA: Baltimore Longitudinal Study of Ageing
* In 90+ cases the % of deaths is reported
** In SOF the vital status is not known for all individuals
*** In MrOS the vital status is not known for all individuals
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Table 2 | General characteristics of replication cohorts.
NECS LLFS
cases (100+) comparison survival analysis
N 801 914 4567
Age at DNA 
draw (median (range))
104 
(95-119)
73
(54-90)
67
(25-110)
Follow-up (median (range)) NA 3 (0-7)
Women, % 72.0 56.0 55.0
Alive, % 3.0 0.0 83.0
Cause of death, %*
CVD 0.0 0.0 0.0
Cancer 0.0 0.0 0.0
Other 0.0 0.0 0.0
Unknown 100.0 100.0 100.0
LLFS: Long Life Family Study; No study specific information for the EU_longevity consortium was available.
* In 100+ cases the % of deaths is reported
None of the SNP-longevity associations reached the genome-wide significance threshold of 
5*10-8 in the discovery phase (Supplementary Figure 1), although the strongest association
was for rs1416280 located 369kb from GRIK2 (OR = 1.24; p-value = 5.09*10-8). In total, 7
loci passed the threshold for suggestive association (< 1*10-5) and were included in the
replication phase (Table 3). For replication, we also included the most significant SNP in
the current study from the known longevity gene, FOXO3. Forest plots of all 8 SNPs can be 
found in Supplementary Figure 2. Though none of the SNPs reached Bonferroni corrected
significance in any of the replication cohorts, consistent results considering direction of 
effect were found for FOXO3 across discovery and replication cohorts (Table 3). Association
results for CADM2 and, to a lesser degree, GRIK2 were consistent across cohorts. In pathway
analysis using the gene networks tool, both CADM2 and GRIK2 genes were found to be
involved in neuronal pathways (Supplementary Table 2).
Of the 24 SNPs identified in the original CHARGE longevity GWAS [27] the p-value for only
one of these (GRIK2; rs954551) improved in the current study (Supplementary Table 3). One 
further region (RGS7) appears among the strongest associations in the current study, but
the association was not strengthened in the replication phase of the study.
Next we aimed to replicate the GWAS of Sebastiani et al conducted on centenarians
(Supplementary Table 4) [20]. 281 SNPs were reported using four different genetic models
[20]. 6 out of the 281 SNPs were reported to have a p-value < 1*10-5 in the additive model.
We attempted to replicate these 6 SNPs, and only the SNP at the APOE locus replicated at
the Bonferroni corrected significance level (OR = 1.20; p-value = 4.8*10-4). Similarly, of the 4
regions identified with linkage analysis of longevity sib-pairs (90+) [31] we also replicated 
only the APOE locus (Supplementary Table 5).
33GWAS of longevity in the CHARGE consortium confirms APOE and FOXO3 |
2
Ta
bl
e 
3 
| 
TT
A
ss
oc
ia
tio
n 
re
su
lts
 fo
r l
on
ge
vi
ty
: d
is
co
ve
ry
 a
nd
 re
pl
ic
at
io
n.
D
is
co
ve
ry
EU
_l
on
ge
vi
ty
Ce
nt
en
ar
ia
n 
(N
EC
S)
Su
rv
iv
al
 (L
LF
S)
SN
P
Ch
rG
en
e
D
is
ta
nc
e
(k
b)
EA
EA
F
p-
va
lu
e
O
R
95
%
 C
I
di
re
ct
io
n
eff
ec
t
p-
va
lu
e
SN
P
r2
*
O
R
p-
va
lu
e
SN
P
r2
*
1/
H
R
p-
va
lu
e
rs
14
16
28
0
6
G
RI
K2
36
9
C
0.
75
5.
09
*1
0-
8
1.
24
1.
15
-1
.3
4
+-
++
++
++
+-
+
+
0.
27
6
rs
93
77
36
1
1.
00
0.
98
0.
83
3
rs
93
77
36
1
1.
00
1.
00
0.
98
1
rs
98
41
14
4
3
CA
D
M
2
-2
36
A
0.
79
9.
66
*1
0-
7
0.
81
0.
74
-0
.8
8
--
--
--
--
-+
-
+
0.
82
5
rs
98
22
73
1
0.
96
1.
03
0.
72
6
rs
98
22
73
1
0.
96
0.
85
0.
05
3
rs
46
11
00
1
1
RG
S7
-2
8
A
0.
97
1.
84
*1
0-
6
1.
79
1.
41
-2
.2
7
+?
-+
++
++
+?
+
-
0.
20
7
rs
75
36
26
0
0.
68
0.
65
0.
01
3
rs
75
36
18
49
1.
00
1.
07
0.
72
8
rs
11
02
37
37
11
SO
X6
-2
8
A
0.
32
3.
64
*1
0-
6
0.
83
0.
77
-0
.9
0
--
--
--
--
--
-
+
0.
68
4
rs
21
96
96
1
0.
27
1.
03
0.
66
8
rs
11
02
37
44
0.
96
1.
06
0.
39
7
rs
11
75
30
77
6
M
BO
AT
1
-7
6
T
0.
64
7.
51
*1
0-
6
1.
17
1.
09
-1
.2
6
++
++
++
+-
+-
+
+
0.
09
5
rs
77
63
81
5
0.
87
1.
04
0.
57
2
sa
m
e
1.
00
1.
03
0.
63
3
rs
10
87
57
46
12
PF
KM
in
tr
on
A
0.
76
7.
83
*1
0-
6
1.
20
1.
11
-1
.3
0
++
++
++
++
+-
+
+
0.
24
0
rs
22
28
50
0
0.
74
1.
03
0.
79
6
rs
22
28
50
0
0.
74
0.
93
0.
34
9
rs
10
00
78
10
4
LI
M
CH
1
in
tr
on
A
0.
23
8.
80
*1
0-
6
1.
20
1.
11
-1
.3
0
+-
++
++
++
++
+
-
0.
97
9
sa
m
e
1.
00
0.
98
0.
84
1
sa
m
e
1.
00
0.
95
0.
52
1
rs
10
45
71
80
6
FO
XO
3
in
tr
on
A
0.
70
8.
56
*1
0-
5
0.
87
0.
81
-0
.9
3
--
+-
--
--
+-
-
-
0.
02
3
rs
21
53
96
0
0.
89
0.
98
0.
82
2
rs
21
53
96
0
0.
89
0.
84
0.
02
1
EU
_l
on
ge
vi
ty
: E
ur
op
ea
n 
co
ns
or
tiu
m
 in
ve
st
ig
at
in
g 
th
e 
ge
ne
tic
s 
of
 lo
ng
ev
ity
 w
ith
 s
im
ila
r 
ph
en
ot
yp
e 
to
 d
is
co
ve
ry
 (c
as
es
: 9
0+
; c
on
tr
ol
s:
 <
65
); 
Ce
nt
en
ar
ia
ns
 (N
EC
S)
: c
en
te
na
ria
n 
ca
se
s 
co
m
pa
re
d 
to
yo
un
ge
r c
on
tr
ol
s;
 S
ur
vi
va
l (
LL
FS
): 
al
l-c
au
se
 m
or
ta
lit
y 
Co
x-
re
gr
es
si
on
 a
na
ly
si
s, 
1/
H
R 
sh
ow
n 
fo
r d
ire
ct
 c
om
pa
ris
on
 o
f t
he
 d
ire
ct
io
n 
of
 th
e 
eff
ec
t. 
In
 N
EC
S 
an
d 
LL
FS
 n
o 
im
pu
ta
tio
ns
 w
er
e 
av
ai
la
bl
e.
*l
in
ka
ge
 d
is
eq
ui
lib
riu
m
 w
ith
 d
is
co
ve
ry
 S
N
P
St
ud
y 
or
de
r f
or
 d
ire
ct
io
n 
co
lu
m
n:
 R
S1
, R
S2
, S
O
F, 
CH
S,
 M
rO
S,
 F
H
S,
 H
RS
, A
G
ES
, R
A
D
C,
 In
CH
IA
N
TI
, B
LS
A
EA
: e
ffe
ct
 a
lle
le
; E
A
F:
 e
ffe
ct
 a
lle
le
 fr
eq
ue
nc
y;
 ‘+
’: 
eff
ec
t a
lle
le
 o
ve
rr
ep
re
se
nt
ed
 in
 c
as
es
; ‘-
’: 
eff
ec
t a
lle
le
 u
nd
er
re
pr
es
en
te
d 
in
 c
as
es
; ‘?
’: 
no
t t
es
te
d 
in
 th
is
 s
tu
dy
.
P-
va
lu
e 
< 
0.
05
 in
 re
pl
ic
at
io
n 
ar
e 
bo
ld
ed
34 | Chapter 2.1
Finally, we examined the original SNP reported for the FOXO3 gene (rs2802292) in the current 
study and added our current study (each cohort individually) to the 4 published studies
reporting on the same FOXO3 SNP (Supplementary Table 6) [21, 23-25]. In the current study, 
rs2802292 reached a p-value of 0.012 (OR = 1.09). When including the published studies in 
the meta-analysis rs2802292 passed the threshold for genome-wide significance (OR = 1.18;
p-value = 1.44*10-8). The Linkage Disequilibrium (LD) as measured by r2 between this SNP 
and the top FOXO3 SNP in the current study (rs10457180) was 0.64. In conditional analyses
including both SNPs only rs10457180 remained significant (OR = 0.94; p-value = 5.53*10-4).
DISCUSSION
In this investigation of 6,036 longevity cases and 3,757 controls we find suggestive evidence
for the involvement of SNPs near CADM2 and GRIK2. We further confirmed the associations 
of APOE and FOXO3 with longevity. 
FOXO3 is a known candidate gene for longevity and part of the well characterized IIS pathway
[6]. Though previously identified in candidate gene studies it did not previously reach
genome-wide significance [21-25]. In our study the strongest signal in the FOXO3 gene was
found for rs10457180 which is in LD (r2 = 0.64) with the known SNP rs2802292. Pooling our 
data with that of independent studies from literature yielded a genome-wide significant
p-value of 1.44*10-8. In a conditional analysis only rs10457180 remained significant. This 
suggests that rs10457180 may be a better tagging SNP for the true causal variant. 
Though replication for both CADM2 and GRIK2 was not consistent, these genes are interesting 
candidate genes for longevity. Both genes are involved in neuronal pathways, in particular
in neuron cell-cell adhesion and regulation of synaptic transmission, glutamatergic (www.
genenetworks.nl). Neuronal pathways have been previously implicated in all-cause 
mortality in a pathway analysis [32].
We did not replicate other previously reported associations with longevity, except for FOXO3
and APOE. Though many attempts to unravel the genetic contribution to the longevity 
phenotype have been undertaken, none of the previously suggestive longevity genes 
identified by GWAS have ever been replicated [26]. GWAS has proven to be able to unravel
the genetics of many complex traits with great success, even when the heritability of the 
trait is modest, as is the case in longevity. Yet the longevity phenotype remains resistant to
the efforts to uncover new genetic associations. There are several potential explanations
for this. First, the longevity phenotype could simply be too complex and heterogeneous
for successful identification of longevity genes. It may require a great number of ‘protective’ 
genes all with small effects to have a genetic advantage to achieve longevity [20]. Though in
highly heritable traits like height these genes have been uncovered, in a trait like longevity
it may be nearly impossible with the current availability of genotyped individuals reaching
longevity. Using biomarkers might be a more fruitful pursuit for finding associations to
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longevity. Unfortunately no good biomarkers of aging currently exist, though many have
been proposed [33]. Telomere length, a marker of senescence, could be an interesting
biomarker of aging and GWAS has already proven successful in identifying genes for this 
trait [34, 35]. An alternative approach could be the development of novel phenotypes like
the healthy aging index, which incorporates information across physiologic systems and
predicts mortality better than age itself [36].
The second potential reason for not finding any genome-wide significant associations with
the longevity phenotype is that GWAS targets common variants [37]. As longevity in the
general population is quite rare, but common in specific long-lived families, it could be 
that rare variants, rather than common variants are involved in the longevity phenotype
[38]. Such variants are not likely to be picked up in GWAS, but may be uncovered with next 
generation sequencing technology [39].
Finally, another reason for not finding significant associations with longevity could be 
found in epigenetics, which could influence the expression of genetic variations. Epigenetic 
modifications such as DNA methylation and histone modification are essential for
development and differentiation, but can also arise later in life [40]. Age related changes
in DNA methylation have been implicated in senescence and longevity [41]. Such changes 
could mask genetic associations.
In conclusion, we confirm the association of FOXO3 and APOE with longevity, but do not find 
any new longevity associations, aside from the suggestive evidence for CADM2 and GRIK2.
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ABSTRACT
Genome-wide association studies (GWAS) of longevity have failed to identify any new genes
beyond the known candidate genes FOXO3 and APOE. It has been postulated that longevity 
is caused by rare variants rather than common variants. An alternative hypothesis is that a
very large number of common variants together determine longevity.
In this study we investigated the association of rare variants, as detected by exome
sequencing, with longevity in a population-based study, the Rotterdam Study (RS-I; n = 202
longevity cases and 267 controls) and replicated using 1000G imputations in the remaining
individuals of the study (802 longevity cases and 864 controls). Additionally, we determined 
the extent to which the heritability of longevity can be explained by common variants using
GCTA using the genome-wide array data.
In single variant analysis none of the exonic variants approached genome-wide significance.
Pathway analysis of the single variants using PANTHER showed the involvement of cell cycle
control mechanisms in longevity. Burden test analysis showed borderline genome-wide
significant association (p-value = 2.87*10-6) with the gene WSCD2 with longevity. OR52L1
is the only gene emerging in both the single variant and burden test analyses, but findings 
are far from significant. When testing whether the joint effect of multiple common variants
explain the heritability we found that up to 81.3% of the heritability can be explained by 
common variants (p-value = 0.01).
Our study suggests that common variants explain a large part of the heritability of longevity. 
We found suggestive evidence for the involvement of rare variants in WSCD2 and OR52L1 in
longevity, but these findings remain to be confirmed.
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INTRODUCTION
In the past two centuries mean life expectancy has significantly increased [1]. In parallel, 
the number of individuals reaching extreme age (e.g. longevity) has increased as well. The 
percentage of individuals reaching 90 years of age is growing dramatically [2]. Heritability 
estimates of age at death range from 20 to 30% in twin registries [3, 4] and 15 to 25% in
population-based samples [5, 6]. Heritability of longevity, on the other hand, was estimated
to be higher, approaching 40% [7].
Despite the substantial heritability, it has been difficult to find the genes involved in
longevity. As early as 1994 APOE was identified as one of the key longevity genes in early
candidate gene studies [8] and was subsequently replicated in recent candidate gene and
genome-wide association studies (GWAS) reaching genome-wide significance [9-14]. Also
the second longevity gene identified, FOXO3, was associated in candidate gene studies 
across ethnicities, though it did not reach genome-wide significance in GWAS [15-19]. Other 
than these candidate genes, GWAS has failed to identify any consistent associations with 
longevity [11, 13, 14, 20-22].
As longevity is common in specific long-lived families, it has been postulated that rare, rather
than common variants are involved in the longevity phenotype [23]. Such variants are not
likely to be picked up in GWAS, but may be uncovered with next generation sequencing
technology [24]. On the other hand, for an increasing number of traits (e.g. height) that are 
highly heritable and do cluster in families there is increasing evidence that the heritability
is explained by a large number of common variants throughout the genome [25] which are
difficult to detect in GWAS as individual effects of genes are small.
In this study we aimed to investigate the genetic architecture of longevity in the Rotterdam
Study (RS-I). We determined the extent to which the heritability of longevity could be
explained by rare exonic variants with large effects rather than common variants with small
effects.
METHODS
Study population
From 1991 to 1995 all inhabitants of Ommoord, a district of Rotterdam, The Netherlands, 
who were 55 years or older, were invited to participate in the RS-I [26, 27]. Genotyping 
information was available for 5,974 participants. All of the participants were followed for
incident diseases through linkage to the general practitioner data base and record review
by trained medical investigators. General practitioners’, hospital records as well as death
certificates were used for identification of deaths and health events through 01.01.2011. 
In the present study longevity was defined as reaching age 90 years or older. Participants
who died between the ages of 55 and 80 years were used as the control group. The control 
group was limited to deceased participants to ensure that no one in the control group could
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subsequently achieve longevity. The minimum age at death was set to match the minimum 
age at enrollment in the study. The maximal age at death was set at age 80 years to include 
the majority of deaths and at the same time to exclude those participants who survived far
beyond the average life expectancy for their respective birth cohort.
In total the RS-I population included 1,004 longevity cases and 1,131 controls. For discovery 
of rare variants we used those samples exome sequenced, which included 202 longevity 
cases and 267 controls. For replication we included those samples not included in exome 
sequencing, but were genotyped on genome-wide array platforms (802 longevity cases 
and 864 controls) and subsequently imputed to the 1000 G reference panel for rare variants.
Details on the measurement of general characteristics can be found elsewhere [28]. 
Summary statistics were calculated using SPSS 20. Unadjusted p-values were derived
using the one-way anova test for continuous variables or the chi-square test for categorical
variables. P-values adjusted for sex were obtained in logistic regression analysis.
Genotyping/Sequencing and imputations
Genomic DNA was extracted from whole blood samples using standard methods [29]. 
Exomes of 1,764 individuals from the RS-I population were sequenced, using the Nimblegen
SeqCap EZ V2 capture kit on an Illumina Hiseq2000 sequencer and the TrueSeq Version3
protocol. The sequences reads were aligned to the human genome build 19 (hg19) using 
Burrows-Wheeler Aligner [30]. Genetic variants were called using the Unified Genotyper Tool 
from GATK. Samples with low concordance to genotyping array (< 95%), high heterozygote 
to homozygote ratio (> 2.0) and low transition/transversion ratio (< 2.3) were removed from
the data. The final dataset consisted of 1,524 individuals and about 900 thousand Single
Nucleotide Variants (SNVs). Annotation of the sequenced variants was performed using 
the SeattleSeq database (http://snp.gs.washington.edu/SeattleSeqAnnotation137/) and 
functional prediction of the variations were performed using Polyphen v2 [33]. For discovery 
we used those individuals included in the exome sequencing, including 202 longevity cases 
and 267 controls.
For replication we used individuals genotyped on the Illumina Infinium II HumanHap550 SNP 
chip array who were not included in the exome sequencing dataset, including 802 longevity 
cases and 864 controls. Imputations on the 1000G reference panel were performed using 
MACH software (http://www.sph.umich.edu/csg/abecasis/MACH/). Analysis was performed
using ProbABEL [34].
Statistical analysis of rare variants
In order to assess the association of rare variants with longevity we performed single 
variant analysis of exome data in PLINK v1.07 software, logistic regression adjusting 
for sex [35]. Multiple testing correction on the number of SNVs tested was performed,
resulting in a genome-wide significance threshold of 5.5*10-8 (0.05/903,316 variants).
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The combined effect/burden of rare variants was assessed using SKAT v0.83, adjusted for
sex [36]. Multiple testing correction on the number of genes resulted in a genome-wide
significance threshold of 2.7*10-6 (0.05/18,390 genes). Association with a p-value of < 10-3
were carried forward to replication in both the single variant and gene-based analysis. In 
order to assess the difference in the total burden of damaging variants between cases and 
controls PLINK was used to create the burden scores (option --score) and SPSS 20 to perform
a logistic regression analysis with the PLINK created score adjusted for sex. The function 
and expression with other genes of identified genes was assessed using the genenetwork 
database (www.genenetwork.nl). Pathway analysis was performed using PANTHER [37]. 
PANTHER is a gene-based pathway analysis tool. We used the gene onthology biological 
processes database as reference.
Variance explained by common variants
In order to determine the extent of heritability of longevity that could be explained by 
common variants with small effects, we estimate the joint effect of common variation using
the GCTA tool [38, 39] on the complete RS-I Illumina Infinium II HumanHap550 SNP chip
array dataset (1,004 longevity cases and 1,131 controls). We excluded SNPs with a minor
allele frequency (MAF) lower than 0.05, more than 0.05 missing values and Hardy-Weinberg
Equilibrium (HWE) p-value lower than 0.05 and individuals with an identity by state (IBS) 
greater than 0.05 in order to adjust for familial relationships closer than and including
second-cousins. For correction of case/control frequency in all analyses we used a frequency
of longevity cases in the population of 3%, which corresponds to the Dutch population 
(Source: CBS).
RESULTS
General characteristics of discovery and replication set can be found in Table 1. Longevity
cases were more likely to be female compared to controls. When adjusted for gender
longevity cases smoked less, consumed less alcohol, were more likely to grade their health
as better than others of their own age, had lower diastolic blood pressure, C-reactive protein 
(CRP), albumin, femoral neck bone mineral density and had higher uric acid levels. Longevity
cases were less likely to die of cancer and more likely to die of dementia or other causes.
None of the variants passed the genome-wide significance threshold in the single variant
analysis of the exome data (p-value < 5.5*10-8). 36 loci (minor allele frequency > 0.01) with 
p-values lower than 10-3 were identified (Table 2 and Supplementary Figure 1). Of these
loci 5 were nominally significant (p-value < 0.05) in the replication set and of those 3 had
odds ratios (ORs) in the same direction as the discovery. The strongest association for those
variants consistently associated in the discovery and replication was seen for rs4979386
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(MAF = 0.22), which is located in an intron of the DFNB31 gene (OR in the meta-analysis
= 1.34; p-value = 2.26*10-4). The second synonymous SNV with a consistent effect was
more rare (MAF = 0.03) and found in OR52L1 (OR meta = 0.44; p-value = 0.001). The third
is a synonymous variant in the WDR11 gene (OR meta = 1.28; p-value = 0.001). As these 
synonymous variants do not translate into a different amino-acid, the association is unlikely
to be biologically relevant. Candidate genes FOXO3 and APOE did not reveal any significant 
associations (Supplementary Table 1). Of note is the absence of exonic variants in FOXO3,
while 9 out of 10 exonic variants in APOE were rare (MAF < 0.01). Formal pathway analysis of 
the genes identified in the single variant analysis using PANTHER suggests the involvement
of cell cycle control (mitosis) and protein transport in longevity (Supplementary Table 2).
Gene based SKAT analysis showed 19 genes with suggestive association to longevity (p-value
< 10-3; Table 3 and Supplementary Figure 2). The gene closest to genome-wide significance
(p-value < 2.7*10-6) was WSCD2 (p-value = 2.87*10-6). The six known damaging variants in 
WSCD2 are rare and therefore not analyzed in single variant analysis. Because of the low 
frequency, the top associated variant could not be found in 1000 Genomes imputations.
Three genes showed suggestive p-values in both the single variant analysis and the SKAT 
analysis, namely OR52L1, MYH11 and ZNF534 (Supplementary Table 3). For the latter two
the leading SNPs did not replicate in that the effect of the same variant was in opposite 
direction (Table 3). In OR52L1 one stop gain and 9 non-synonymous variants contributed
to the p-value in the burden test. Formal pathway analysis of the genes identified in
SKAT analysis resulted in no nominally significant associations (Supplementary Table 4). 
A genome-wide burden test of predicted damaging variants did not yield a significant
difference between cases and controls (Supplementary Table 5).
Finally, we tested the hypothesis that common variants jointly explain a major part of the
heritability using GWAS. In this analysis we ignore the effects of single genes but combine
common variants to explain longevity. The total variance explained by common variants
can be found in Table 4. Unidentified common variants explain 32.5% of the phenotypic 
variation (p-value = 0.01). As only 40% of the variance is explained by genetics, a large part
of the heritability is explained by the joint effect of common variants. Based on a heritability 
of 40% up to 81.3% of the heritability is explained by yet unidentified common variants.
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Table 4 | Total variance explained by common variants in 1004 cases and 1131 controls.
V(G)/Vp_L variance se p-value h2 (85+) h2 explained
0.325 0.144 0.01 0.40 0.813
V(G)/Vp_L: ratio of genetic variance to phenotypic variance
DISCUSSION
In this study investigating the association of rare variants with longevity we find suggestive
evidence for WSCD2 in a gene-based test which shows a p-value that is borderline significant.
The pathways emerging from the single exonic variant analysis involve cell cycle control
and protein transport. Moreover, we show that 81.3% of the heritability of longevity can be 
explained by common variants captured in genome-wide association arrays which include
common variants in coding and non-coding regions.
Comparison of environmental factors between longevity cases and controls revealed 
significant differences in smoking habits and alcohol consumption. Additionally, longevity
cases had lower diastolic blood pressure, CRP, albumin and femoral neck bone mineral
density and they were more likely to rate their health as better than others their own age. 
Significant differences between all these risk factors have been described in our population
previously in a less extreme longevity phenotype (80+) [28]. The present analysis shows 
that findings can be translated from 80+ to 90+ but also underscores the power of our
study design to detect strong associations to clinical and epidemiological risk factors. In the
present analysis of the Rotterdam Study, we observe significant differences in the causes of 
death between longevity cases and controls, with cases more likely to die of dementia and
controls more likely to die of cancer. This is consistent with statistics showing that cancer is 
the number one cause of death in younger individuals [40], while dementia is very prevalent
at old age [41].
In the single variant analysis of the exome variants we identified no rare variants for which
the association with longevity reached genome-wide significance. Most of the suggestive 
variants were common except of the synonymous variant in ORL521. Rs4979386 in DFNB31
showed the lowest p-value (2.26*10-4). This is a common variant with a relatively small OR
(1.34) that, if genotyped or imputed, should have surfaced in GWAS. DFNB31 has been
implicated in a recessive form of sensorineural hearing loss [42]. Gene Ontology suggests 
that this gene is involved in mineralocorticoid metabolic processes. The fact that this
common variant is not found in GWAS makes it less likely to be a true positive finding.
Indeed the p-value for this variant was 0.28 in a GWAS of the CHARGE consortium (personal
communication). The findings on ORL521 are of interest although the single variant analysis
shows no strong evidence for association based on the p-value (p-value = 0.001). However,
this gene was also suggestively associated in the gene-based analysis (p-value = 5.58*10-5),
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in which 14 variants were analyzed simultaneously of which 9 were non-synonymous and
1 was a stop gain.
In the gene-based analysis using SKAT, one gene approached genome-wide significance, 
WSCD2. The leading SNVs could not be replicated in 1000 Genomes imputations as the
variants are not found in the 1000 Genomes. All variants included in the gene-based analysis 
were rare (median = 3.55*10-4; interquartile range = 3.36*10-4 to 4.32*10-4), making it difficult 
to replicate this finding. Even in one of our own other studies (the Erasmus Rucphen Family 
Study) the variants were not found. Coverage of the region was sufficient to call variants with
a median of 25.8 (interquartile range = 17.5 to 32.7). WSCD2 has previously been associated
to bipolar disorder [43]. Gene Ontology suggests a function in long-term memory for this
gene linking this gene to APOE, which is also involved in memory. Although we reported
earlier the relation of APOE with longevity (Deelen et al, submitted), we did not detect APOE
in this analysis as a top finding.
There are several reasons for not finding any significant associations for rare variants in the 
discovery. First, our sample size is small with only 202 longevity cases and 267 controls. This
implies that we have an 80% power to detect variants with a frequency of 1-3% if the effect
in terms of the OR is 14 or higher. For more moderate effect sizes we are underpowered.
The low power to detect moderate to small effect sizes may explain why we did not detect
common variants in APOE or FOXO3. Second, our sample is population-based and not 
selected for long-lived families in which longevity is enriched and where rare variants are
expected to have a larger role in determining longevity [10, 23].
Our study of common variants was better powered as the total dataset was used and
variants are easier to detect in a genome-wide analysis investigating the joint effect of 
all variants. When estimating the total variance explained by common variants jointly we
found that a large part of the heritability of longevity can be explained by common variants 
(81.3%). This study suggests that the genetics of longevity is for a large part the result of a
large number of variants with small effects. Yet GWAS studies have failed to uncover them.
The main reason for not finding associations with longevity in GWAS may be that the effects 
are small resulting in low power to detect these variants. Enlarging the sample size may
help in locating common variants associated with longevity. Similar to other outcomes with
a high heritability, for example height and depression [25, 44], we found for longevity that 
a large part of the heritability is explained by common variants which on themselves have 
very small effects.
In summary, we attempted to identify rare exomic variants associated with longevity. We
found suggestive evidence for the association of multiple rare variants in OR52L1 and WSCD2
with longevity, but these findings remain to be replicated. A very compelling finding of our
study is that the heritability of longevity is likely determined for a large part (81.3%) by a 
large number of common variants with very small effects. The challenge for the near future
will be to identify these variants.
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ABSTRACT
The heat shock protein (HSP) 70 family has been implicated in the pathology of Alzheimer’s 
disease (AD). In this study, we examined common genetic variations in the 80 genes
encoding HSP70 and its co-chaperones.
We conducted a study in a series of 462 patients and 5238 unaffected participants derived
from the Rotterdam Study, a population-based study including 7983 persons aged 55 years
and older. We genotyped a total of 12,053 Single Nucleotide Polymorphisms (SNPs) using
the HumanHap550K Genotyping BeadChip from Illumina. Replication was performed in two
independent cohort studies, the Framingham Heart study (FHS; N = 806) and Cardiovascular 
Health Study (CHS; N = 2150).
When adjusting for multiple testing, we found a small but consistent, though not
significant effect of rs12118313 located 32kb from PFDN2, with an OR of 1.19 (p-value from 
meta-analysis = 0.003). However this SNP was in the intron of another gene, suggesting
it is unlikely this SNP reflects the effect of PFDN2. In a formal pathway analysis we found 
nominally significant evidence for an association of BAG, DNAJA and prefoldin with AD. 
These findings corroborate with those of a study of 2032 AD patients and 5328 controls, in
which several members of the prefoldin family showed evidence for association to AD. Our
study did not reveal evidence for a genetic variant if the HSP70 family with a major effect 
on AD. However, our findings of the single SNP analysis and pathway analysis suggest that
multiple genetic variants in prefoldin are associated with AD.
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INTRODUCTION
Heat shock proteins (HSPs) have been implicated in the pathophysiology of Alzheimer’s
disease (AD) and its major pathological characteristics, neurofibrillary tangles (NFTs) and
β-amyloid (Aβ) [1-3]. AD is an example of a protein-folding disorder, with Aβ plaques as
main misfolded protein [1, 3]. HSPs are the major chaperones mediating proper (re)folding
of proteins [4]. 
There is increasing evidence for the involvement of the heat shock protein 70 (HSP70) family
in AD. It has been shown that Aβ plaques co-localize with HSP70 [1, 5, 6]. Further, HSP70
participates in the neuroprotective response to Aβ plaques [7]. HSP70 has also been found
to promote tau solubility and tau binding to microtubules, thereby suppressing formation
of NFTs [8].
HSP70 has numerous co-chaperones that support its function. The largest group of co-
chaperones comprises the HSP40 family, also called J domain protein family. HSP40 can be
subdivided into 3 subclasses (A, B and C) and each member has both common and unique
functions in the cell [9]. A role of HSP40 proteins in neurodegenerative disorders, like AD,
has been suggested in several studies [10]. Other important groups of co-chaperones
include the BCL2-associated anthanogene (BAG) proteins, Hip, Hop, CHIP and prefoldin [11,
12]. At autopsy, the prefoldin protein complex was found to be up-regulated in brains of 
patients with AD [13].
We have tested 79 genes encoding all members of these HSP families and assessed their
association with AD. First we have conducted a single SNP analysis. Second we performed a
formal pathway analysis in which we test for evidence of multiple SNPs in various genes in
a single pathway which contribute jointly to the evidence of association. To our knowledge, 
this is the first large-scale genomic study of the association of HSP70 and its co-chaperones
with AD to be performed.
METHODS
Discovery Study
Our discovery cohort was the Rotterdam Study (RS1). RS1 is a population-based cohort
study that investigates the occurrence and determinants of diseases in the elderly [14].
Baseline examinations, including a detailed questionnaire, physical examination and blood 
collection, were conducted between 1990 and 1993. The Medical Ethics Committee at
Erasmus Medical Center approved the study protocol.
Dementia is one of the focus disorders of the Rotterdam Study. The diagnosis of dementia 
was made following a stringent three-step protocol [15]. Briefly, all subjects were screened
at follow-up visits (1997-1999, 1999-2000 and 2000-2003) using two tests of cognition: the
Mini-Mental State Examination (MMSE) [16] and Geriatric Mental State Schedule (GMS)
[17]. Participants that were screen-positive (MMSE score < 26 or GMS organic level > 0)
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underwent the Cambridge examination for mental disorders of the elderly (CAMDEX). When
additional neuropsychological testing was required for diagnosis, a neuropsychologist
examined subjects who were suspected of having dementia. In addition, the total cohort
was continuously monitored for incident dementia through a computerized link between 
the study databases and digitalized medical records from general practitioners and the
Regional Institute for Outpatient Mental Health Care until January 1, 2005. The diagnosis of 
dementia and subtypes of dementia was made in accordance with internationally accepted 
criteria for dementia (DSM-III-R) [18] and Alzheimer disease (NINDS-ADRDA) [19] by a panel
consisting of a neurologist, a neuropsychologist and a research physician. We used only 
incident patients in the discovery study.
Genomic DNA was extracted from whole blood samples using standard methods [20]. 
Genome-wide SNP genotyping was performed using Infinium II assay on the HumanHap550
Genotyping BeadChips (Illumina Inc, San Diego, USA). Approximately 2 million SNPs were
imputed using release 22 HapMap CEU population as reference. The imputations were 
performed using MACH software10 (http://www.sph.umich.edu/csg/abecasis/MACH/). The
quality of imputations were checked by contrasting imputed and actual genotypes at 
78,844 SNPs not present on Illumina 550K for 437 individuals for whom these SNPs were
directly typed using Affymetrix 500K. Using the “best guess” genotype for imputed SNPs 
the concordance rate was 99% for SNPs with R2 (ratio of the variance of imputed genotypes
to the binomial variance) quality measure greater than 0.9; concordance was still over 90%
(94%) when R2 was between 0.5 and 0.9.
The genome wide association study has been analyzed and is submitted elsewhere [21]. For 
the study of HSP proteins presented here, a total of 12,053 SNPs in 79 genes were initially
selected for the association test on the basis of the following criteria: (1) position within the
genes of interest with a margin of 100kb on each side of the genes according to NCBI build
36.3, (2) P-value for Hardy-Weinberg equilibrium test ≥ 0.0001, and (3) call rate ≥ 95%. For
further analysis and selection of SNPs selected for evaluation of the consistency of findings a
R2 higher than 0.8 and a minor allele frequency (MAF) higher than 0.05 was used as selection
criterion for a SNP.
Single SNP analyses
First we analyzed the individual SNPs using ProbABEL [22]. We used allele-based logistic
regression to test the association between a single SNP and AD. Odds Ratios (ORs) for each 
SNP were derived adjusting for age and sex. To calculate empirical significance for SNPs, 
permutations were performed per region of interest (ROI) [23, 24]. Briefly, the empirical
distribution of the region-wide maximum of the test statistic under the null was obtained
in 10,000 replications. To estimate empirical significance each observed test statistic was
compared with null statistics obtained empirically and the p-value was estimated as the
proportion of replicas generating the test statistics greater than or equal to the observed
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statistic. The permutation analysis keeps the original genotypes for each individual, but
randomly allocates the phenotypes for each consecutive permutation. Therefore the linkage
disequilibrium (LD) structure of genes is not broken up. We did not perform any additional
correction for the number of ROIs after permutations as we used the permutation analysis to
significantly reduce the number of SNPs to be sent for validation of the effect of the SNP. For 
each suggestively associated ROI (p-valuepermuted < 0.10) we next selected the ‘independently 
associated’ SNPs in a backward stepwise logistic regression until only nominally significant
SNPs remained in the model. These independently associated SNPs were then followed 
up in two independent cohorts. As effect estimates are expected to be small, a positive
replication based on the p-value and odds ratio (OR) observed in individual replication
studies, might be difficult to achieve due to power issues. Therefore we evaluated whether 
a SNP was showing an OR in the same direction in all three cohorts, i.e., whether findings
were consistent over the various cohorts. Similar to genome wide association studies, we
performed a joint meta-analysis of the discovery and the two independent cohorts and
tested whether the joint p-value was significant using a Bonferoni correction for the number
of SNPs validated in independent cohorts.
We used two studies that are part of the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium to evaluate whether findings were consistent. Data
on AD were available in the Cardiovascular Health Study (CHS) and the Framingham Heart
Study (FHS) [25]. Again only incident patients were studied. The CHS is a population-based
cohort study of risk factors for CHD and stroke in adults ≥ 65 years conducted across 
four field centers. The original predominantly European ancestry cohort of 5201 persons 
was recruited in 1989-1990 from random samples of the Medicare eligibility lists and an
additional 687 African-Americans were enrolled subsequently for a total sample of 5888
[26]. For compatibility with the discovery samples, however, these analyses were limited
to the participants of self-described European ancestry. Blood was drawn for genotyping 
at the baseline examination. Persons were examined annually from enrollment to 1999,
and the examination included a 30 minute screening cognitive battery [27]. In 1992-94 and 
again, in 1997-99, participants were invited to undergo brain MRI and detailed cognitive
and neurological assessment as part of the CHS Cognition Study [27].Persons with prevalent
dementia were identified, and all others were followed until 1999 for the development of 
incident dementia and AD. Since then, CHS participants at the Maryland and Pennsylvania 
centers have remained under ongoing dementia surveillance [28]. The sample for this study 
included all incident cases between 1992 and December 2006. 
FHS is a single-site study that comprises three generations of participants including the 
Original cohort followed since 1948 (n = 5209), [29] and their offspring and spouses of 
the offspring (n = 5124) followed since 1971 [30]. The original cohort has been evaluated 
biennially since 1948, was screened for prevalent dementia in 1974-76 and has been
under surveillance for incident dementia since then [31, 32]. The offspring were examined
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once every 4 years, were screened for prevalent dementia in 1979-1983 and have since
been under surveillance for incident dementia [33, 34]. In order to be consistent with the
sampling frame for the CHS sample, we excluded FHS subjects with a baseline age < 65
years at the time of DNA draw which was in the 1990s. To minimize survival biases persons
who developed dementia prior to the date of DNA draw were treated as prevalent cases
and subsequent events occurring prior to December 2006 were included in the incident 
analyses.
Pathway analysis
As we targeted distinct families within a larger pathway we next conducted a pathway 
analysis, using the SNP Ratio Test (SRT) tool, which allows for the testing of a specific,
‘user defined’ hypothesis [35]. Users can define their own pathways to test. We tested 
each HSP family, namely HSP40, its three subclasses, BAG, CHIP-like, prefoldin and HSP70 
separately. We created 1000 simulation studies to test whether our observed number of 
‘significant’ SNPs superseded what could be expected by chance. According to the principle
of permutation analysis, all original genotypes remain and the phenotypes are randomly
allocated with each simulation before rerunning the association analysis. This deals with
any potential bias due to LD, as the same LD patterns are present in the original analysis
and in each simulation analysis. All SNPs previously selected for the individual SNP analysis
(SNPs within a 100kb window for the flanking region and a cut-off for the R2 0f 0.8 and MAF 
of 0.05) in RS1 were entered in SRT. SRT deals with differences in gene size and number of 
SNPs per gene, by completely discarding the concept ‘gene’. SRT simply counts the number 
of significant SNPs in a defined pathway and divides this by the total number of SNPs in that 
pathway to create a ratio. Significance of the original SNPs is determined by one of three
cut-off p-values, namely 0.05, 0.01 or 0.001. In each simulation analysis SRT deals with LD 
and sizes of genes similar to the original analysis. The p-value is determined by dividing the 
number of simulations that have a more extreme ratio by the total number of simulations
performed. The analysis was adjusted for age and sex. The findings of the SRT analyses were 
compared to a genome-wide pathway analyses published earlier by Hong et al [36].
RESULTS
General characteristics of the discovery population as well as the two samples used to
check the ORs for consistency are shown in Table 1. As expected in all cohorts the cases
are significantly older than controls and there are significantly more women and APOE*4
carriers among them. A summary of all SNPs tested in HSP70 and its co-chaperones in RS1
can be found in the Supplementary Table 1. Of note is that 3 HSP70 genes located on
chromosome 6 have overlapping regions and are taken as 1 Region of Interest (ROI) with 
148 SNPs. Also of note is that the HSPs are currently undergoing a change in nomenclature 
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[37]. In the table are the official gene names and the gene names according to the new
nomenclature. Here we will use the names of the new nomenclature.
Table 1 | General Characteristics for the discovery and cohorts used to test the consistency of effects.
RS1 CHS FHS
Cases Controls Cases Controls Cases Controls
N 462 5238 366 1784 76 730
Age (mean+se) 76 (7) 68 (9) 80 (6) 75 (5) 87 (6) 76 (7)
Female (%) 74 57 53 62 81 57
APOE*4 carrier (%) 45 27 38 24 38 20
RS1: Rotterdam Study; CHS: Cardiovascular Health Study; FHS: Framingham Heart Study
Figure 1 shows the observed versus the expected chi2 of the 12,053 SNPs tested in RS1. The
plot shows some excess of low p-values for the tested SNPs. Supplementary Figure 1a-1c
shows an overview of the p-values in all genes tested in RS1. After adjusting for multiple 
testing by permutation analysis, 8 genes showed suggestive evidence (p-permuted < 0.10) 
for association to AD in RS1 (Table 2). These genes encode four members of the HSP40
family (DNAJA4, DNAJC14, DNAJC17 and DNAJC28), one Prefoldin subunit (PFDN2), one BAG
gene (BAG2) and two HSP70 genes (HSPA5 and HSPA12B). The following SNPs were selected 
for validation of their effects in two independent studies: rs8027394 in DNAJA4, rs1463592
in DNAJC14, rs7915 in DNAJC17, rs7280365 in DNAJC28, rs12118313 in PFDN2, rs7760349 
and rs13213618 in BAG2, rs13294021 in HSPA5 and rs3899452 in HSPA12B. Two SNPs in BAG2 
were selected as both showed independent evidence for association to AD in RS1 when
including all SNPs in the ROI in the model. In the validation phase 2 SNPs were consistent in
direction of ORs across populations (Table 2), with a nominal p-value of the meta-analysis
at or close to a Bonferoni adjusted p-value for significance (0.05/9 = 0.0056). One SNP
(rs1463592) did not surpass the adjustment for multiple testing (DNAJC14; p-value = 0.007). 
Figure 2a shows the Forrest plot of the meta-analysis of PFDN2 rs12118313. The summary 
OR for the SNP rs12118313 is 1.19 (95% CI 1.06-1.33; p-value = 0.003) for the C allele. Though
this SNP is not replicated when considering the p-value corrected for testing multiple SNPs 
< 0.05, findings are consistent across cohorts in terms of effect size and direction. In Figure
2b a regional plot of the SNPs tested in PFDN2 from the original RS1 cohort can be found. 
The figure shows that the p-value was most significant in RS1. Although there are multiple 
marginally associated SNPs in and flanking the PFDN2 gene (see Supplementary Table 2), 
rs12118313 in located in the intron of another gene (ARHGAP30).
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Figure 1 | Observed versus Expected p-value plot for the 12053 SNPs tested in the Rotterdam study
(chi2 are given at the x-axis and y-axis).
In order to evaluate whether there is a joint effect of multiple SNPs in the PFDN2 region 
and elsewhere we next conducted a formal pathway analysis. Table 3 presents the results
for the SRT pathway analysis on the different HSP families in RS1. We chose three cut-off 
p-values for selection of the SNPs in the discovery set (0.05, 0.01, 0.001) as was suggested
in the original paper on the SRT approach. For the prefoldin HSP family we found an effect 
at the higher p-value cut-off (0.01), this effect is explained by 29 SNPs including 3 SNPs 
in ARGHAP30. When excluding the SNPs in ARGHAP30 from the analysis, the p-value for 
the pathway was 0.03, suggesting that there are many prefoldin SNPs with smaller effects 
implicated. We further find nominally significant evidence for a role of the DNAJA and BAG
families of HSPs when applying the smallest p-value cut-off (0.001). For the replication
we used a data mining approach of a genome-wide pathway analysis of 2032 patients
with AD and 5328 controls [36]. The major pathway identified in this paper was related to
intracellular transmembrane protein transport. We used supplementary data to validate our
SRT analyses. The PFDN gene family emerges with different genes (PFDN1, PFDN2, PFDN6) 
with p-values varying from 3.85*10-2 (PFDN6) to 6.80*10-8 (PFND1). A total of 42 SNPs in the 
gene family were associated with marginal p-values < 0.05. There was little support for
the BAG family (best p-value 0.02 for BAG2) nor for the DNAJA family (DNAJA4: p-value =
6.11*10-6). 
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2a | Forrest plot
2b | Regional plot in RS-1
Figure 2 | The meta-analysis of the PFDN2 rs12118313 to AD in the three population-based studies.
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Table 3 | SNP Ratio Test (SRT) pathway analysis results.
HSP family Total # SNPs P = 0.05 P = 0.01 P = 0.001
HSP40 6352 0.72 (279) 0.68 (50) 0.31 (7)
 DNAJA 542 0.62 (13) 0.19 (9)  (7)
 DNAJB 1390 0.49 (70) 0.96 (1) 1.00 (0)
 DNAJC 4420 0.67 (196) 0.56 (40) 1.00 (0)
BAG 517 0.68 (16) 0.20 (10) (9)
CHIPlike 292 1.00 (0) 1.00 (0) 1.00 (0)
Prefoldin 912 0.10 (93)  (29) 0.11 (3)
HSP70 1880 0.78 (94) 0.34 (29) 0.37 (2)
Pathway analysis results of the different HSP families at three different cut-offs for significance (P = 0.05, P = 0.01 and 
P = 0.001). The p-values given in the table depict the chance that the number of SNPs found to be significant at the given 
p-value cut-off is more than expected by chance. In bold are those p-values passing a nominal threshold of significance. In
brackets are the number of SNPs passing the threshold of significance depicted. DNAJA, DNAJB and DNAJC are sub-families
of HSP40.
DISCUSSION
In our study, we did not find significant evidence for a role of the individual SNPs in or directly
flanking the HSP genes. However, in the pathway analysis we found nominally significant
evidence for a joint effect of multiple SNPs in the DNAJA, BAG and prefoldin families. In
this paper we did not adjust for multiple testing of the pathway analysis. Multiple testing 
adjustments on pathway analysis are difficult because many, if not all, pathways are not 
independent of one another. HSP70 cannot function properly without its co-chaperones
and the different groups of co-chaperones compete for association to HSP70. Most other
pathway tools therefore often clump all HSP families together as one huge pathway. As we 
wanted to test specifically which HSP family is the best candidate for association with AD we
decided to divide them in separate, but not independent, pathways. It is therefore arguable
whether or not to adjust for multiple testing in the pathway analysis. We have analyzed 8
pathways for association with AD. Although the HSP pathway was not the major pathway 
implicated in AD in an analysis of 2032 patients with AD and 5328 controls [36], there also
is marginal evidence for the prefoldin family in this study. Specifically, PFDN1, PFDN2 (the 
gene we detected), PFDN6 surface also in this GWAs supporting our findings at the pathway 
level.
PFDN2 showed evidence for association with AD both in the single SNP analysis as in the 
pathway analysis as a part of the prefoldin HSP family. As the single SNP analysis showed 
an association with a SNP in another gene, the findings of the pathway analyses were most
convincing, although the 3 SNPs located in ARGHAP30 have contributed to the p-value, 
these do not explain the association fully. When excluding the 3 SNPs the pathway was
still significant. From a biological perspective, there is no evidence that these 3 SNPs are
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involved in the expression of PFDN2, however we cannot exclude this as this is based on eSNP 
analyses in lymphocytes. PFDN2 is located in a chromosomal region known to be associated
with AD in linkage studies [38] and it is a subunit of the prefoldin complex. Prefoldin is an 
intermediary factor between HSP70 and the TCP-1 ring complex (TRiC). The TRiC complex 
is involved in about 10% of the protein folding in the cytosol. Prefoldin is necessary for the
transport of unfolded proteins to this complex [11]. Prefoldin has also been shown to induce 
in vitro formation of soluble Aβ oligomers similar in size to those found in AD brains [39].
It is speculated that the function of Prefoldin is to prevent aggregation, causing more of 
the highly toxic soluble Aβ oligomers to be present in the brain [39]. Moreover, the PFDN2 
protein has been found to be upregulated in the brains of patients with AD [13]. This makes
the PFDN2 gene a plausible candidate gene for AD.
There is some evidence in our study and the study of Hong et al [36] for a role of DNAJA.
The HSP family DNAJA is a subfamily of the larger HSP40 family. HSP40 has been shown to
reduce aggregate formation in other neurodegenerative diseases [40] and recruits HSP70 
to aggregates [41]. It is required for HSP70 to bind these aggregated proteins and process
them [42]. Genetic variants in HSP40 genes may modify their ability to recruit and guide
HSP70 to aggregates, at least partly explaining their association to AD at the protein level
[5].
The last group of genes we find evidence for association for is the BAG domain protein 
family. A direct physical interaction with HSP70 was shown for all members of the BAG
family [43]. The BAG proteins have therefore been proposed to serve as targeting factors for
HSP70 [44]. However there is little evidence for association of the BAG family to AD in the
paper of Hong et al [36].
Our study has a major advantage since the discovery cohort is embedded within a large, 
population based-study (RS1). Further, the studies used to evaluate the consistency of effects
are also established epidemiological cohorts. We did not reach genome wide significance
in the present study. A limitation in the interpretation of our data is that our findings were
significant in the meta-analysis but did not reach significance in the individual cohorts 
except for in the RS1 cohort. The smaller number of cases in CHS and FHS in combination
with the small effect in terms of OR could explain why the finding was not significant in 
those populations. 
Until now, no large-scale studies have been performed on the role of HSP70 and its co-
chaperone genes in patients with AD. In our genomic study in three population-based 
cohorts, we found evidence suggesting that genetic variants in the prefoldin family are 
associated with the risk of AD. Although larger case-series are needed to achieve genome
wide significance for individual SNPs, combining these data with those of earlier functional
studies makes it likely that this family of genes plays a role in AD.
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Parkinson’s disease (PD) is the most common neurodegenerative movement disorder,
characterized by progressive degeneration of dopaminergic neurons in the substantia
nigra and the presence of Lewy bodies in the affected neurons, comprised of aggregated 
α-synuclein [1-2]. PD can therefore be considered an example of a protein-folding disorder 
[3]. Heat Shock Proteins (HSPs) are the major chaperones mediating (re)folding of proteins, 
ensuring that these proteins stay in their native formations during conditions of stress to
the cell [4]. We tested 27 genes encoding all members of the HSP10, HSP60, HSP70, HSP90 
and the heat shock factors (HSF) families and assessed their association with PD.
Our discovery cohort was the Rotterdam Study (RS), which is a population-based cohort 
study that investigates the occurrence and determinants of diseases in the elderly [5]. The 
Medical Ethics Committee at Erasmus Medical Center approved the study protocol. Genomic
DNA was extracted from whole blood samples using standard methods [6]. Genome-wide
SNP genotyping was performed using Infinium II assay on the HumanHap550 Genotyping 
BeadChips (Illumina Inc, San Diego, USA). Approximately 2 million SNPs were imputed using
release 22 HapMap CEU population as reference. The imputations were performed using 
MACH software (http://www.sph.umich.edu/csg/abecasis/MACH/).
A total 3828 SNPs in 27 genes were initially selected for the association test on the basis
of the following criteria: (1) position within the genes of interest with a margin of 100kb 
on each side of the genes according to NCBI build 36.3, (2) p-value for Hardy-Weinberg
equilibrium test ≥ 0.0001, and (3) call rate ≥ 95%. For further analysis and selection of SNPs 
for replication analysis only SNPs with an imputation quality greater than 80% and a minor
allele frequency (MAF) higher than 0.05 were selected.
We analyzed the individual SNPs using ProbABEL [7]. We used allele-based logistic regression 
to test the association between a single SNP and PD. Odds Ratios (ORs) for each SNP were
derived adjusting for age and sex. To calculate empirical significance for SNPs, permutations
were performed per region of interest (ROI). Briefly, we performed 10,000 replications
with randomly allocated phenotypes. To estimate empirical significance each observed
test statistic was compared with null statistics obtained empirically and the p-value was
estimated as the proportion of replicas generating the test statistics greater than or equal 
to the observed statistic.
For each suggestively associated ROI (p-valuepermuted < 0.10) we next selected the 
‘independently associated’ SNPs in a backward stepwise logistic regression until only
nominally significant SNPs remained in the model. These independently associated SNPs
were then followed up. Further suggestively associated SNPs inside the gene were also 
sent for replication. For replication we used online available genome wide association 
studies (GWAS) on PD and selected the study from Simón-Sánchez et al published in Nature 
Genetics in 2009 [8]. This study included a total of 5,197 PD cases and 8,803 controls. In their 
supplementary tables, the authors present p-values and effect estimates for all SNPs with a
p-value lower than 1*10-4 in the discovery stage. 
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General characteristics of the discovery population are shown in Table 1. A total of 134
cases of Parkinson Disease were identified. The cases are significantly older than controls. 
A summary of all SNPs tested in the HSP genes in the discovery phase can be found in
Supplementary Table 1. As HSP10 (HSPE1) and HSP60 (HSPD1) are located head to head on 
chromosome 2 these were taken as 1 Region of Interest (ROI) with 52 SNPs (Chaperonin).
The same applies to 3 HSP70 genes located on chromosome 6 with 148 SNPs (HSPA1).
Table 1 | General Characteristics for cases and controls in the discovery cohort.
Cases Controls
N 134 5422
Age (mean ± sd) 74.2 ± 8.0 68.5 ± 8.5
Gender (% female) 58.5 53.0
Figure 1 shows an overview of the p-values in all genes tested in RS1. After adjusting for
multiple testing by permutation analysis, 3 genes still showed evidence for assocation to 
PD in RS1. These genes encode Chaperonin, HSP70 member HSPA13 and HSF member HSF5. 
For replication the following SNPs were selected: rs17730989 and rs788016 for Chaperonin,
rs2822686 for HSPA13 and rs9889631 for HSF5. Two SNPs in Chaperonin were selected as
both were intronic SNPs for HSPD1. The results for the SNPs we attempted to replicate are in
Table 2. None of these SNPs had a p-value lower than 1*10-4 in our replication sample. We 
did not find significant evidence for an association between SNPs in or directly flanking the
HSP genes with PD.
Chaperonin was the best candidate for association with PD to reach significance in the
discovery cohort, but none of the SNPs in HSPD1 were replicated. Chaperonin is an interesting
candidate for association with PD as it is the major folding machine of the mitochondria [9].
Its important influence on mitochondrial function is underlined by findings that yeast cells 
carying a null mutation in HSP60 have severe defects in folding of mitochondrial proteins
and are non-viable [10]. In contrast, yeast cells with conditional mutations in HSP60 tend 
to accumulate misfolded proteins that are unable to perform their functions, similar to
α-synculein aggregation in PD [10].
The importance of mitochondrial dysfunction in PD is widely accepted. All major genes 
previously identified for familial PD influence mitochondrial functioning [11]. The
importance of HSPD1 in mitochondrial functioning could be an explanation for the absence 
of an association with PD. Only variants with very small ORs are to be expected in such a 
critical gene, leaving our study underpowered to reach statistical significance.
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In summary, we examined associations between 3828 SNPs in and around 27 genes
encoding the Chaperonin, HSP70, HSP90 and HSF gene families in two unrelated cohorts, 
and found no statistically significant associations with PD. Despite evidence on the protein
level for involvement of these genes, no large-scale studies have been performed on the
role of HSPs in patients with PD, until now.
Figure 1 | The -log(p-values) of all SNPs tested are presented, where the SNPs are sorted on the genes 
on x-axis. The horizontal lines show the -log(p-values) of 0.05, 0.01 and 0.001 respectively.
Table 2 | Association of the SNPs significantly associated with PD in the Rotterdam Study.
Rotterdam Study Simón-Sánchez et al.
Gene SNP Chr Position RA Freq OR 95% CI Freq OR 95% CI
HSPD1 rs17730989 2 198070769 C 0.49 0.67 0.52-0.86 NF NF NF
HSPD1 rs788016 2 198060538 G 0.49 0.68 0.53-0.87 NF NF NF
HSPA13 rs2822686 21 14773971 T 0.82 0.61 0.46-0.8 NF NF NF
HSF5 rs9889631 17 53985358 T 0.93 0.55 0.37-0.81 NF NF NF
RS1: Rotterdam study; Chr: chromosome; RA: risk allele; Freq: frequency; OR: Odds Ratio; 95% CI: 95% Confidence Interval;
NF: not found with a p-value of 10-4.
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ABSTRACT
Experimental mild heat shock is widely known as an intervention that results in extended
longevity in various models along the evolutionary lineage. Heat shock proteins (HSPs), are 
highly up-regulated immediately after a heat shock. The elevation in HSP levels was shown
to inhibit stress-mediated cell death and recent experiments indicate a highly versatile role
for these proteins as inhibitors of programmed cell death.
In this study, we examined common genetic variations in 31 genes encoding all members of 
the HSP70, small HSP (sHSP) and Heat Shock Factor (HSF) families for their association with 
all-cause mortality. Our discovery cohort was the Rotterdam Study (RS1) containing 5974 
participants aged 55 years and older (3174 deaths). We assessed 4430 Single Nucleotide
Polymorphisms (SNPs) using the HumanHap550K Genotyping BeadChip from Illumina.
After adjusting for multiple testing by permutation analysis, 3 SNPs showed evidence for
association with all-cause mortality in RS1. These findings were followed in 8 independent 
population-based cohorts, leading to a total of 25007 participants (8444 deaths). In the
replication phase only HSF2 (rs1416733) remained significantly associated with all-cause
mortality. Rs1416733 is a known cis-eQTL for HSF2.
Our findings suggest a role of HSF2 in all-cause mortality.
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INTRODUCTION
Experimental mild heat shock is widely known as an intervention that results in extended
longevity [1]. Brief exposure to elevated heat resulted in a 15% increase in the mean life 
span of Caenorhabditis elegans, compared to non heat-shocked controls [1-3]. Similar 
effects have also been seen in Drosophila melanogaster [4-5], in yeast [6] and in cultured 
human cells [7]. In the early 1960s a group of proteins, now known as heat shock proteins 
(HSPs), were discovered, which were highly up-regulated immediately after a heat shock 
[8-9]. Whether HSPs are responsible for longevity is still under debate, as their levels are 
only elevated for a short period of time after a heat shock [10]. However, the elevation in
HSP levels during the heat shock response was shown to inhibit stress-mediated cell death,
and recent experiments indicate a highly versatile role for these proteins as inhibitors of 
programmed cell death [11].
HSPs can be subdivided in several smaller families, including HSP90, HSP70, HSP60, HSP40, 
small HSP (sHSP) and HSP10 [12]. From these families, HSP70 and sHSPs show an association
with longevity. In C. elegans extra copies of a homolog of HSPA9 (member of HSP70),
otherwise known as mortalin, extended life span up to 45% [13]. In humans decreased 
serum levels of HSP70 have been associated with exceptional longevity (95+) [14]. However, 
the same study evaluated 2 Single Nucleotide Polymorphisms (SNPs) in HSPA1A and HSPA1B
which were not found to be associated to exceptional longevity [14].
The over-expression of members of the sHSP family has been shown to extend life of C. 
elegans and D. melanogaster by up to 32% [15-16]. Conversely, the absence of expression of 
a sHSP member decreases lifespan of D. melanogaster by 40% [17].
HSP expression is regulated by a group of transcription factors known as heat shock factors 
(HSFs), of which HSF1 is considered to be the master-switch of HSP expression [18]. Strong
evidence exists for a highly important role for HSF1 in longevity. Reduced activity of HSF1 
in C. elegans leads to a rapid aging phenotype with a markedly reduced lifespan of 60%
[19]. Conversely, animals with an additional HSF1 gene copy lived approximately 40%
longer than normal [20]. A strong relationship was found between HSF1 and DAF-16, which
functions in the C. elegans insulin/IGF-1 signaling pathway [20]. Both genes were shown to 
function, at least in part, by increasing sHSP gene expression [20].
We have tested 31 genes encoding all members of the HSP70, sHSP and HSF families and
assessed their association with all-cause mortality. To our knowledge, this is the first large-
scale candidate gene study of these HSPs and their association to all-cause mortality to be
performed.
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METHODS
Discovery Study
Our discovery cohort was the Rotterdam Study (RS1). RS1 is a population-based cohort 
study that investigates the occurrence and determinants of diseases in the elderly [21]. 
Baseline examinations, including a detailed questionnaire, physical examination and blood
collection, were conducted between 1990 and 1993. The Medical Ethics Committee at
Erasmus Medical Center approved the study protocol. All of the participants were followed
for incident diseases through linkage to the general practitioner data base and record review 
by trained medical investigators. General practitioners’, hospital records as well as death 
certificates were used for identification of deaths (all-cause mortality) through 01.01.2009.
Genomic DNA was extracted from whole blood samples using standard methods [22]. 
Genome-wide SNP genotyping was performed using Infinium II assay on the HumanHap550
Genotyping BeadChips (Illumina Inc, San Diego, USA). Approximately 2 million SNPs were
imputed using release 22 HapMap CEU population as reference. The imputations were 
performed using MACH software (http://www.sph.umich.edu/csg/abecasis/MACH/). The 
quality of imputations were checked by contrasting imputed and actual genotypes at
78,844 SNPs not present on Illumina 550K for 437 individuals for whom these SNPs were 
directly typed using Affymetrix 500K. Using the “best guess” genotype for imputed SNPs
the concordance rate was 99% for SNPs with R2 (ratio of the variance of imputed genotypes
to the binomial variance) quality measure greater than 0.9; concordance was still over 90%
(94%) when R2 was between 0.5 and 0.9. The GWAS of all-cause mortality has been analyzed
and is published elsewhere [23].
For the study of HSPs presented here, a total of 4430 SNPs in 31 genes were initially selected
for the association test on the basis of the following criteria: (1) position within the genes 
of interest with a margin of 100kb on each side of the genes according to NCBI build 36.3,
(2) P-value for Hardy-Weinberg equilibrium test ≥ 0.0001, and (3) call rate ≥ 95%. For further
analysis and selection of SNPs for replication analysis only SNPs with a R2 higher than 0.8
and a minor allele frequency (MAF) higher than 0.05 were selected.
Analysis
We performed single SNP analyses using ProbABEL [24]. We used survival analysis (semi-
parametric Cox proportional hazard model), adjusted for age at DNA blood collection and 
for sex, to model continuous time to death in individuals that were older than 55 years 
at baseline. To calculate empirical significance for SNPs, permutations were performed
per region of interest (ROI) [25-26]. Briefly, the empirical distribution of the region-wide 
maximum of the test statistic under the null was obtained in 10,000 replications. To estimate 
empirical significance each observed test statistic was compared with null statistics obtained
empirically and the p-value was estimated as the proportion of replicas generating the test 
statistics greater than or equal to the observed statistic. The permutation analysis keeps 
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the original genotypes for each individual, but randomly allocates the phenotypes for each 
consecutive permutation. Therefore the linkage disequilibrium (LD) structure of genes is 
not broken up. We did not perform any additional correction for the number of ROIs after 
permutations as we used the permutation analysis to significantly reduce the number of 
SNPs to be selected for validation of the effect of the SNP. For each suggestively associated
ROI (p-valuepermuted < 0.10) we next selected the ‘truly associated’ SNPs in a backward 
stepwise survival analysis until only nominally significant SNPs remained in the model. These 
independently associated SNPs were then followed up in 8 independent cohorts. As effect
estimates are expected to be small, a strict replication based on the p-value and hazard ratio 
(HR) observed in individual replication studies, might be difficult to achieve due to power 
issues. Therefore we evaluated whether a SNP was showing a HR in the same direction in all
cohorts, i.e., whether findings were consistent over the various cohorts. Similar to genome
wide association studies, we performed a joint meta-analysis of the discovery and the
replication samples and tested whether the joint p-value was significant using a Bonferroni
correction for the number of SNPs validated in the replication phase.
We used 4 studies that are part of the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium [27] plus an additional 4 associated cohorts to evaluate
whether findings were consistent. The studies included in this replication are: Cardiovascular
Health Study (CHS); Framingham Heart Study (FHS); Atherosclerosis Risk Communities 
Study (ARIC); Age, Gene/Environment Susceptibility -Reykjavik Study (AGES); Health, Aging 
and Body Composition (HABC); Baltimore Longitudinal Study of Ageing (BLSA); InCHIANTI
(ICH); and Study of Health in Pomerania (SHIP). All studies are longitudinal population-
based studies periodically assessing the health and vital status of their participants. All
participants included in this analysis were at least 55 years of age at the time of blood draw
for DNA and provided written informed consent. Detailed information on the replication
studies can be found in the supplement.
RESULTS
General characteristics of the discovery cohort as well as the 8 replication cohorts are shown 
in Table 1. In the discovery cohort there were 3174 deaths with a mean age at death of 83.2 
and mean follow-up of 12.5 years. In RS1 and replications combined there were 8444 deaths
with a mean age at death of 81.1. The mean follow-up time ranged from 5.2 to 15.7 years. A 
summary of all SNPs tested in the HSP genes in RS1 can be found in Supplementary Table
1. Three HSP70 genes are located head to head on chromosome 6 and are taken as one 
ROI with 148 SNPs (HSPA1). Similarly, 2 sHSP genes on chromosome 11 with 66 SNPs were
located nearby each other and taken as one ROI (ROIchr11). Also of note is that the HSPs
are currently undergoing a change in nomenclature [12]. Supplementary Table 1 provides
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both the official gene names and the gene names according to the new nomenclature. Here
we will use the aliases from the new nomenclature.
Table 1 | General characteristics.
Study N N deceased Mean age at
Baseline (±SD)
Mean age at
death (±SD)
Sex,
% female
Mean follow-up
time in years (±SD)
RS1 5974 3174 69.4 (9.1) 83.2 (8.3) 59% 12.5 (5.2)
CHS 3267 1718 72.3 (5.4) 83.4 (6.3) 61% 12.3 (4.2)
FHS 3136 654 70.0 (10.2) 83.0 (9.3) 56% 6.0 (2.4)
ARIC 4511 1108 59.4 (2.9) 71.3 (5.4) 50% 15.7 (3.7)
AGES 3219 558 76.4 (5.5) 79.3 (5.9) 58% 5.2 (1.3)
HABC 1661 460 73.8 (2.8) 80.4 (3.7) 47% 8.2 (2.3)
BLSA 620 183 62.0 (8.8) 86.8 (8.0) 41% 15.7 (8.2)
InCHIANTI 902 183 72.5 (7.7) 85.4 (7.9) 56% 5.9 (0.9)
SHIP 1717 406 66.4 (7.2) 76.9 (7.2) 47% 9.2 (2.4)
TOTAL 25007 8444 69.0 (8.9) 81.1 (8.4) 55% 10.6 (5.4)
Figures 1 A-C illustrate the observed versus the expected chi2 of the SNPs tested in the
different HSP gene families in RS1. The plots show an excess of low p-values for tested
SNPs in sHSP (1B) and HSF (1C), but not for HSP70 (1A). Supplementary Figure 1 shows
an overview of the p-values in all HSP70, sHSP and HSF genes tested in RS1. After adjusting
for multiple testing by permutation analysis, 3 genes showed evidence for association to
mortality in RS1. These genes encode HSP70 member HSPA8, sHSP member HSPB1 and HSF
member HSF2. Table 2 shows the 3 SNPs that were selected for replication. In the replication
phase only one SNP reached a Bonferroni adjusted p-value for significance (0.05/3 = 0.017).
Figure 2A shows the Forest plot of the meta-analysis of HSF2 rs1416733. The direction of 
effect was consistent across populations with only one study (HABC) showing an opposite 
HR. The summary HR for this SNP was 0.95 (95% CI 0.92-0.98; p-value = 0.003) for the A allele.
When excluding the discovery cohort from the meta-analysis, the HR remained virtually 
unchanged (0.97: CI 0.93-1.00). In Figure 2B a regional plot of all SNPs tested in HSF2 from
the original RS1 cohort can be found. In the plot we can see that rs1416733 is located 11.7 
Kb from the 5’ region of the HSF2 gene, with no other genes nearby.
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Figure 1 | Observed versus Expected p-value plot for the SNPs tested in the Rotterdam study (chi2 are
given at the x-axis and y-axis) A. HSP70; B. sHSP; C. HSF 
Legend: black line depicts the expected findings, red line the observed ones
2A | Forrest plot
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2B | Regional plot in RS1
Figure 2 | The meta-analysis of the HSF2 rs1416733 SNP in the 9 population cohorts.
DISCUSSION
In our study, we found a significant association between HSF2 and all-cause mortality. The
top associated variant, rs1416733, is located 11.7 Kb from the 5’ region of the HSF2 gene on
chromosome 6 and is a known cis-eQTL for HSF2 [28]. Each additional copy of the A allele
for SNP rs1416733 increased lifespan with a HR of 0.95 in a meta-analysis of 9 independent
cohort studies. This effect was consistent in direction in 8 out of 9 cohorts.
The HSF family, like most HSP families, is a highly conserved family across species, indicating 
a vital role for the survival of the respective organism [29]. Unlike many other HSP families,
there is virtually no redundancy in the HSF family, with HSF1 as the most crucial family
member [18]. The importance of HSF1 is advocated strongly by the large effects of genetic
mutations in this gene on longevity in C. elegans [19-20]. These large effects are not 
anticipated in human research, which could explain why we find no evidence for association
of SNPs in HSF1 with all-cause mortality [23]. HSF2 is less known in longevity research. It 
has previously been mainly described for its role as a development- and differentiation-
specific factor [30-31]. The role of HSF2 in later life has remained unknown for a long time
[32]. Recently evidence is emerging to suggest that HSF2 modulates HSF1 activity [18]. It
has been shown that HSF2 activation leads to activation of HSF1, revealing a functional
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interdependency [33]. It has been proposed that heterotrimerization of HSF1 and HSF2
integrates transcriptional activation in response to distinct stress and developmental 
stimuli [33]. Additionally, though HSF2 was never considered to be heat-inducible, a recent
study shows that a mild heat-shock in the physiological range does activate HSF2 and has a 
significant impact on the proteostasis of the cell [34].
We found no evidence for association of HSP70 with all-cause mortality. HSP70 is the only
HSP family for which SNPs in a couple of genes have been studied for longevity in humans
previously. However, these studies only studied 2 or 3 SNPs and only in the heat-inducible
members of HSP70, namely HSPA1A, HSPA1B and HSPA1L, all located on chromosome 6 [14,
35-36]. In our study no association was found for these 3 genes with longevity. We add a
more thorough investigation of these genes and the other HSP70 genes by extensively
covering common variance.
The sHSPs have been named most often in animal studies for their relationship with 
longevity [15-17]. However, we find no significant associations for single SNPs in these
genes. Off course, what we find in animal studies doesn’t always translate well to humans.
For example, though genetic variations in IGF-1 signaling have been found in humans, they 
don’t have nearly as strong effects on longevity as in animal models [37]ÿÿÿÿÿÿT. Another
study has found that mutations in HSF1 lead to up-regulated sHSP expression in C. elegans
[20]. We cannot exclude that genetic variation in HSF2 activates a similar mechanism in 
humans, through its effect on HSF1.
Our study has a major advantage since the discovery cohort – the Rotterdam Study – is a
large, population based-study. Further, the eight replication cohorts are also relatively large,
established population-based epidemiological cohorts. A limitation in the interpretation
of our data is that our findings were significant in the meta-analysis but did not reach
significance in the individual cohorts except for the RS1 cohort; however a total of eight 
out of nine studies showed an effect in the same direction for HSF2. This could be explained
by the markedly smaller percentage of deaths in most replication cohorts (except CHS)
compared to the discovery cohort. The number of deceased is critical for the statistical
power of the study. Even though some of these studies had a longer mean follow-up time
(ARIC and BLSA), the population in these studies were on average younger at baseline
compared to RS1, which explains the fewer number of deaths and leaves the individual
replication studies underpowered to identify rs1416733.
Until now, no large-scale studies have been performed investigating the role of HSP70,
sHSP or HSF genes in all-cause mortality in humans. In our candidate gene study in nine 
population-based cohorts, we found significant evidence suggesting that genetic variants
in HSF2 are associated with all-cause mortality. Combining these data with those of earlier 
functional studies, in particular in C. elegans, makes it likely that HSF2 plays a role in human
all-cause mortality.
87Association of Heat Shock Proteins with all-cause mortality |
3
REFERENCES
1. Cypser, J. and T.E. Johnson, Hormesis extends the correlation between stress resistance and life span 
in long-lived mutants of Caenorhabditis elegans. Hum Exp Toxicol, 2001. 20(6): p. 295-6; discussion 
319-20.
2. Cypser, J.R. and T.E. Johnson, Multiple stressors in Caenorhabditis elegans induce stress hormesis and
extended longevity. J Gerontol A Biol Sci Med Sci, 2002. 57(3): p. B109-14.
3. Lithgow, G.J., et al., Thermotolerance and extended life-span conferred by single-gene mutations and 
induced by thermal stress. Proc Natl Acad Sci U S A, 1995. 92(16): p. 7540-4.
4. Hercus, M.J., V. Loeschcke, and S.I. Rattan, Lifespan extension of Drosophila melanogaster through 
hormesis by repeated mild heat stress. Biogerontology, 2003. 4(3): p. 149-56.
5. Le Bourg, E., et al., Effects of mild heat shocks at young age on aging and longevity in Drosophila 
melanogaster. Biogerontology, 2001. 2(3): p. 155-64.
6. Shama, S., et al., Heat stress-induced life span extension in yeast. Exp Cell Res, 1998. 245(2): p. 379-88.
7. Rattan, S.I., Repeated mild heat shock delays ageing in cultured human skin fibroblasts. Biochem Mol 
Biol Int, 1998. 45(4): p. 753-9.
8. Ritossa, F., A new puffing pattern induced by heat shock and DNP in Drosophila. Cellular and molecular 
life sciences, 1962. 18: p. 571.
9. Ritossa, F., Discovery of the heat shock response. Cell Stress Chaperones, 1996. 1(2): p. 97-8.
10. Link, C.D., et al., Direct observation of stress response in Caenorhabditis elegans using a reporter 
transgene. Cell Stress Chaperones, 1999. 4(4): p. 235-42.
11. Garrido, C., et al., Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties.
Cell Cycle, 2006. 5(22): p. 2592-601.
12. Kampinga, H.H., et al., Guidelines for the nomenclature of the human heat shock proteins. Cell Stress 
Chaperones, 2009. 14(1): p. 105-11.
13. Yokoyama, K., et al., Extended longevity of Caenorhabditis elegans by knocking in extra copies of 
hsp70F, a homolog of mot-2 (mortalin)/mthsp70/Grp75. FEBS Lett, 2002. 516(1-3): p. 53-7.
14. Terry, D.F., et al., Serum heat shock protein 70 level as a biomarker of exceptional longevity. Mech 
Ageing Dev, 2006. 127(11): p. 862-8.
15. Morrow, G., et al., Overexpression of the small mitochondrial Hsp22 extends Drosophila life span and
increases resistance to oxidative stress. FASEB J, 2004. 18(3): p. 598-9.
16. Walker, G.A., et al., Heat shock protein accumulation is upregulated in a long-lived mutant of 
Caenorhabditis elegans. J Gerontol A Biol Sci Med Sci, 2001. 56(7): p. B281-7.
17. Morrow, G., et al., Decreased lifespan in the absence of expression of the mitochondrial small heat 
shock protein Hsp22 in Drosophila. J Biol Chem, 2004. 279(42): p. 43382-5.
18. Akerfelt, M., R.I. Morimoto, and L. Sistonen, Heat shock factors: integrators of cell stress, development 
and lifespan. Nat Rev Mol Cell Biol, 2010. 11(8): p. 545-55.
19. Garigan, D., et al., Genetic analysis of tissue aging in Caenorhabditis elegans: a role for heat-shock 
factor and bacterial proliferation. Genetics, 2002. 161(3): p. 1101-12.
20. Hsu, A.L., C.T. Murphy, and C. Kenyon, Regulation of aging and age-related disease by DAF-16 and 
heat-shock factor. Science, 2003. 300(5622): p. 1142-5.
21. Hofman, A., et al., The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol, 2011.
26(8): p. 657-86.
22. Miller, S.A., D.D. Dykes, and H.F. Polesky, A simple salting out procedure for extracting DNA from human 
nucleated cells. Nucleic Acids Res, 1988. 16(3): p. 1215.
23. Walter, S., et al., A genome-wide association study of aging. Neurobiol Aging, 2011. 32(11): p. 2109 
e15-28.
88 | Chapter 3.3
24. Aulchenko, Y.S., M.V. Struchalin, and C.M. van Duijn, ProbABEL package for genome-wide association
analysis of imputed data. BMC Bioinformatics, 2010. 11: p. 134.
25. Churchill, G.A. and R.W. Doerge, Empirical threshold values for quantitative trait mapping. Genetics, 
1994. 138(3): p. 963-71.
26. Fisher, R., The Design of Experiments. 3 ed. Vol. 3. 1935, London: Oliver & Boyd Ltd. 252.
27. Psaty, B.M., et al., Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts.
Circ Cardiovasc Genet, 2009. 2(1): p. 73-80.
28. Zeller, T., et al., Genetics and beyond--the transcriptome of human monocytes and disease susceptibility.
PLoS One, 2010. 5(5): p. e10693.
29. Liu, X.D., et al., Conservation of a stress response: human heat shock transcription factors functionally 
substitute for yeast HSF. EMBO J, 1997. 16(21): p. 6466-77.
30. Kallio, M., et al., Brain abnormalities, defective meiotic chromosome synapsis and female subfertility in
HSF2 null mice. EMBO J, 2002. 21(11): p. 2591-601.
31. Wang, G., et al., Targeted disruption of the heat shock transcription factor (hsf )-2 gene results in
increased embryonic lethality, neuronal defects, and reduced spermatogenesis. Genesis, 2003. 36(1):
p. 48-61.
32. Wu, C., Heat shock transcription factors: structure and regulation. Annu Rev Cell Dev Biol, 1995. 11: p.
441-69.
33. Sandqvist, A., et al., Heterotrimerization of heat-shock factors 1 and 2 provides a transcriptional switch 
in response to distinct stimuli. Mol Biol Cell, 2009. 20(5): p. 1340-7.
34. Shinkawa, T., et al., Heat shock factor 2 is required for maintaining proteostasis against febrile-range
thermal stress and polyglutamine aggregation. Mol Biol Cell, 2011. 22(19): p. 3571-83.
35. Altomare, K., et al., The allele (A)(-110) in the promoter region of the HSP70-1 gene is unfavorable to
longevity in women. Biogerontology, 2003. 4(4): p. 215-20.
36. Ross, O.A., et al., Increased frequency of the 2437T allele of the heat shock protein 70-Hom gene in an 
aged Irish population. Exp Gerontol, 2003. 38(5): p. 561-5.
37. Kuningas, M., et al., Genes encoding longevity: from model organisms to humans. Aging Cell, 2008.
7(2): p. 270-80.
4C h a p t e r
The role of telomere length in  
morbidity and mortality

4.1C h a p t e r 
Meta-analysis of telomere length in 
19,713 subjects reveals high heritability, 
stronger maternal inheritance and a 
paternal age effect
Linda Broer, Veryan Codd, Dale R Nyholt, Joris Deelen, Massimo Mangino, 
Gonneke Willemsen, Eva Albrecht, Najaf Amin, Marian Beekman,  
Eco JC de Geus, Anjali Henders, Christopher P Nelson, Claire J Steves,  
Margie J Wright, Anton JM de Craen, Aaron Isaacs, Mary Matthews,  
Alireza Moayyeri, Grant W Montgomery, Ben A Oostra, Jacqueline M Vink,  
Tim D Spector, P. Eline Slagboom, Nicholas G Martin, Nilesh J Samani,  
Cornelia M van Duijn, Dorret I Boomsma
Published: European Journal of Human Genetics; 2013
92 | Chapter 4.1
ABSTRACT
Telomere length (TL) has been associated with ageing and mortality, but individual
differences also are influenced by genetic factors with previous studies reporting heritability
estimates ranging from 34% to 82%.
Here we investigate the heritability, mode of inheritance and the influence of parental age
at birth on TL in six large, independent cohort studies with a total of 19,713 participants. 
The meta-analysis estimate of TL heritability was 0.70 (95% CI 0.64 - 0.76) and is based on a 
pattern of results that is highly similar for twins and other family members. We observed a 
stronger mother-offspring (r = 0.42; p-value = 3.6*10-61) than father-offspring correlation (r = 
0.33; p-value = 7.0*10-5), and a significant positive association with paternal age at offspring
birth (beta = 0.005; p-value = 7.0*10-5). Interestingly, a significant and quite substantial 
correlation in TL between spouses (r = 0.25; p-value = 2.8*10-30) was seen, which appeared
stronger in older spouse pairs (mean age ≥ 55 years; r = 0.31; p-value = 4.3*10-23) than in
younger pairs (mean age < 55 years; r = 0.20; p-value = 3.2*10-10).
In summary, we find a high and very consistent heritability estimate for telomere length, 
evidence for a maternal inheritance component and a positive association with paternal 
age.
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INTRODUCTION
Telomeres are specialized DNA structures located at the terminal ends of chromosomes
[1]. Their primary function is to maintain genomic stability. Due to the inability of DNA
polymerase to fully replicate the 3’ end of the DNA strand, i.e. the ‘end-replication
problem’, telomeres naturally shorten with each cell division and, therefore, with age [2-
4]. In epidemiological studies, both of cross sectional and prospective design, decreased 
telomere length in leukocytes was associated with increased mortality [5-8], although 
this finding was not consistent [9, 10]. Increased telomere length in leukocytes has been
associated with longevity in a comparison of long-lived Ashkenazi Jews and their offspring
with younger controls [11]. Genetic association studies have revealed associations between
single nucleotide polymorphisms (SNPs) in the TERC and TERT genes and telomere length 
[11-17]. Other studies reported associations between SNPs in TERC and POT1 with human
longevity [11, 17, 18], suggesting that genes regulating telomere length may influence 
human longevity.
That genetic variants would be found associated with telomere length was expected from
earlier twin and family studies indicating genetic influence on telomere length. An early
study in twins of different ages showed a heritability of 78% for telomere length in 4-, 17-
and 44-year olds [4], with no evidence for genotype x age interaction in this age range. In
older twins (N = 287 pairs aged 73 to 95 years) estimates for heritability were 34% in women,
while for the smaller male sample the heritability was lower [19]. In a sample of 55 female
monozygotic (MZ) and 1,025 dizygotic (DZ) middle-aged twin pairs, Andrew et al reported 
a heritability estimate of 36% and an unexpectedly large shared familial effect of 49% [20]. 
Another study comprising 258 sib-pairs returned a heritability estimate of 82% [21]. There is 
a need to reconcile these divergent estimates, which might in part be caused by differences 
in sample composition or telomere length assessments [22]. A remaining question that
also needs to be addressed is the extent to which estimates of heritability based on twin
data are comparable to those based on other relatives such as parents and offspring from
multigenerational studies or non-twin sibling-pairs.
Several studies have been conducted to assess the potential mechanisms for telomere
inheritance. An early study suggested that telomere length was maternally inherited
via an X-linked mechanism [23]. However, an increasing number of larger studies have
reported stronger father-offspring than mother-offspring correlations for telomere length,
suggesting the inheritance of this trait is mainly paternally determined [8, 24-26]. In addition
to a paternal pattern of inheritance, a positive correlation between offspring telomere
length and paternal age at birth has been observed [24, 27, 28]. Unlike somatic cells, sperm
cell telomere length has been shown to increase with the age of the donor [24, 29] due to 
the presence of active telomerase, suggesting that offspring of older fathers would inherit
longer telomeres.
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In the current study, we investigated the heritability, mode of inheritance and influence
of parental age at birth on telomere length in six large, independent cohort studies with a 
total of 19,713 participants.
MATERIALS AND METHODS
Populations
The Erasmus Rucphen Family (ERF) study is a cross-sectional cohort including more
than 3,000 living descendants of 22 couples who had at least 6 children baptized in the
community church between 1850 and 1900. The participants were not selected on the basis
of any disease or other outcome. Details about the genealogy of the population have been 
previously described [30, 31]. The study protocol was approved by the medical ethics board 
of the Erasmus MC Rotterdam, the Netherlands.
The GRAPHIC study is comprised of individuals from 520 white Caucasian nuclear families 
recruited from the general population in Leicestershire, UK, between 2003 and 2005, for
the purpose of investigating the genetic determinants of blood pressure and related
cardiovascular traits. Inclusion criteria were that both parents (aged 40-60 years) and two
offspring ≥ 18 years were willing to participate. Further details are provided elsewhere [32].
For the Leiden Longevity Study (LLS), long-lived siblings of Dutch descent were recruited
together with their offspring and the partners of the offspring. Families were included if at 
least two long-lived siblings were alive and fulfilled the age criterion of 89 years or older for
males and 91 years or older for females, representing less than 0.5% of the Dutch population
in 2001 [33]. In total, 944 long-lived proband siblings were included with a mean age of 94
years (range, 89-104), 1,671 offspring (61 years, 39-81), and 744 partners (60 years, 36-79).
For this study only the offspring and their partners were included.
The Netherlands Twin Register (NTR: http://www.tweelingenregister.org/) recruits twins
and their family members to study the causes of individual differences in health, behavior 
and lifestyle. Participants are followed longitudinally; details about the cohort have been
published previously [34]. A subsample of unselected twins and their family members has
taken part in the NTR-Biobank [35] in which biological samples, including DNA and RNA, 
were collected in a standardized manner after overnight fasting. Study protocols were
approved by the medical ethics board of the VUMC Amsterdam, the Netherlands.
The Queensland Institute of Medical Research (QIMR) adolescent study comprised twins 
and their non-twin siblings living in south-east Queensland, Australia [36]. Most (98% by
self-report) are of mixed European ancestry, mainly from the British Isles. The participants 
are not selected on the basis of any disease or other outcome. Blood samples were collected
at the end of testing sessions from participants and, if possible, from their parents. Pedigree
relationships and zygosity were confirmed by genotype data. Further details are provided 
elsewhere [37].
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The TwinsUK cohort (www.twinsuk.ac.uk) is an adult twin British registry shown to be
representative of singleton populations and the United Kingdom population [38]. A total 
of 6,038 twins with telomere length measurement were included in the analysis. The age
range of the TwinsUK cohort was 16-99. Ethical approval was obtained from the Guy’s and 
St. Thomas’ Hospital Ethics /':Committee. Written informed consent was obtained from 
every participant in the study.
Telomere length assessment
All samples from all studies were measured in the same laboratory under standard
conditions. Mean leukocyte telomere length was measured by quantitative PCR-based 
technique as previously described [12, 39]. This method expresses telomere length as a 
ratio (T/S) of telomere repeat length (T) to copy number of a single copy gene, 36B4(S),
within each sample. Samples were quantified relative to a calibrator sample used on each
run (DNA from the K562 cell line) [12]. Mean inter-run coefficient of variations (CVs) were 
calculated for all study cohorts and these ranged from 3.30-3.72%.
Analysis
To summarize resemblance between family members, correlations of telomere length
between monozygotic (MZ) and dizygotic (DZ) twins, non-twin siblings, parents and
offspring and between spouses, adjusting for age, gender and potential batch effects were
calculated in R, version 2.12.1 [40]. If data on more than two siblings were available, the data
from the oldest two non-twin siblings were analyzed. 
Maximum likelihood analyses as implemented in POLY [41] was used to evaluate different 
models of familial resemblance and these analyses were based on all data (i.e. allowing
for more than 2 siblings per family). In these analyses telomere length was adjusted for
age, gender and batch by specifying these as fixed effects on telomere length. Data from 
the six cohorts were first analyzed individually followed by meta-analysis, whereby each 
cohort took into account the unique structure in the data, such as the highly complex
pedigree structure in the ERF cohort. In those studies where the pedigree structure allowed
for evaluating sub models that included an additive genetic variance component, a non-
additive genetic variance component (dominance) or a sibling-shared environment variance
component respectively, were compared. A model in which variance was partitioned into
an additive genetic variance component and a random environmental variance component 
gave the best description of all data and heritability was estimated based on this model.
In order to investigate differences between maternal or paternal inheritance for telomere
length, family trios or duos were selected. When data on two or more children were
available, data from the oldest child were selected for this analysis. We assessed the age, 
gender and batch adjusted correlations between fathers and their offspring and mothers 
and their offspring. 
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Paternal and maternal ages at the birth of their children were obtained based on the date 
of birth of the parents and offspring if available, or by subtracting the child’s age from the 
parental age. The association of paternal and maternal age with telomere length were 
compared by regressing telomere length on parental age in addition to own age and
gender (e.g. telomere length ~ age + gender + parental age). In order to correct significance
testing for familial dependencies, these analyses were also done in POLY. Meta-analyses 
were performed using the R package rmeta [42]. 
RESULTS
General characteristics of each cohort are described in Table 1. The mean age ranged from 
27.9 (QIMR) to 59.2 (LLS). Overall, approximately half of the participants are female in each 
population. Three cohorts (NTR, QIMR and TwinsUK) had twin data, with NTR and TwinsUK 
having more MZ twins and QIMR more DZ twins. As expected telomere length showed a
significant negative association with age and was significantly longer in women in each
population (Supplementary Table 1). 
Table 1 | General characteristics of the study populations.
ERF GRAPHIC LLS NTR QIMR TwinsUK
Sample size 2,769 2,011 2,322 4,550 2,025 6,036
Telomere length# 1.78 (0.36) 1.60 (0.26) 1.46 (0.27) 2.75 (0.48) 3.41 (0.61) 3.72 (0.68)
Age# 49.8 (14.9) 39.3 (14.5) 59.2 (6.8) 38.8 (14.1) 27.9 (15.6) 51.1 (13.5)
Age range 17-89 18-61 30-80 15-82 7-73 16-99
Women* 1,539 (55.6%) 995 (49.5%) 1,272 (54.8%) 2,951 (64.9%) 1,075 (53.1%) 5,461 (90.5%)
MZ twins* NA NA NA 834 (36.7%) 154 (15.2%) 1,546 (51.2%)
DZ twins* NA NA NA 689 (30.3%) 227 (22.4%) 1,256 (41.6%)
# Mean (sd); * n (%); complete twin pairs are depicted, representing the percentage of total population with telomere length 
measurements
MZ twins were significantly more alike than DZ twins (p-value = 1.85*10-24, Table 2) and 
siblings were significantly correlated within each cohort and this correlation was very 
similar to that of DZ twins (Table 2). Spouses had significantly correlated telomere lengths
(r = 0.25; p-value = 2.82*10-30) and this effect was more pronounced in older spouses (mean
age ≥ 55 years) compared to younger spouses (mean age < 55 years) (p-value = 0.010; Table
2) suggesting that there is a significant influence of environmental factors.
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Table 2 | Sibling, twin and spousal correlations, adjusted for age, gender and batch effects.
n r p-value
Siblings
 ERF 444 0.48 5.20*10-27
 GRAPHIC 481 0.60 4.76*10-49
 LLS 419 0.41 5.30*10-18
 NTR 47 0.43 0.003
 QIMR 162 0.32 3.84*10-5
 TwinsUK NA NA NA
 Meta-analysis 1,553 0.49 3.46*10-96
Monozygotic twins
 ERF NA NA NA
 GRAPHIC NA NA NA
 LLS NA NA NA
 NTR 834 0.62 7.70*10-90
 QIMR 154 0.70 3.17*10-24
 TwinsUK 1,546 0.72 1.93*10-245
 Meta-analysis 2,534 0.69 0*
Dizygotic twins
 ERF NA NA NA
 GRAPHIC NA NA NA
 LLS NA NA NA
 NTR 689 0.34 2.01*10-20
 QIMR 227 0.57 4.96*10-21
 TwinsUK 1,256 0.57 5.21*10-110
 Meta-analysis 2,172 0.50 1.24*10-146
Spouses (all)
 ERF 218 0.28 2.34*10-5
 GRAPHIC 502 0.19 1.45*10-5
 LLS 702 0.34 6.74*10-20
 NTR 108 0.32 0.001
 QIMR 410 0.15 0.002
 TwinsUK NA NA NA
 Meta-analysis 1,940 0.25 2.82*10-30
Spouses (< 55)
 ERF 78 0.21 0.065
 GRAPHIC 311 0.17 0.003
 LLS 183 0.39 4.20*10-8
 NTR 22 -0.05 0.809
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n r p-value
Spouses (< 55) (cont'd)
 QIMR 368 0.14 0.006
 TwinsUK NA NA NA
 Meta-analysis 962 0.20 3.24*10-10
Spouses (> 55)
 ERF 140 0.33 8.80*10-5
GRAPHIC 191 0.24 6.70*10-4
LLS 519 0.32 1.94*10-13
NTR 86 0.40 1.37*10-4
QIMR 41 0.20 0.202
TwinsUK NA NA NA
Meta-analysis 977 0.31 4.27*10-23
Complete pairs included only. In case of > 2 sibs,  the oldest two non-twin pair sibs were chosen for analysis. Mean spousal 
age was used for cut-off of 55 years of age.
*Limits of statistical software reached
Despite the evidence for the influence of environmental factors, neither the dominant
variance component nor the sibling-shared variance component influenced the 
estimates of familial resemblance in those studies where the analysis could be performed 
(Supplementary Table 2) suggesting that any residual shared-environment or non-additive 
genetic effects are small. In the heritability analyses, three cohorts (ERF, NTR and QIMR) had
nearly identical heritability estimates of 0.62 (Table 3). The highest heritability estimate was
found in LLS (h2 = 0.86). In the meta-analysis of all six cohorts, the heritability was estimated
to be 0.70 (95% Confidence Interval (CI): 0.64-0.76; p-value = 2.31*10-111).
The correlations between parental and offspring telomere length as a function of gender 
showed an effect of parental gender, but not of offspring gender. Both father-offspring
(r = 0.33; p-value = 5.66*10-4) and mother-offspring (r = 0.42; p-value = 5.01*10-5) telomere 
lengths were significantly correlated (Table 4). The mother-offspring correlation was
significantly larger than the father-offspring correlation (p-value = 0.007). There was no
difference in correlation structure between male and female offspring and their parents.
Finally, we investigated whether parental age plays a role in telomere length (Table 5). In 
each cohort the association between paternal age and telomere length went in the positive
direction. After meta-analysis, we found a significant association between paternal age and
telomere length (n = 5,127; beta = 0.005; p-value = 7.01*10-5). Maternal age was found to be
significantly associated with telomere length after meta-analysis (n = 5,500; beta = 0.003;
p-value = 0.012). This association was no longer significant when additionally adjusting
for paternal age (beta = -0.003; p-value = 0.357). The paternal age association remained 
significant when additionally adjusting for maternal age (beta = 0.007; p-value = 0.011).
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Table 3 | Heritability of telomere length.
h2 Confidence interval p-value
ERF 0.65 0.59-0.72 1.45*10-61
GRAPHIC 0.73 0.68-0.78 2.10*10-94
LLS 0.86 0.77-0.95 6.53*10-57
NTR 0.62 0.59-0.65 2.51*10-125
QIMR 0.62 0.57-0.67 4.88*10-63
TwinsUK 0.74 0.72-0.75 2.45*10-92
Meta-analysis 0.70 0.64-0.76 2.31*10-111
DISCUSSION
In six independent family-based cohorts from Europe and Australia we investigated
three aspects of familial relationships in telomere length, namely the heritability, mode
of inheritance and parental age at birth of their children. We found a high heritability, a 
significant stronger maternal than paternal inheritance and a positive association with
paternal age.
The meta-analysis estimate for heritability of telomere length in the six populations was 0.70.
Heritability estimates from the separate studies were remarkably similar across populations,
with three of them showing near identical estimates. The highest estimate was observed in
the oldest participants (LLS; h2 = 0.86) which may reflect a selection effect [33]. Even though 
only the offspring with their spouses of long living participants were selected from the LLS
study, the selection of the parents for old age might have influenced the total telomere
length distribution in their relatives.
Spousal correlations for telomere length have not been reported before [25]. Interestingly,
we observed a significant correlation in telomere length between spouses. This was more
pronounced in older spouses (mean age ≥ 55; r = 0.31) compared to younger spouses (mean
age < 55; r = 0.20), suggesting a possible influence on telomere length due to living together
for an extended amount of time. The hypothesis that resemblance in adults is induced by
living together for extended periods of time does not need to be conflicting with the finding
that modeling of the twin-family data did not detect shared-environmental influences. In a
twin design shared environment is reflected in the portion of the phenotypic correlation 
in MZ and DZ twins that exceeds above the pattern expected if the similarity of twins was 
only a function of their genetic resemblance. By assuming that the common environment 
applies to those factors that are always shared 100% between twins, or siblings, the scope of 
this component for quantifying shared family environment tends to be limited to influences 
of the early environment, and ignores factors that are shared by individuals who share
a household later in life. Another explanation could be an ascertainment effect. In older 
100 | Chapter 4.1
Ta
bl
e 
4
TT
 | 
In
he
rit
an
ce
 p
at
te
rn
s:
 fa
th
er
-o
ffs
pr
in
g 
an
d 
m
ot
he
r-
off
sp
rin
g 
co
rr
el
at
io
ns
 in
 te
lo
m
er
e 
le
ng
th
.
ER
F
G
RA
PH
IC
N
TR
Q
IM
R
M
et
a-
an
al
ys
is
Re
la
tio
ns
hi
p*
n
r
p-
va
lu
e
n
r
p-
va
lu
e
n
r
p-
va
lu
e
n
r
p-
va
lu
e
n
r
p-
va
lu
e
Fa
th
er
-o
ffs
pr
in
g
32
0
0.
29
1.
79
*1
0-
7
50
1
0.
34
3.
23
*1
0-
15
11
1
0.
49
5.
32
*1
0-
8
31
2
0.
28
5.
90
*1
0-
7
1,
24
4
0.
33
1.
15
*1
0-
32
Fa
th
er
-s
on
16
9
0.
29
1.
59
*1
0-
4
38
0
0.
39
6.
18
*1
0-
15
44
0.
43
0.
00
3
19
8
0.
27
1.
34
*1
0-
4
79
1
0.
34
2.
57
*1
0-
23
Fa
th
er
-d
au
gh
te
r
20
3
0.
33
1.
86
*1
0-
6
37
4
0.
31
1.
31
*1
0-
9
75
0.
49
9.
59
*1
0-
6
23
0
0.
31
2.
42
*1
0-
6
88
2
0.
33
3.
99
*1
0-
24
M
ot
he
r-
off
sp
rin
g
40
7
0.
34
1.
32
*1
0-
12
50
2
0.
48
9.
31
*1
0-
30
11
0
0.
49
6.
57
*1
0-
8
36
9
0.
39
7.
80
*1
0-
15
1,
38
8
0.
42
3.
60
*1
0-
61
M
ot
he
r-
so
n
19
3
0.
35
5.
52
*1
0-
7
38
0
0.
50
7.
53
*1
0-
26
43
0.
41
0.
00
7
23
4
0.
31
1.
01
*1
0-
6
85
0
0.
42
5.
06
*1
0-
37
M
ot
he
r-
da
ug
ht
er
28
5
0.
37
1.
22
*1
0-
10
37
5
0.
46
2.
67
*1
0-
21
75
0.
54
7.
25
*1
0-
7
27
0
0.
38
6.
94
*1
0-
11
1,
00
5
0.
42
2.
99
*1
0-
45
* If
 b
ot
h 
a 
so
n 
an
d 
da
ug
ht
er
 w
er
e 
av
ai
la
bl
e 
fo
r a
na
ly
si
s, 
th
e 
ol
de
st
 w
as
 u
se
d 
fo
r p
ar
en
t-
off
sp
rin
g,
 w
hi
le
 e
ac
h 
w
as
 u
se
d 
fo
r p
ar
en
t-
so
n 
or
 p
ar
en
t-
da
ug
ht
er
 re
sp
ec
tiv
el
y.
Ta
bl
e 
5
TT
 | 
A
ss
oc
ia
tio
n 
of
 p
at
er
na
l a
nd
 m
at
er
na
l a
ge
 a
t b
irt
h 
w
ith
 te
lo
m
er
e 
le
ng
th
.
Pa
te
rn
al
 a
ge
M
at
er
na
l a
ge
n
m
ea
n 
(s
d)
be
ta
se
p-
va
lu
e
n
m
ea
n 
(s
d)
be
ta
se
p-
va
lu
e
ER
F
56
0
26
.7
 (4
.1
)
0.
00
86
0.
00
38
0.
02
4
57
8
25
.0
 (4
.7
)
0.
00
35
0.
00
28
0.
21
1
G
RA
PH
IC
98
3
28
.3
 (4
.2
)
0.
00
53
0.
00
30
0.
07
7
98
4
26
.4
 (4
.1
)
-0
.0
01
1
0.
00
29
0.
70
4
LL
S
1,
58
7
35
.5
 (5
.9
)
0.
00
29
0.
00
21
0.
16
7
1,
57
8
32
.7
 (5
.4
)
0.
00
30
0.
00
21
0.
15
3
N
TR
1,
30
5
30
.0
 (4
.6
)
0.
00
80
0.
00
31
0.
01
0
1,
54
5
28
.1
 (4
.2
)
0.
00
64
0.
00
31
0.
03
9
Q
IM
R
69
2
32
.2
 (5
.3
)
0.
00
66
0.
00
48
0.
16
9
81
5
29
.5
 (4
.6
)
0.
00
72
0.
00
48
0.
13
4
M
et
a-
an
al
ys
is
5,
12
7
N
A
0.
00
53
0.
00
13
7.
01
*1
0-
5
5,
50
0
N
A
0.
00
32
0.
00
13
0.
01
2
101Familial effects in telomere length determination |
4
spouse pairs both individuals have survived for extended periods of time, and are therefore
likely to have above average telomere length for their age. The age-correction performed
might not completely control for this.
Mother-offspring correlations were significantly higher than the father-offspring
correlations (p-value = 0.007), though both were statistically significant on their own. This 
did not change when additionally adjusting the father-offspring correlation for paternal
age (data not shown). In 2004, Nawrot et al also showed a significant correlation between
mother-offspring (n = 71) and father-daughter (n = 47), but not between father-son (n = 34)
[23]. Recently, a paternal inheritance model has been gaining favor [8, 24-26]. The most
recent study suggesting paternal inheritance from Nordfjall et al contained a total of 217
parent-offspring pairs [26]. In our study we included a total of 1,244 father-offspring pairs
and 1,388 mother-offspring pairs and found both significant mother-offspring and father-
offspring correlations for telomere length. Our findings are in contrast with those from 
other studies, as we found a significantly stronger mother-offspring than father-offspring 
correlation, which previously was attributed to an X-linked mechanism in telomere length 
determination [23]. A prime candidate gene for this X-linked mechanism is DKC1 encoding
dyskerin, which is important for the function of telomerase and has been found to cause
congenital dyskeratosis which is characterized by short telomeres [43]. However, if an 
X-linked mechanism is in effect, a stronger father-daughter correlation would be expected,
compared to the father-son correlation, which we do not observe. Other potential
explanations for the larger mother-offspring correlation include mitochondrial DNA or 
other parent-specific ‘imprinting’. Non-paternities were excluded as an explanation, based
on genotype data.
Finally, we found significant evidence for a positive association of paternal age with telomere 
length supporting earlier reports [24, 27, 28]. At first glance, any positive association of 
telomere length with age seems counter-intuitive. However, telomere length is known to 
be maintained, and even lengthened, in sperm, despite both mitotic and meiotic divisions
during the proliferation and differentiation of the cells [44]. In humans, this leads to a gain
of approximately 71 base-pairs of telomere length per year [29]. Recently it was shown that
the paternal age effect may be cumulative over generations [45]. Our finding is opposite 
of the recent publication that paternal age is the major determinant of novel mutations 
leading to autism [46]. Thus high paternal age may have both positive and negative effects 
on the health of the offspring, assuming that long telomeres in children are healthy.
In summary, we find a high and very consistent heritability estimate for telomere length. In
addition, we find evidence for a maternal inheritance component and a positive association
with paternal age.
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ABSTRACT
Telomere shortening has been associated with aging, disease and mortality but findings 
have not been consistent. One of the reasons for inconsistencies may be a reduced variance
in telomere length in the elderly: a survivor effect. A previous study attributed this survivor
effect to a selection against those with short and with long telomeres.
Using a multigenerational family study in the Erasmus Rucphen Family (ERF) study we
aimed to explore the variability of telomere length in different age-categories. Building
upon the high heritability of telomere length, we next used the telomere length of the
(grand)children of the oldest-old as a proxy for the telomere length of the oldest-old at
younger ages.
We found a significant reduction in variance in telomere length from young adulthood to 
old age (p-value = 4.23*10-6). The decline in telomere length variance was stronger in men 
(69.9%) compared to women (59.7%). The mean telomere length of the (grand)children 
of the oldest-old was significantly longer compared to others in the same age-range
(p-value = 2.60*10-4). In only one out of 13 families telomere length of the (grand)children 
was shorter than average early in life.
Our study shows a reduction in the variance of telomere length over age. Further our study
suggests that those with long telomere length survive longest.
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INTRODUCTION
Telomeres are specialized repetitive DNA structures located at the terminal end of 
chromosomes and protect against spontaneous DNA damage and thus preserve genomic
integrity [1, 2]. Telomeres progressively shorten with each cell division [3], until a critically
shortened length is achieved upon which the cell enters replicative senescence [4]. 
Telomere shortening has been associated with organismal aging, disease and mortality
[5-9], though not consistently [10-15]. Further a reduction in variability in telomere length 
has been observed with aging [16]. This may be the result of selective mortality in those
with short telomeres at birth but perhaps also those with long telomeres early in life. It has 
been speculated that the latter have an increased risk of cancer [16]. Most of the studies
investigating the association between telomere length and mortality have been performed
in the elderly where such selection could have already occurred causing a survivor effect
[17].
Halaschek-Wiener et al [16] attributed the survivor effect to the risk associated with both
long and short telomeres, suggesting there may be an optimal telomere length that is
protective for healthy aging. In order to study survivor effects in a longitudinal study, a long 
follow-up is required assessing telomere length early and late in life. However, given the 
high heritability (h2 ~ 0.70) of telomere length an alternative design is a multigenerational
family study. Such a study can mimic a longitudinal study using the telomere lengths seen
in the (grand)children as a proxy for the telomere length of an individual early in life [18].
In the current study we explore the variation in telomere length in various generations in 
a multigenerational Erasmus Rucphen Family (ERF) study using the telomere length of the
(grand)children of the oldest-old as a proxy for the telomere length of the oldest-old (85+
years of age) at early life. In this way we aim to investigate the telomere length early in life
that is related to healthy aging.
METHODS
The Erasmus Rucphen Family study (ERF) is a cross-sectional family-based study including
3,000 living descendants of 22 couples around 1850-1900 [19, 20]. All participants are 
screened for many quantitative traits related to neurodegenerative, cardiovascular and
endocrine diseases. For all participants the genealogical relationships are available from
church records. These relationships were validated using genetic data from genome-wide 
association studies. The study protocol was approved by the medical ethics board of the
Erasmus MC Rotterdam, the Netherlands.
Mean leukocyte telomere length was measured using a quantitative PCR-based technique
as previously described [21, 22]. This method expresses telomere length as a ratio (T/S)
of telomere repeat length (T) to copy number of a single copy gene, 36B4(S), within each 
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sample. Samples were quantified relative to a calibrator sample used on each run (DNA
from the K562 cell line) [22]. Mean inter-run CV was calculated to be 3.48%.
Heritability analysis was performed in SOLAR (version 2.05, http://solar.sfbrgenetics.org),
adjusting for age and gender using an additive genetic variance component and random 
environment variance component. Association of age and gender with telomere length
was determined in the same model. Survival analysis in SPSS version 17 was performed to 
determine the association of telomere length with all-cause mortality. All-cause mortality,
obtained from obituaries, was complete until February 2012.
We simulated the effect of four different selection scenarios on the reduction of telomere 
length variance, namely A) no selection; B) selection against short telomeres; C) selection 
against long telomeres; D) selection against both short and long telomeres. We simulated 
individuals with the longest and shortest telomere length. For the rate of telomere length
decline with age we took -0.1 T/S ratio for every 10 years, which is consistent across
populations [23]. For the longest and shortest telomeres at young age we chose 3.3 and 1.3
T/S ratio respectively, which is consistent with the ERF data. For mortality we applied a two-
fold increase in mortality in the group selected upon compared to the non-selected group.
In order to investigate the reduction in telomere length variation over age empirically, 
we created 10-year age-categories starting with the youngest age group included at 18
years. Using the Levene’s test in SPSS version 20, we compared the variance in each age-
category with the youngest age-category, as well as between consecutive age-categories. 
We calculated the rate of decline in telomere length variance as a percentage of the original 
variance. Next, we extrapolated the telomere length of the oldest-old using the telomere
lengths of their (grand)children. We compared the mean telomere length of the (grand)
children to all others in the age-range using an independent t-test in SPSS version 20.
RESULTS
General characteristics are found in Table 1. As expected telomere length is decreasing with
age (p-value = 1.56*10-102) and women have longer telomere length (p-value = 2.54*10-7).
In our family study, the heritability of telomere length was 65% and highly significant
(p-value = 1.45*10-61).
Table 1 | General characteristics of the study population.
mean (sd) beta se p-value
telomere length 1.78 (0.36) na na na
age 49.8 (14.9) -0.0086 0.0004 1.56*10-102
sex (% female) 55.6 0.0634 0.0123 2.54*10-7
Regression coefficient (beta), standard error (se) and p-value from linear regression model with telomere length as outcome.
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Telomere length was strongly associated with all-cause mortality (Hazard Ratio (HR) = 0.21;
p-value = 1.52*10-13; Table 2). When adjusting for age at baseline the mortality is still 1.5 
times reduced but is no longer statistically significant (HR = 0.69; p-value = 0.125) due to the 
strong correlation between telomere length and chronological age.
Table 2 | Association of telomere length with all-cause mortality. 
overall adjusted for age
n n_death follow_up HR se p-value HR se p-value
total 2514 204 7.93 (1.44) 0.21 0.21 1.52*10-13 0.69 0.24 0.125
men 1107 109 7.79 (1.54) 0.20 0.30 5.4*10-8 0.62 0.34 0.158
women 1407 95 8.04 (1.35) 0.24 0.31 3.81*10-6 0.89 0.35 0.736
HR = hazard ratio; n = total sample size; n death = number of deceased; se = standard error
Figure 1 visualizes the effect of selection on the variance in the population under four
different selection scenarios, namely A) no selection; B) selection against short telomeres; 
C) selection against long telomeres; D) selection against both short and long telomeres. If 
no selection against telomere length occurs the variance in telomere length will be similar 
at young and old age (Figure 1A). However, if selection occurs a reduction in variance will
be observed in all scenarios (Figure 1B-D). These scenarios (B-D) are difficult to distinguish. 
Independent of selection, the telomere length decreases with age according to the
increasing mitotic divisions.
Figure 2 shows telomere length of the entire ERF population for both genders plotted
against age. The graph shows a decline in the variance of telomere length as reflected by
the funnel shape of the scatter plot from age 20 years to age 90 years. Statistical analysis 
using Levene’s test for the differences in variance reveals a significant decline in the variance
(p-value = 4.23*10-6) when categorized in 10-year age intervals (Table 3). The decline in
telomere length variance was 69.9% in men compared to 59.7% in women. The first two age-
categories (18-28 years and 28-38 years) did not show a significant difference in telomere
length variance in the total cohort (p-value = 0.214) nor in the gender specific analyses.
We next tested whether there was evidence for mortality in those with long telomeres, short
telomeres or both groups, assuming that this information can be deduced from the (grand)
children given the high heritability. Figure 3 shows the individuals that reached 85+ years
(oldest-old) and connects their telomere length with that of the mean telomere length of 
their children and grandchildren. Telomere length is shown on the vertical axis. With the
exception of one family (family 11; one child and one grandchild), the (grand)children
of the oldest-old have longer telomeres than the oldest-old themselves. Mean telomere
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length of the grandchildren was significantly longer compared to others in the same age-
range (p-value = 0.001; Table 4), suggesting that the oldest-old were most likely born with
telomeres that were longer on average than the general population.
Figure 1 | Graphical representation of the relation between telomere length and age using different
selection scenarios.
A. No selection
B. Selection against short telomeres only
C. Selection against long telomeres only
D. Selection against both short and long telomeres
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Figure 2 | Association of age and gender with telomere length.
Figure 3 | The relation of the telomeres in the oldest-old to their (grand)children. 
Table 4 | Telomere length of (grand)children of the oldest-old compared to the population.
generation age range mean (sd)
(grand)children
mean (sd)
population
p-value
grandchildren 18-48 2.08 (0.34) 1.89 (0.37) 0.001
children 38-68 1.81 (0.23) 1.75 (0.33) 0.220
sd = standard deviation
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DISCUSSION
In this study, we observed a significant reduction in telomere length variability in the 
population from young adulthood until late in life. Additionally, we observed that the
(grand)children of the oldest-old have long telomeres for their age, suggesting that the
oldest-old themselves were also born with telomeres that were longer on average than the
general population.
Our study confirmed the previously observed reduction in telomere length variability
between mid-life and oldest-old as reported by Halaschek-Wiener et al [16]. Further, our
study shows that this strong reduction in telomere length variability can be measured after
the age of 38 years, implying that selection on telomere length also starts early and can be
measured already around the age of 40 years, the age at which the reduction in variance
was statistically significant. Another implication of our study is that telomere length at old 
age are not representative for those at the start of life. This could explain why almost half 
of previously published studies investigating the association between telomere length and 
mortality did not find a significant association [5-15]. In studies conducted late in life not
only the telomere length is not representative anymore for early life but the variance is
significantly reduced making it statistically difficult to identify associations. In our study 
telomere length is associated with a 1.5 fold increase in mortality, though when adjusting
for age at baseline the association lost its statistical significance. Telomere length and
chronological age are extremely strongly associated which explains the loss of significance. 
A single measurement of telomere length after age 40 seems to add little information over 
chronological age in predicting mortality. As has been demonstrated previously in birds, it
is more likely that the differences in telomere length measured at early and middle age will 
be associated with mortality [24]. Indirectly our finding of the reduced variance points in
this direction as this suggests that there is differential mortality based on telomere length
early in life.
The most important finding of this study is that the grandchildren of the oldest-old had
telomeres longer than the average for their age, which strongly suggests that the oldest-
old started life with long telomeres. This finding is at odds with the hypothesis of optimal
telomeres as suggested by Halaschek-Wiener et al [16]. Short telomeres in the (grand)
children was observed in only one out of 13 families of which the grandparents reached old
age (> 85 years), while all other families had long telomeres. Our data therefore suggests
that predominantly short telomeres are selected against and that critically short telomeres
induce replicative senescence and are associated to mortality [4, 25, 26]. A limitation of our 
study is the small sample size in the oldest-old, resulting in relatively few families to be 
investigated. Further, we did not have information on the spouses of the oldest-old and their
families, which could explain the observation in the family in which the grand(children) had
shorter telomeres than the oldest-old.
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In our study, we further observed a larger rate of decline in telomere length variation in
men compared to women (69.9% compared to 59.7%). Differences in telomere attrition rate
between genders have been described [27]. In men, a significantly stronger attrition has
been seen, in line with our findings [27].
To summarize, we found a strong association of telomere length with mortality. Our study 
further shows that telomere length variability in the population strongly reduces with age, 
which is most likely explained by a survivor effect. Our study suggests that most of the
oldest-old were born with telomeres that were longer than others in the age category, 
indicating that those with long telomeres have a better probability of survival. These 
findings ask for multiple assessments of telomere length to study the relation of telomere
length with mortality.
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ABSTRACT
Telomere length is a trigger of cellular senescence and is considered to be a marker of 
biological age. A male-specific inverse association between telomere length and height has
been observed across species. Here we study the association between telomere length and
height in 3,625 individuals in the Consortium on Health and Aging Network of Cohorts in
Europe and the United States (CHANCES).
Partial correlation analysis of telomere length and height, adjusting for age and sex,
was performed in males, females and the combined sample. Additionally Mendelian
randomization analysis was performed to determine causality.
We find a small but significant inverse association between telomere length and height in
the total cohort (r = -0.04; p-value = 0.012). In the gender-specific analysis only men showed 
a statistically significant correlation (r = -0.08; p-value = 5.8*10-4), while women showed no
statistical evidence for correlation (r = -0.02; p-value = 0.302). Mendelian randomization
analysis are compatible with the hypothesis that differences in height cause differences in
telomere length, as several genes involved in height are associated with telomere length in
the inverse direction.
Our study in three populations suggests that telomere length is inversely associated to
height.
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INTRODUCTION
Telomeres are tandem repeats present at the ends of the chromosomes, which protect the 
terminal ends of the chromosomes by preventing chromosomal fusion and degradation of 
coding DNA [1] . Telomeres shorten with each replication until a critical length is achieved, 
thus achieving the point of replicative senescence [2-5]. The enzyme telomerase plays a 
key role in telomere restoration by adding base pairs de novo [6]. However this enzyme is
down-regulated in humans [7]. Short telomere size and high attrition rate have previously 
been associated with increased mortality [8-12], though not consistently in all studies [13-
18]. On average, women have longer telomeres than men when matched for age [9, 19],
although mean telomere length at birth does not show any sex-related differences [20]. This 
suggests a slower telomeric attrition rate in women [21] and corroborates with the finding
that women outlive men in every age group [22].
As a larger body size requires more cellular replications both for growth and maintenance, 
there is evidence that increased body size results in higher telomeric attrition rate [21],
despite the fact that telomerase activation also increases with growth [23]. In line with
this observation, in virtually all vertebrates studied smaller body size is associated with 
longevity [24-26]. This phenomenon has been attributed to the Insulin/Insulin-like Growth 
Factor (IGF)-1 signaling (IIS) pathway [27].
Sex is an important modifier of the association between height and life expectancy. Sex-
biased mortality is more pronounced in species that show sexual size dimorphism in body
size [28]. Females show greater telomerase activity and this finding is an evolutionary 
conserved mechanism even in species in which the body size of the female is larger than 
that of males [29, 30], suggesting sex-dependent telomere attrition is independent of body
size [29]. In a wide variety of animal species (reptiles and birds), the association between
body size and telomere length is seen predominantly in males, even in species in which 
males are larger than females such as dunlins [31, 32]. In humans, to our knowledge, the
association between height and telomere length has never been investigated.
In this study, we aim to investigate the association between telomere length and height in
3,625 individuals in the Consortium on Health and Aging Network of Cohorts in Europe and
the United States (CHANCES) overall and stratified by sex. Since both height and telomere 
length are highly heritable, we used the principle of Mendelian randomization analyses 
to evaluate the evidence for a causal relationship and the direction of the relationship
between height and telomere length. That is with Mendelian randomization we aimed to 
answer the question whether height through growth influences telomere length or does 
telomere length determine height?
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METHODS
Participating cohorts
The Erasmus Rucphen Family study (ERF) is a cross-sectional family-based study including
3,000 living descendants of 22 couples baptized in the community church around 1850-
1900. The participants are not selected on any disease or other outcome. Details about the
genealogy of the population have been described elsewhere [33, 34]. The study protocol 
was approved by the medical ethics board of the Erasmus MC Rotterdam, the Netherlands.
Mean leukocyte telomere length was measured using a widely reported quantitative PCR-
based technique as previously described [35, 36]. This method expresses telomere length
as a ratio (T/S) of telomere repeat length (T) to copy number of a single copy gene, 36B4 (S), 
within each sample. Samples were quantified relative to a calibrator sample used on each 
run (DNA from the K562 cell line) [36]. Mean inter-run CV was calculated to be 3.48%. Height
was measured with the participants standing upright without wearing shoes. 
The ESTHER study (Epidemiological Study on the Chances of Prevention, Early Recognition,
and Optimized Treatment of Chronic Diseases in the Older Population) participants were
aged 50-74 years and were recruited between July 2000 and December 2002 during a 
general health check-up in Saarland, south-west Germany, by their general practitioners. 
Information on age, sex, self-reported weight and height were obtained by detailed 
questionnaires in a standardized manner. Serum samples were obtained from all participants
from peripheral blood. Genomic DNA was extracted by high salt method and stored at 
-80°C. The ESTHER study is approved by the ethics committees of the medical faculty of the
University of Heidelberg and of the medical board of the state of Saarland. Telomere length 
was measured by quantitative PCR (qPCR) [35]. In this study 36B4 was used as the single
copy gene. Two quality-control samples were inserted into each PCR plate in order to assess
the coefficients of inter- and intra-plate variability. All samples were measured in triplicates
and the mean of the two closest measurements was used. Calculation of telomere length 
was based on comparison of the distinct cycle number determined by threshold values 
(Ct) at a constant fluorescence level. PCRs were performed on the Prism 7900 Sequence 
Detection System (Applied Biosystems, Foster City, USA).
The Zutphen Elderly Study consists of men born between 1900 and 1920. The study
started in 1960 as the Dutch contribution to the Seven Countries Study [37]. The Zutphen
Elderly Study consisted of 553 men in 1993, of whom 390 participated, and 345 had 
a blood sample. However, only 203 (59%) buffy coats could be used for DNA isolation
because 142 samples were unavailable. Written informed consent was obtained from all
participants. The Zutphen Elderly Study (in 1993 and in 2000) was approved by the Medical
Ethics Committee of The Netherlands Organization for Applied Scientific Research (TNO).
Telomere length was determined by quantitative PCR as described previously [35]. Two
master mixes were prepared: one with telomere primers and one with human b-globin
primers (1× IQ SYBRgreen supermix from BioRad-Laboratories BV, Veenendaal, The
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Netherlands). To confirm reproducibility of the applied method, we repeated for 20 samples
the telomere length measurement by using an additional reference gene, acidic ribosomal
phosphoprotein PO (36B4), 300 nM forward primer (5'-CAGCAAGTGGGAAGGTGTAATCC-3'), 
and 500 nM reverse primer (5'-CCCATTCTATCATCAACGGGTACAA-3'). Each sample was run
in triplicates. The coefficient of variation for the triplicates of the telomere reaction was 
4.11% and for the reference gene 3.03%.
Statistical analysis
In order to standardize telomere length measurements across cohorts a Z-transformation
was applied. Samples deviating more than 4 standard deviations from the mean for either
telomere length or height were removed. We performed a partial overall correlation 
analysis including both men and women adjusting for age and sex, and if necessary for
family relationships (ERF) and also sex-specific correlation analyses adjusted for age. Meta-
analysis was performed using R-package metacor, implementing DerSimonian-Laird (DSL) 
random-effect meta-analytical approach with correlation coefficients as effect sizes [38, 
39]. Between-study heterogeneity was assessed using rmeta [38]. We used the Bonferroni 
corrected p-value threshold for significance of 0.017 (= 0.05/3).
Association analysis does not establish causality. A way to defer directionality of association
is to use genetic data in a so-called Mendelian randomization analysis [40]. As genotypes 
are randomly assigned when passed from parent to offspring during meiosis, the
genotype distribution in the population is unrelated to potential confounders. Mendelian
randomization assumes that the genotype can only affect the outcome indirectly via its
effect on the exposure of interest [40]. If the assumption is met, Mendelian randomization 
can be seen as a “natural” randomized controlled trial [40]. This implies that if telomere 
length causally influences height, one would expect that genetic factors, for instance, 
Single Nucleotide Polymorphisms (SNPs) associated with telomere length will also be 
associated with height. We have tested three potential scenarios, namely 1) differences in
telomere length cause differences in height and thus genes involved in telomere length 
should associate to height (Figure 1A); 2) differences in height cause differences in telomere
length and thus genes involved in height should associate to telomere length (Figure 1B);
3) an untested third factor causes differences in both height and telomere length and the
association between height and telomere length is explained as confounding. In order to
test the first two scenarios, we use published genome-wide association studies (GWAS) [41,
42]. Assuming that the genes identified to date capture a sufficient part of the variance in 
height and telomere length, the absence of association supporting the first two scenarios 
suggests that the third scenario is likely to be the underlying biological reason for finding 
an association or that the association is spurious. To test for a joint-effect of all known SNPs
from published GWAS on the trait to be explained (e.g. telomere length SNPs on height) we 
used the betas from published GWAS as weights in a meta-analysis of all SNPs in rmeta [38].
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Figure 1 | Graphical representation of Mendelian Randomization.
A. Telomere length is causally associated to height
B. Height is causally associated to telomere length
As genes associated to height or telomere length are involved in various pathways, it may be 
speculated that only a limited number of genes from a distinct pathway are associated. The
biological function of genes of the Mendelian randomization experiment were therefore 
evaluated using Ingenuity Pathways Analysis (Ingenuity Systems, http://www.ingenuity.
com). This software analyses data in the context of known biological response, regulatory 
networks and pathways. Fisher’s exact test was used to calculate a p-value determining the
probability that each biological function or disease assigned to that dataset was lower than
due to chance.
RESULTS
The general characteristics of the study populations are depicted in Table 1 stratified for 
sex. The mean age of the participants ranged from 48 years of age to nearly 79 years of age.
In ERF and ESTHER approximately 40% of the participants were male, while the Zutphen 
Elderly Study consisted of 100% male participants. 
The results of the partial correlation analysis of telomere length and height are presented 
in Table 2. In the overall meta-analysis we observed a significant inverse correlation
between telomere length and height (r = -0.04; p-value = 0.01). The sex-stratified meta-
analysis revealed a stronger and more significant inverse correlation between height and 
telomere length in men (r = -0.08; p-value = 5.8*10-4), and a non-significant correlation in
women (r = -0.02; p-value = 0.30). There was no evidence for between-study heterogeneity 
in the analyses (lowest p-value for heterogeneity overall or in the sex-stratified analysis
p-value > 0.51).
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Table 3 shows the results of the association of known genome-wide significant telomere 
SNPs with height (Mendelian randomization scenario 1; Figure 1A). There were 7
independent SNPs known to associate with telomere length at a genome-wide significance 
level [41]. One SNP (rs9420907; OBFC1) was also significantly associated with height at
a Bonferroni corrected level of significance of 0.007 (=0.05/7). The allele associated with 
increased telomere length was also associated with increased height. From the height to
telomere relationship an inverse association was expected, which suggests that for this
SNP the assumption of an effect of the genotype on height through telomere length was 
not met. A risk score of all variants associated with telomere length was not significantly
associated with height (beta = 0.004; p-value = 0.11).
Table 3 | Association with height of SNPs genome-wide significantly associated with telomere length.
telo_ENGAGE height_GIANT
SNP Chr Gene EA beta p-value beta se p-value N
rs10936599 3 TERC C 0.097 2.54*10-31 0.002 0.005 0.640 133814
rs2736100 5 TERT C 0.078 4.38*10-19 -0.001 0.005 0.864 103310
rs7675998 4 NAF1 G 0.074 4.35*10-16 0.002 0.006 0.785 133810
rs9420907 10 OBFC1 C 0.069 6.90*10-11 0.019 0.006 0.004 133721
rs8105767 19 ZNF208 G 0.048 1.11*10-9 0.010 0.005 0.045 133855
rs755017 20 RTEL1 G 0.062 6.71*10-9 -0.014 0.009 0.124 75729
rs11125529 2 ACYP2 A 0.056 4.48*10-8 0.012 0.006 0.056 133807
OVERALL 0.004 0.002 0.110
EA = Effective allele
Telo_ENGAGE = genome-wide significant results from published telomere GWAS
Height_GIANT = look up of telomere SNPs in publically available height GWAS results
In Table 4 the association of known height SNPs with telomere length is given. Table 4
shows the SNPs that at least reached a p-value < 0.05 in the association with telomere 
length (Mendelian randomization scenario 2; Figure 1B). The complete list of SNPs (n = 115) 
can be found in Supplementary Table 1. Several of the height associated SNPs showed
nominal association with telomere length, though none of the tested SNPs passed the
Bonferroni corrected level of significance of 4.35*10-4 (= 0.05/115). There are twice as many 
of these SNPs associated in the expected direction (67%) than in the opposite direction.
When combining the SNPs (p-value < 0.05) in a risk score, the overall effect of the height 
genes on telomere length is indeed inverse (beta = -0.013; p-value = 0.002) as expected.
Ingenuity pathway analysis of the six genes (POLR2B, ZBTB38, HMGA1, SERPINH1, PAPPA
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and TGFB2) that are associated in the expected direction showed that four of these genes 
(HMGA1, SERPINH1, PAPPA and TGFB2) are involved in cell proliferation (p-value = 0.04; 
Supplementary Table 2). The complete risk score of all 115 height-associated variants was
not significantly associated with telomere length (beta = -1.19*10-4; p-value = 0.925).
Table 4 | Association with telomere length of SNPs associated genome-wide significantly with height 
(p-value < 0.05).
height_GIANT telo_ENGAGE
SNP Chr Gene EA beta p-value beta se p-value N
rs17081935 4 POLR2B T 0.030 4.77*10-8 -0.027 0.009 0.002 37633
rs724016 3 ZBTB38 G 0.070 4.47*10-52 -0.020 0.007 0.006 37323
rs2079795 17 TBX2 T 0.040 1.22*10-16 0.018 0.008 0.022 37205
rs2780226 6 HMGA1 C 0.076 1.02*10-18 -0.038 0.017 0.024 32536
rs634552 11 SERPINH1 T 0.039 1.35*10-9 -0.026 0.012 0.026 29826
rs751543 9 PAPPA T 0.026 4.51*10-8 -0.019 0.009 0.034 32272
rs6569648 6 L3MBTL3 C 0.040 8.93*10-12 0.019 0.009 0.039 34469
rs6684205 1 TGFB2 G 0.028 1.97*10-11 -0.016 0.008 0.043 37638
rs6439167 3 C3orf47 C 0.034 7.20*10-10 0.019 0.009 0.044 34618
OVERALL -0.013 0.004 0.002
EA = Effective allele
Telo_ENGAGE = look up of known height SNPs in telomere length GWAS
Height_GIANT = genome-wide significant results from published height GWAS
DISCUSSION
In this study, including 3,625 subjects derived from three population-based studies in the
CHANCES consortium, we found evidence for a significant inverse correlation between
telomere length and adult height. In the sex-stratified analysis the correlation was
predominantly seen in men. Mendelian randomization analysis showed no evidence for a
relation to height of the genes genome-wide significantly associated with telomere length.
The analyses of all genetic variants genome-wide significantly associated with height failed
to show an association with telomere length. However, we observed an overrepresentation 
of genes involved in cell proliferation in those height genes nominally associated with
telomere length.
A limitation in the interpretation of our correlation analysis results is that in only the ERF
population the association between height and telomere length reached significance. This 
may be for a large part explained by the differences in sample size. All three cohorts show
effects in the same direction with similar effect sizes, strengthening our finding. Additionally,
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no significant between-study heterogeneity was observed. Our findings may be confounded
by unknown risk factors at young age which determine height and telomere length or by
differential mortality later in life. However, the findings of the Mendelian randomization
make this explanation less likely. Also the finding that the association is virtually limited to
men makes confounding a less likely explanation as this has to occur only in men.
The inverse male-specific association between telomere length and height has been 
seen throughout various classes of vertebrates, pointing to an evolutionary conserved
mechanism. Interestingly, this is not entirely explained by the larger body size of males, 
which requires more cellular replications to attain and maintain a large body size [43, 44]. In
dunlins, female birds are on average larger than males, yet an association between height
and telomere length is seen in males and not in females, similar to our findings in the
present paper [32]. An explanation could be the difference in telomerase activity, which is 
lower in males compared to females [7, 30]. 
In the Mendelian randomization analysis, we did not find evidence supporting the
hypothesis that genes determining telomere length also lead to a small body size. Although
our knowledge of the genes determining telomere length is far from complete [41], the
genes with a large effect on telomere length such as TERT do not show any evidence
for association with height. Also biologically this explanation is less likely as early in life
telomere length is similar in males and females [20], which predicts a similar body size in
males and females if the hypothesis was true that telomere length determines height. We
found that several height genes are associated with telomere length at nominal significance.
Four of the six genes (67%) for which the direction of the association is in the direction 
anticipated are involved in cell proliferation. This is in line with the observation that high
cell proliferation results in both increased height and decreased telomere length [2, 44, 
45]. Our study suggests that this mechanism is partly genetically determined. Of note is 
however that there are over 160 genes implicated in height explaining in total 10% of the
variation in height [42] while only 6 associated here with telomere length. On the one hand 
this may imply that not all pathways implicated in height are involved in telomere length,
but rather the genes involved in a distinct pathway, i.e., cell proliferation. On the other hand,
we cannot exclude a false positive association.
Of interest is whether the observed association between telomere length and height is
related to the IIS pathway. Animal models including C. elegans, D. melanogaster, mice and
dogs suggest that low IGF-1 levels are associated with longevity [24, 25, 46-48]. IGF-1 is also
a major determinant of height in the population and has been associated with telomere 
length [49-51]. As measurements of IGF-1 are not available, we could not investigate this 
directly in the present paper. Since high IGF-1 levels relate to increased height, our findings
predict an inverse association between IGF-1 and telomere length. However, previously,
three studies have found a positive association between IGF-1 levels and telomere length
[49-51], which is at odds with our findings. This issue remains to be resolved: the positive 
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association between IGF-1 levels and telomere length [49-51] is also at odds with the
findings in many studies in animal models that show that lower IGF-1 levels are associated
with longevity, predicting an inverse association between IGF-1 and telomeres. Up until 
now, IGF-1 levels have not been associated with human longevity consistently [27, 52-57].
Yet in the same study, researchers find that genes in the IIS pathway associated with lower
height, also associate with survival to old age [27]. A recent report from the same group
focusing on the genetic variants in a larger set of genes spanning the IIS pathway shows 
that several genes (AKT1, AKT3, FOXO4, IGF2, INS, PIK3CA, SGK, SGK2, and YWHAG) are jointly
associated with longevity [58]. The GIANT GWAS hits on height contain 2 SNPs located in 
the vicinity of IIS pathway genes (IGF1R and IGF2BP2). However, in our study these 2 SNPs 
did not associate with telomere length. Our findings and that of others raise the question 
whether the inverse association between height and telomere length is explained by IGF-
1 levels in the blood. A problem in the interpretation of human data is that IGF-1 levels 
decrease with age [59-61]. As a consequence, cross-sectional studies of IGF-1 levels may be
biased as age related decline may be genetically determined [62].
In summary, we found consistent and significant evidence for an inverse correlation
between telomere length and height, predominantly in men. We find nominal significant
evidence consistent with the hypothesis that several genes involved in height through cell
proliferation are also involved in telomere length.
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ABSTRACT
Oxidative stress and inflammation are major contributors to accelerated age-related relative 
telomere length shortening. Both conditions are strongly linked to leptin and adiponectin,
the most prominent adipocyte-derived protein hormones. As high leptin levels and low
levels of adiponectin have been implicated in inflammation, one expects adiponectin to
be positively associated with telomere length while leptin should be negatively associated.
Within the ENGAGE consortium, we investigated the association of telomere length with 
adiponectin and leptin in 7 independent cohorts with a total of 11,460 participants. 
We performed partial correlation analysis on Z-transformed telomere length and LN-
transformed leptin/adiponectin, adjusting for age and sex. In extended models we adjusted 
for body mass index (BMI) and C-reactive protein (CRP).
Adiponectin showed a borderline significant association with telomere length. This 
appeared to be determined by a single study and when the outlier study was removed, this
association disappeared. The association between telomere length and leptin was highly
significant (r = -0.05; p-value = 1.81*10-7). Additional adjustment for BMI or CRP did not 
change the results. Sex-stratified analysis revealed no difference between men and women.
Our study suggests that high leptin levels are associated with short telomere length.
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INTRODUCTION
Both leptin and adiponectin are among the most prominent adipocyte-derived protein
hormones. Their origin in adipocytes and ability to affect the expression of various markers 
of systemic inflammation has led to the notion of both protein hormones as adipokines [1]. 
High leptin levels have been implicated in contributing to inflammation, insulin resistance, 
glucose intolerance and atherosclerosis [2]. Low levels of adiponectin, on the other hand,
have been linked to inflammation, insulin resistance, impaired endothelium-dependent
vasodilatation, elevated systemic blood pressure and further deteriorating effects on 
cardiovascular and metabolic health [3]. Interestingly, for both adipocytokines, impaired 
efficacy at the level of the receptors have been considered to be a mechanism potentially
akin to that seen under the condition of sustained elevated insulin levels (insulin resistance)
[4].
Telomeres are tandem repeats of long hexamers (TTAGGG) at the end of chromosomes 
that protect against spontaneous DNA damage and thus preserve genomic integrity [5, 6].
Oxidative stress and inflammation are major causative contributors to accelerated relative 
telomere length shortening [7-10]. Given the associations of the adipocytokines with
inflammation and oxidative stress, one would expect that adiponectin should be positively
associated with telomere length while leptin should be negatively associated.
Only a limited number of studies have investigated the association of adipocytokines 
with telomere length and have yielded conflicting findings. Up to now, 6 studies have 
been published on the relation between telomere length and leptin with sample sizes
varying from 317 to 2,721 subjects [11-16]. An inverse association was found in two studies 
[11, 15] while two did not find evidence for a significant association [12, 16]. One study 
found borderline significant evidence for a positive association [13]. The last study found 
borderline significant evidence for a positive association when adjusting for percentage 
body fat [14]. There have been 3 previous studies on the association between telomere
length and adiponectin, including 193 to 570 subjects [12, 16, 17] with one showing a 
positive association [17]. In the present study we aimed to investigate the association of 
telomere length with adiponectin and leptin in 7 independent cohorts with a total of 11,460
participants.
METHODS
Study populations
The Erasmus Rucphen Family (ERF) study is a cross-sectional cohort including 3,000 living 
descendants of 22 couples who had at least 6 children baptized in the community church 
around 1850-1900. The participants are not selected on any disease or other outcome. 
Details about the genealogy of the population have been described elsewhere [18, 19]. The 
study protocol was approved by the medical ethics board of the Erasmus MC Rotterdam,
the Netherlands. 
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The KORA (Cooperative Health Research in the Region of Augsburg) study is a series
of independent population-based epidemiological surveys and follow-up studies of 
participants living in the region of Augsburg, Southern Germany [20]. All survey participants 
are of German nationality, identified through the registration office. Informed consent has 
been given by all participants. The present study includes data of the KORA F3 (2004/2005)
survey which is a follow-up study of the KORA S3 survey (1994/1995), as well as data of the
KORA F4 (2006-2008) study which is a follow-up study of the KORA S4 survey (1999-2001).
All KORA F4 participants were fasting. In KORA F3, adjustment for fasting status was made.
For the Leiden Longevity Study (LLS), long-lived siblings of Dutch descent were recruited
together with their offspring and the partners of thereof. Families were included if at least
two long-lived siblings were alive and fulfilled the age criterion of 89 years or older for males
and 91 years or older for females, representing less than 0.5% of the Dutch population in
2001 [21]. In total, 944 long-lived proband siblings from 421 families with a mean age of 94 
years (range, 89-104), 1,671 offspring (61 years, 39-81), and 744 partners (60 years, 36-79) 
were included in the study. DNA from the LLS was extracted from samples at baseline using
conventional methods [22]. For the current analysis only the offspring and their partners
were used.
The TwinsUK cohort (www.twinsuk.ac.uk) is an adult twin British registry shown to be 
representative of singleton populations and the United Kingdom population [23]. A total 
of 6,038 twins with telomere length measurement were included in the analysis. The age
range of the TwinsUK cohort was 16-99 years. Ethical approval was obtained from the Guy’s
and St. Thomas’ Hospital Ethics Committee. Written informed consent was obtained from
every participant in the study.
The SAPHIR Study (Salzburg Atherosclerosis Prevention program in subjects at High 
Individual Risk) is an observational study in a healthy working population conducted
in the years 1999-2002 involving 1532 healthy unrelated subjects with telomere length 
measurement available: 539 females aged 42-67 years and 993 males aged 39-66. All
subjects were recruited by health-screening programs in companies in and around the 
Austrian city Salzburg (1999-2002) [24]. At baseline, all study participants were subjected 
to a comprehensive screening examination with a detailed personal and family history
assessed via standardized questionnaires and a physical examination. Subjects suffering
from severe obesity (BMI > 40kg/m2), established coronary artery disease, congestive heart 
failure, valvular heart disease, chronic alcohol consumption (more than three drinks per
day), drug abuse or pregnancy were excluded.
The Finnish twin participants were recruited from two population-based longitudinal
studies, FinnTwin16 and FinnTwin12, each consisting of five consecutive birth cohorts
(1975-1959, n = 5601 subjects in FinnTwin16 and 1983-1987, n = 5184 in FinnTwin12,
respectively) [25]. All pairs were of Caucasian origin. Except for one obese male subject who
had recently developed type 2 diabetes and used insulin, the subjects were healthy and
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did not take any medications. Zygosity was confirmed by genotyping of ten informative 
genetic markers [26]. For the current study only those individuals with measurements on
both telomere length and adipokines were included (n = 190). They had taken part in a sub-
study of metabolic factors related to obesity, and were representative of the distribution
of BMI in the two twin cohorts. No further exclusion criteria were used. The protocol was
designed and performed according to the principles of the Helsinki Declaration and was 
approved by the Ethical Committee of the Helsinki University Central Hospital.
Relative TL, adiponectin and leptin measurements
Details on the measurements of adiponectin, leptin and telomere length for the individual
cohorts have been published elsewhere and are provided for this paper in the supplementary
material. In all studies telomere length was measured in leukocytes by qPCR [27]. For 4 out 
of the 7 studies telomere length was determined in one central laboratory according to
common protocol. Adiponectin was available in all cohorts, while leptin was not available
in SAPHIR.
Data analysis
In order to standardize telomere length measurements across cohorts a Z-transformation
was applied. Adiponectin and leptin levels were transformed using a LN-transformation. 
Samples deviating more than 4 standard deviations from the mean were removed. We
performed partial correlation analysis, adjusting for age and sex, and if necessary, for family
relationships and/or fasting status. In the extended model we additionally adjusted for body
mass index (BMI) or C-reactive protein (CRP). We also performed sex-specific analyses, thus 
resulting in a Bonferroni corrected p-value threshold for significance of 0.006 (= 0.05/9).
RESULTS
The general characteristics of the study populations are depicted in Table 1 stratified for 
men and women. Most cohorts had a mean age around 50 years, except for Finnish Twins
in which the mean age was 28 years at the time of assessment. Most cohorts also had an
approximately equal number of men and women, except for TwinsUK which includes only
women.
Table 2 contains the partial correlation analysis of telomere length and BMI. We observed a 
nominally significant correlation between BMI and telomere length in the total population
(r = -0.02, p-value = 0.021). We did not observe a significant correlation between CRP and
telomere length (r = -0.01, p-value = 0.444, Supplementary Table 1).
Table 3 shows the partial correlation analysis of telomere length and adiponectin. In the 
overall meta-analysis, we observed a nominally significant correlation between telomere 
length and adiponectin (r = 0.02, p-value = 0.047). There was significant evidence for
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heterogeneity (I2 = 69.8%). The high heterogeneity was caused by one outlying study
(ERF). In a sensitivity analysis we removed ERF from the meta-analysis, which completely 
resolved the heterogeneity and resulted in a loss of significance (r = 0.004, p-value = 0.763).
Additionally adjusting for BMI (r = 0.02, p-value = 0.104) or CRP (r = 0.02, p-value = 0.083) did 
not change the results (Supplementary Table 2).
Table 1 | General characteristics of study populations.
Men Women
n mean sd n mean sd
Telomere length (t/s ratio)
ERF 1,230 1.74 0.35 1,539 1.81 0.36
KORA F3 1,517 1.69 0.28 1,607 1.75 0.29
KORA F4 1,456 1.79 0.32 1,568 1.90 0.32
LLS 1,043 1.43 0.25 1,262 1.48 0.26
TwinsUK NA NA NA 1,428 3.50 0.63
SAPHIR 985 0.85 0.17 539 0.85 0.18
Finnish Twins 107 1.29 0.28 83 1.24 0.23
Adiponectin (mg/L)
ERF 904 8.06 4.13 1,188 12.36 5.79
KORA F3 1,535 8.67 3.66 1,624 12.14 4.57
KORA F4 581 8.95 5.38 550 14.56 7.35
LLS 1,036 4.81 2.19 1,207 7.23 3.12
TwinsUK NA NA NA 1,185 7.82 3.65
SAPHIR 985 7.05 3.30 539 11.07 5.14
Finnish Twins 107 2.30 0.77 83 3.22 1.02
Leptin (ng/mL)
ERF 687 24.91 29.38 905 74.85 65.35
KORA F3 800 9.53 9.41 825 30.76 26.12
KORA F4 1,467 9.58 11.37 1,584 28.18 23.70
LLS 1,042 9.66 8.98 1,206 26.19 18.28
TwinsUK NA NA NA 1,428 16.89 11.52
SAPHIR NA NA NA NA NA NA
Finnish Twins 107 5.58 4.69 83 20.96 15.89
Age (yr)
ERF 1,230 50.17 14.65 1,539 49.44 15.05
KORA F3 1,545 57.73 13.15 1,639 57.10 12.66
KORA F4 1,486 56.64 13.41 1,594 55.51 13.14
LLS 1,063 59.87 6.85 1,288 58.60 6.76
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Men Women
n mean sd n mean sd
TwinsUK NA NA NA 1,428 48.71 13.48
SAPHIR 985 48.85 5.46 539 55.63 4.18
Finnish Twins 107 28.25 1.86 83 28.08 1.60
BMI (kg/m2)
ERF 1,191 27.24 4.13 1,472 26.65 5.10
KORA F3 1,531 28.01 3.86 1,626 27.27 5.16
KORA F4 1,480 27.93 4.19 1,583 27.33 5.32
LLS 904 25.77 3.05 1,101 25.10 3.94
TwinsUK NA NA NA 1,426 24.85 4.41
SAPHIR 984 26.91 3.70 539 26.59 4.75
Finnish Twins 107 24.92 3.72 83 24.19 5.23
CRP (mg/L)
ERF 849 3.53 10.50 1,131 3.92 8.13
KORA F3 144 4.06 5.72 117 5.06 10.67
KORA F4 1,477 2.40 5.18 1,582 2.61 5.41
LLS 1,029 2.11 2.89 1,234 2.53 3.66
TwinsUK NA NA NA 1,250 3.02 4.44
SAPHIR 983 0.26 0.73 538 0.35 0.51
Finnish Twins 107 0.75 1.03 83 2.31 3.36
NA: not available
The results of the partial correlation analysis of telomere length and leptin are depicted in 
Table 4. We observed a weak, but highly significant, correlation between telomere length
and leptin in the overall meta-analysis (r = -0.05, p-value = 1.81*10-7). No heterogeneity was
observed (I2 = 0%). When removing the cohort with the strongest association (KORA F4) 
from the analysis, the correlation did not change (r = -0.04, p-value = 1.17*10-3). Additionally 
adjusting for BMI (r = -0.04, p-value = 1.93*10-5) or CRP (r = -0.06, p-value = 2.10*10-8) did 
not change the results (Supplementary Table 3). The multivariate analysis shows that leptin 
explains 0.16% of the telomere length variance. The sex-stratified analysis also showed very 
similar correlations for men and women (r = -0.06 and r = -0.05 respectively), which indicates 
that the association between telomere length and leptin is not sex-specific.
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DISCUSSION
In this study including data of 11,460 subjects derived from population-based studies, we
found evidence for a significant negative association between telomere length and serum 
leptin levels. The relationship was independent of age, sex, BMI and CRP. However, no
relationship was found between telomere length and adiponectin. A nominally significant 
association of telomere length with BMI was also observed.
The correlation between leptin and telomere length, adjusted for age and sex was small
but highly significant (r = -0.05, p-value = 1.81*10-7). Based on the assumption of an
association between high leptin levels and inflammation [2], we observed an inverse
association between leptin and telomere length. The current study is the largest study on 
the association between telomere length and leptin to date with 10,093 subjects studied 
compared to the previous studies with sample size ranging from 317 to 2,721 subjects
[11-16]. Two out of the six previously performed studies on the association between leptin
and telomere length also found an inverse association only in women [11, 15]. The present
study therefore provides a strong confidence in the observed association and elucidates the
association in both men and women.
High leptin levels have been implicated in contributing to inflammation, to insulin resistance,
glucose intolerance and atherosclerosis [2]. Furthermore, leptin is an important mediator
in stress-induced cardiovascular activity mainly by raising circulating catecholamine
concentrations and by stimulating heart rate and arterial blood pressure [1, 28]. Though
the percentage of variance explained is small (~0.16%), the observed association between
leptin and telomere length is interesting, due to the biological link with both inflammation
and oxidative stress of both variables.
The findings on adiponectin were not consistent over studies with evidence for substantial 
heterogeneity. Removing the outlier study (ERF) led to a non-significant association. There 
may be various explanations for this finding. Although differences between populations 
may exist in terms of BMI and metabolic syndrome (to which adiponectin is strongly
related) [29], it is less likely that these differences fully explain the discrepancies as the leptin 
association is highly consistent and is also strongly associated to BMI and the metabolic
syndrome [30]. Additionally we attempted to elucidate why ERF showed a very different
association from the other populations by additionally adjusting for metabolic syndrome,
but this did not change the results. Therefore, it is most likely that the association in ERF was
a chance finding.
It is currently unclear whether high adiponectin levels are part of a protective effect due 
to an ongoing inflammation or whether individuals with low adiponectin levels are prone 
to inflammation. Another possibility would be that changes in adiponectin levels might
be an epiphenomenon. Several prospective studies reported an association of high rather 
than low adiponectin levels with outcomes such as (cardiovascular) mortality [31-35],
progression of chronic kidney disease [36-38] and dementia [39]. This positive association
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was mainly observed in patients suffering already at baseline from a chronic disease. Other
studies reported low adiponectin levels to be associated with several diseases such as
insulin resistance [40-42], type 2 diabetes [43-45], atherosclerosis or cardiovascular disease 
[46]. It has been proposed that reverse epidemiology [47] or adiponectin resistance [48, 49] 
may be an explanation. 
A limitation of our study is that we do not have detailed measurements of adiposity, except
BMI. Though adjusting for BMI did not change our results for either adiponectin or leptin
and most adiposity measures are highly correlated to each other, we cannot completely 
exclude that adjusting for some other adiposity measurement might have changed the
results. Observed differences in telomere length measurements across cohorts are mainly
related to age differences between the various populations.
A major strength of the present study is its large sample size. This large number of samples
requires telomere measurement to be done by a qPCR method instead of Southern Blot 
techniques. This approach for assessing telomere length has some important advantages, 
including the high-throughput capacity and the requirement of only low amounts of DNA. 
However, we are also aware of the potential limitations of this method which are e.g. the 
type of the reference sample [50]. However, if performed in a highly standardized way, 
telomere qPCR is a valuable method for large epidemiological studies without consuming
large amounts of DNA. The alternatively used method of telomere length measurement
is the telomere restriction fragment (TRF) analysis (Southern Blot) where the absolute
telomere length (kb) is estimated directly from a telomeric smear signal from blot pictures.
However, this approach consumes a considerable amount of DNA, the required reagents
are costly, and the methodology itself is cumbersome and labor-intensive. The results of 
the Southern Blot method can be influenced by several factors such as restriction enzymes, 
hybridization targets, hybridization probes and hybridization conditions, gel calibration,
background subtraction, as well as the calculation formula and the analysis window [50]. 
Despite these limitations, to compare results of different studies, accurately measured 
absolute telomere length might be a more adequate and concrete method as a relative
approach by qPCR. However, since the measurements in our meta-analyses were performed 
to a large extent in one laboratory and difference between methods were considered by 
using a Z-transformation of the data, we consider the qPCR method with the large number
of samples as a major advantage.
Another advantage of our study is the population-based and multicenter design which
allows the evaluation of consistent findings over populations. Though the meta-analysis 
also includes studies with relatedness (ERF, LLS, TwinsUK, Finnish twins), the relatedness
of subjects within families was taken into account statistically in order to derive correct 
standard errors and p-values. The impact of modern living environment is undisputable. 
Nutrition, activity as well as the exposure to a wide range of man-made chemicals plays 
an important role and may have an effect on insulin action, metabolic rate and other 
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physiological processes [51, 52]. Nevertheless, we observed an association of telomere
length and leptin in population-based studies of unrelated individuals as well as studies with 
related individuals sampled from the population without ascertainment for any disease.
In summary, our study is by far the largest addressing the relation between telomere
length and adipocytokines. We found consistent and significant evidence for an inverse
correlation between telomere length and leptin, which was not caused by increased BMI 
or CRP. However, we could not find a consistent association between telomere length
and adiponectin. This study has elucidated the association between adipocytokines and
telomere length in both sexes.
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ABSTRACT 
Telomere shortening has been associated with multiple age-related diseases and 
with mortality. However, biological mechanisms responsible for these associations are
partially unknown. Recent metabolomics techniques enables capturing a wide range of 
intermediate metabolites in serum. In an effort to better understand the biology behind
the association of telomere length with age-related disease and mortality, we investigate
the association between telomere length and serum metabolites in 8,192 individuals from
seven independent cohorts from European ancestry.
We measured 163 serum metabolites with mass spectrometry and telomere length was 
determined using quantitative polymerase chain reaction. Using partial correlation analysis, 
we identified six metabolites to be significantly associated with telomere length, including
three phosphatidylcholines (PCs), two amino acids (methionine and tyrosine) and one
acyl-carnitine. Additionally we performed pathway analysis using Taverna to delve deeper
into the biological mechanisms and identified homocysteine metabolism as the biological
mechanism underlying the in common associations with telomere length between PCs and
methionine. 
In conclusion we found evidence for the involvement of lipid, homocysteine and thyroid 
metabolism in telomere length attrition, shedding light on the association of telomere 
length with age-related diseases and mortality.
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INTRODUCTION
Telomeres are located at the end of chromosomes and protect against spontaneous DNA 
damage, thus preserving genomic integrity [1, 2]. The progressive shortening of telomere
length with each subsequent cell division underlies the so-called mitotic clock, i.e. the
limited replicative capacity of a cell [3]. Replicative senescence and subsequent cell death
occurs when the mean telomere length reaches a critical value and telomere length is
therefore seen as a marker for biological age [4-6]. 
Short telomere length has been associated with multiple age-related diseases including 
coronary heart disease, hypertension and dementia [7-10]. In prospective studies, short 
telomere length has been associated to mortality [11-14], although not all studies confirm
this [15-17]. Also, the postulated causal factors of aging, oxidative stress and inflammation, 
are major contributors to accelerated telomere length shortening [18-21]. Although there is 
some evidence that telomere length is a marker of disease risk and early mortality, biological 
mechanisms underlying the association of telomere length with age-related diseases and
mortality are unknown.
Longevity in humans has been associated with various metabolic traits in the elderly, 
including blood pressure and lipids suggesting that changes at metabolic level are a 
key feature in longevity. Metabolic profiles, as generated by metabolomics [22], have
been associated with age and various aging-related diseases, such as type 2 diabetes,
atherosclerosis, cancer and Alzheimer’s Disease [23-27]. Metabolic profiles capture the effect 
of genes and environment, providing new and exciting opportunities to gain new insight 
in the underlying mechanism of the association between telomere length and mortality.
In this study we investigated the association between telomere length and serum 
metabolites in 8,192 individuals from 7 independent population-based cohorts from
Europe and Australia. Additionally we aimed to diverge which metabolic pathways are
represented by the metabolites significantly associated with telomere length in order to 
better understand the biology behind the associations.
METHODS
Cohort descriptions and measurements of telomere length and metabolites
Details on the separate cohorts can be found in the supplementary material. Details on 
the measurement of telomere length and the metabolites as measured by the AbsoluteIDQ 
p150 kit (Biocrates AG, Innsbruck, Austria) are also provided in the supplementary material.
Both telomere length and metabolite concentrations were measured centrally according 
to a common protocol. Telomere length and metabolite measurements were performed
in samples taken at the same time point. To ensure data quality each metabolite had
to meet three criteria for inclusion in the study, namely 1) coefficient of variation not
exceeding 25%; 2) less than 5% missing values; 3) median of metabolite concentrations
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above the limit of detection. This was done on a per cohort basis. The metabolites measured
include hexoses (H1), amino acids (AA), acyl-carnitines (AC), sphingomyelins (SMs), diacyl
phosphatidylcholines (PC aa), acyl-alkyl PCs (PC ae) and lyso PCs.
Analysis and multiple testing correction
In order to standardize telomere length measurement across populations we used a
Z-transformation. Metabolite concentrations were natural log transformed to attain a 
better approximation of the normal distribution. We performed partial correlation analysis,
adjusting for age and sex, and, if necessary, for family relationships. In the extended model
we additionally adjusted for body mass index (BMI). Meta-analysis was performed using 
R-package metacor, implementing DerSimonian-Laird (DSL) random-effect meta-analytical 
approach, per metabolite over all cohorts for which this metabolite passed pre-defined QC
parameters [28, 29]. Supplementary Table 1 contains the reasons for exclusion from the 
analysis of each metabolite.
A multiple testing-corrected statistical significance threshold for association of metabolite
concentrations with telomere length was defined at the meta-analysis level. We accounted
for multiple testing by Bonferroni-Sidak correction based on the effective number of 
independent variables (VeffLi) in the metabolite concentration data [30] (http://gump.
qimr.edu.au/general/daleN/matSpDlite/). The number of VeffLi was determined on the
correlation matrix of the quality controlled and log-transformed metabolomics data in the
ERF and NTR cohorts.
Biological interpretation of significantly associated metabolites
For interpretation of the observed associations we followed two bioinformatics approaches 
in parallel. First we employed a bioinformatics pipeline based on a workflow management
software tool called Taverna (http://www.taverna.org.uk) [31]to determine if the metabolites
significantly associated with telomere length shared a network space within two reaction
steps. We took as input any two metabolites; all the reactions within a radius of two steps
in the reaction space of the first metabolite are obtained from the KEGG database [32]. The
second metabolite is searched against the substrates and the products of the reactions 
obtained in the previous step. The presence of the second metabolite in any of the reaction 
steps is an indication that the two metabolites participate in reactions within two steps of 
each other; in the final step the path between the two metabolites is returned to the user. In 
order to prevent non-specific connections, an intermediate step filters out hub metabolites 
such as ATP, ADP, and NADP etc.
Second we derived a correlation matrix for the significantly associated metabolites and
visualized this in a correlogram using R package corrgram [28]. In the correlogram a blue
color represents a positive correlation while a red color represents a negative correlation. A 
darker color indicates a stronger correlation between two variables.
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RESULTS
General characteristics of the study populations are depicted in Table 1. Mean age of the 
cohorts ranged from 18.4 to 62.9 years. BMI was not available at the time of metabolite 
assessment in QIMR and was on average between 25 and 27 kg/m2 in the other cohorts.
Separate analyses to determine the effective number of independent variables of the 
metabolite concentration data for two cohorts that participated in this study (NTR and 
ERF) resulted in 46 VeffLi in both ERF and NTR, illustrating the consistency in the number of 
independent variables present in the metabolomics data from both cohorts. This resulted 
in a p-value of 0.001 (= 0.05/46) as significance level.
Table 1 | General characteristics of study populations.
telomere length
(T/S ratio)
Age
(years)
BMI
(kg/m2)
n n_BMI* % female mean sd mean sd mean sd
KORA 3003 2988 51.8 1.85 0.33 56.08 13.25 27.61 4.80
NTR 1314 1307 33.3 2.54 0.47 50.60 14.13 25.97 3.80
EGCUT 1084 1081 50.3 1.90 0.30 37.78 15.70 25.16 4.56
TwinsUK 1149 1149 100.0 3.58 0.64 53.72 10.76 26.44 5.35
ERF 806 806 53.7 1.79 0.37 47.76 13.97 27.17 4.81
LLS 643 643 50.1 1.44 0.27 62.91 6.61 26.65 4.01
QIMR 193 0 48.2 3.43 0.56 18.44 12.65 NA NA
*Number of samples with BMI measurements at the time of sampling for metabolite and telomere length analysis.
Of the 163 measured metabolites 131 passed quality control in at least one study. 27 
metabolites showed at least nominally significant correlation (p-value <= 0.05) with
telomere length (Table 2). The associations of six of these metabolites, lysoPC a C17:0, 
Met, Tyr, PC aa C32:1, C3-OH, PCaeC38:4, with telomere length passed the multiple-testing
corrected statistical significance threshold. When additionally adjusting for BMI the 
association with telomere length for five metabolites remained significant (lysoPC a C17:0,
Met, Tyr, PC aa C32:1, C3-OH). The top hit is for lysoPC a C17:0 with a correlation coefficient of 
0.05 in the age and sex adjusted model (p-value = 7.10*10-6) and a correlation coefficient of 
0.04 in the model additionally adjusted for BMI (p-value = 4.72*10-4). A list of all metabolite
correlations for both models with telomere length can be found in Supplementary Table 2. 
Supplementary Table 3 contains study-specific results for the age and sex-adjusted model.
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The pathway analysis using the Taverna Workflow shows that PCs and Met participate within 
two reaction steps of each other in homocysteine metabolism. Briefly, PC is converted to
betaine which is used to convert homocysteine to methionine. A correlogram of the six
metabolites significantly associated with telomere length in the first model is presented in 
Figure 1. The amino-acids Metionine and Tyrorsine are highly correlated with one another.
Metionine also shows strong correlation with the PC and lysoPC species.
Figure 1 | Correlogram of 6 metabolites associated with telomere length after correction for multiple
testing.
DISCUSSION
In this study we find significant association between telomere length and 6 metabolites, 
including three phosphocolines, two aminoacids and one acylcarnitine. Longer leukocyte
telomeres are associated with higher levels of lysoPCaC17:0 and PCaeC38:4, and with lower 
levels of Methionine, Tyrosine, PCaaC32:1 and C3-OH. Additional pathway analysis points to
an involvement of homocysteine metabolism in telomere length.
PCs constitute more than two-thirds of the total phospholipid content in HDL-cholesterol
[33], which is known to have anti-oxidant and anti-inflammatory properties [34, 35]. 
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Additionally, a common feature of cellular senescence, which is triggered by short telomeres,
is an increased cell surface and a higher uptake of PCs from HDL-Cholesterol with long-
chain fatty-acid residues thereby removing them from the serum [36]. Therefore, a possible
biological mechanism can be constructed tying lipid metabolism to telomere length and
aging. Short telomeres trigger cellular senescence which leads to an increase in the uptake
of PCs, thereby lowering their serum levels. 
Lower concentrations of methionine are associated with longer leukocyte telomere length.
Methionine is an essential amino acid and is important for methylation reactions and as 
a precursor for cysteine. However, excessive intake of methionine is known to be highly 
toxic and leading to increased oxidative stress [37]. Though some of the harmful effects of 
methionine have been attributed to its product homocysteine, there is evidence for a direct
toxic effect as well [38, 39]. Additionally, in animal studies it has been shown that restricting
methionine consumption increases lifespan [40].
Furthermore, lower tyrosine levels associate with longer leukocyte telomere length.
Tyrosine is a non-essential amino acid that is a precursor for several neurotransmitters,
including dopamine, as well as thyroid hormones (T3 and T4) [41, 42]. Low thyroid hormone 
levels have been associated with increased lifespan in multiple animal models [43-45]. This 
association has also been observed in humans [46-48]. The observed inverse association 
between telomere length and tyrosine therefore makes biological sense and links telomere
length to thyroid metabolism in longevity determination.
Pathway analysis using the Taverna Workflow revealed that four of the metabolites that
associated with telomere length (i.e., the three PCs and Met) participate in homocysteine
metabolism. Elevated homocysteine levels have previously been associated with shortened
telomere length [49]. Additionally, exposure of endothelial cells to homocysteine has been
shown to significantly increase senescence and to increase the amount of telomere length
lost per population doubling [50]. Homocysteine has also been associated to age-related 
disease and mortality previously [51-54]. Taking all evidence together, a biological link 
between homocysteine metabolism and telomere length in the determination of longevity
seems likely. The correlogram shows strong positive correlation between the two amino-
acids as well as between methionine and the PC and LPC species. Given that methionine
and PCs are in the same pathway (homocysteine metabolism) the correlogram supports the
findings of the Taverna Workflow.
A major strength of this study is that both telomere length and the metabolites were 
measured centrally and using standard protocols. A limitation of the Taverna pathway 
analysis is that it does not accept individual PC species as separate terms in the analysis nor
provides p-values.
In conclusion we find evidence for the association of homocysteine, thyroid and lipid
metabolism with telomere length in 8192 individuals from 7 independent cohorts. Thereby
shedding light on the biology underlying the association between telomere length and
mortality and age-related related diseases.
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ABSTRACT
Distinguishing true from false positive findings is a major challenge in human genetic 
epidemiology. Several strategies have been devised to facilitate this, including the positive
predictive value (PPV) and a set of epidemiological criteria, known as the “Venice” criteria. The 
PPV measures the probability of a true association, given a statistically significant finding,
while the Venice criteria grade the credibility based on the amount of evidence, consistency
of replication and protection from bias. A vast majority of journals use significance thresholds
to identify the true positive findings. We studied the effect of p-value thresholds on the PPV 
and used the PPV and Venice criteria to define usable thresholds of statistical significance.
Theoretical and empirical analyses of data published on AlzGene show that at a nominal 
p-value threshold of 0.05 most “positive” findings will turn out to be false if the prior
probability of association is below 0.10 even if the statistical power of the study is higher 
than 0.80. However, in underpowered studies (0.25) with a low prior probability of 1*10-3, a
p-value of 1*10-5 yields a high PPV (> 96%). 
Here we have shown that the p-value threshold of 1*10-5 gives a very strong evidence of 
association in almost all studies. However, in the case of a very high prior probability of 
association (0.50) a p-value threshold of 0.05 may be sufficient, while for studies with very
low prior probability of association (1*10-4; genome-wide association studies (GWAS) for 
instance) 1*10-7 may serve as a useful threshold to declare significance.
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INTRODUCTION
Distinguishing true from false positive findings is one of the most important challenges in
genetic epidemiology [1, 2]. Even though reaching formal statistical significance (p-value 
< 0.05), many published research findings were not replicated in further studies [3]. 
Several methodologies have been developed to address this issue and identify the true
positive findings. One of the approaches that were proposed to distinguish true from false
positives is the False Positive Report Probability (FPRP) [4]. FPRP measures the probability
of no true association between a genetic variant and disease given a statistically significant 
finding. The FPRP is a function of type 1 error (α), power (1-β) and prior probability (π)
( ). FPRP has been shown to never reach ‘acceptable’ values if the
prior probability is low [5]. This makes its application rather impractical in case of genome-
wide association studies (GWAS) in which millions of genetic variants are tested and only 
hundreds to thousands are expected to be associated [6, 5]. Although, a general problem 
of any Bayesian method is the necessity of a prior probability, however, in the case of the 
FPRP it is not possible to update it directly with a new prior probability [6-9, 5]. This is crucial 
in moving findings from gene discovery (GWAS) to a replication study in which the prior 
probability has increased substantially.
As an alternate Weitkunat and Ioannidis et al suggested true report probability (TRP) also 
known as the positive predictive value (PPV) [3, 5], which measures the probability of a true
association, given a statistically significant finding. The PPV is also a function of type 1 error,
power and prior probability ( ). As one would expect the FPRP and PPV 
are complementary probabilities to each other [3, 5]. In contrast to the FPRP, the PPV can be
viewed as the posterior probability of an association, which reflects the update of the prior
probability through the results of a study [5]. The PPV can be used as prior for subsequent
studies and was used to show that replication rather than power in the discovery phase
increases the credibility of a genetic association [5]. This conclusion has also been supported
by others [3, 10].
A more epidemiological approach is the evidence based criteria that were developed
at a workgroup meeting of the Human Genome Epidemiology Network (HuGENet) in
Venice, Italy, (subsequently we refer it to as the “Venice criteria”) to grade the credibility of 
cumulative genetic association evidence [11]. The Venice criteria assess genetic associations
on the basis of the 1. “amount of evidence based on sample size”; 2. “consistency of 
replication” across studies, and 3. “protection from bias”. Using these criteria, statistically 
significant meta-analyses in large populations with little heterogeneity between the results
of the individual studies and without evidence of bias are considered to display “strong” 
credibility in favor of the genetic association, whereas one or more violations of the criteria 
result in only “moderate” or “weak” credibility. As the criteria are only applied to statistically
significant associations, an implicit fourth criterion of the Venice criteria is that statistical 
significance can be determined [11]. A problem not addressed in the criteria is how to 
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define significance. As recognized for long in classical and clinical epidemiology, the major
problem in gene discovery studies is to define the threshold.
While most classical and clinical epidemiological studies use the threshold of 0.05 and ignore
the multiple testing, most GWAS adjust for multiple testing and use the p-value threshold
of 5*10-8 [12]. The rationale to adjust for multiple testing is based on the large number of 
tests performed (millions of genetic markers in a single study) in combination with the low
prior probability for association of a single variant. A less conservative p-value for GWAS is
based on the false discovery rate [13]. For 2.5 million SNPs tested, a p-value of 1*10-7 implies 
that the expected number of false positive results is equal to or less than 1, suggesting 
that the generally accepted p-value threshold of 5*10-8 might be slightly conservative [14]. 
Conversely a p-value of 0.05 for candidate gene studies is often used [11], based on the
argument that these targeted studies should be penalized less severely for multiple testing
as fewer tests are conducted. However, this threshold is recognized to be lenient and often
results in false-positive associations [11, 15].
Although we recognize the arbitrariness of defining a threshold for significance, in practice 
not only the Venice criteria but also the vast majority of (clinical) journals uses thresholds
(< 0.05, < 0.01, < 0.001) [16]. These thresholds have been reviewed recently, showing that 
the threshold determines whether a finding is published as well as the impact of the journal 
in which it is published [16]. In this paper we studied the effect of p-value thresholds on 
the PPV extending the work of Weitkunat and Ioannidis et al, we then used the PPV and 
the Venice criteria to define usable thresholds of statistical significance for various types of 
(genetic) association studies. 
MATERIALS AND METHODS
First, we performed simulations to determine the PPV for a combination of different p-value
thresholds, statistical power and prior probability of association. Second, we verified the
theoretically suggested thresholds by assessing the robustness of formally significant
genetic associations (p-value < 0.05) in the AlzGene database, which uses the Venice criteria
to grade nominally significant meta-analysis results after systematically combining genetic
association data in Alzheimer’s disease (AD), between 2005 and 2010 [17].
Venice criteria
The Venice criteria grade the strength of the epidemiological credibility of genetic 
associations by taking into account the amount of evidence, consistency of replication and
protection from bias [11]. In most applications to-date, the amount of evidence is graded as
“strong” (grade ‘A’) when the combined number of cases and controls in the minor genetic 
group exceeds 1000. The amount of evidence is scored as “moderate” (grade ‘B’) when the
number is between 100 and 1000, and “weak” (grade ‘C’) when it is below 100. For consistency 
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of replication, the degree of heterogeneity between study results (I2) is considered [18]. 
Point estimates of I2 below 25% receive an ‘A’, I2 between 25% and 50% receive a ‘B’ and I2
exceeding 50% receive a ‘C’. This criterion does not apply to meta-analyses with a p-value 
< 1*10-7 after exclusion of the initial dataset(s), as described in Khoury et al, 2009 [15]. For
protection from bias, the guidelines propose to consider potential sources of bias at the
level of individual studies including errors in phenotypes, genotypes and confounding, and 
at the level of meta-analysis including publication, first study and other selective reporting
biases [11]. Associations receive an ‘A’ when bias is not likely to affect the presence of the
association, a ‘B’ when there is no demonstrable bias, but important information is missing 
for its appraisal and a ‘C’ when there is potential or evident bias that may have invalidated
the association. “Strong” epidemiological credibility for significant association is assigned to
the meta-analyses that receive three A’s, “moderate” credibility to those that receive any ‘B’,
but no ‘C’, and “weak” credibility to those that receive a ‘C’ in any of the three criteria.
AlzGene database
The AlzGene database is a publicly available database of published genetic association
studies in AD (available at www.alzgene.org) and provides regularly updated meta-analyses
of eligible polymorphisms after inclusion of all available, published data [17]. Genetic
association studies are identified through systematic, regularly updated literature searches. 
Studies are included in AlzGene if they assess the association of polymorphisms and AD
risk and if they are published in English in peer-reviewed journals. Meta-analyses using the 
DerSimonian-Laird random-effects model [19] are conducted for polymorphisms for which
at least four independent datasets are available. Furthermore, meta-analyses are performed
after stratification for ancestry if three or more datasets are available, which typically is only
the case for studies using Caucasian and Asian descent populations. Nominally significant 
meta-analysis results are highlighted in a specific section of AlzGene (“Top Results”); the 
credibility of these associations is assessed on the basis of the Venice criteria, and results 
of this assessment are displayed online alongside the meta-analysis results (http://www.
alzgene.org/TopResults.asp). The criteria are implemented as described above with the
amount of evidence quantified as the number of minor alleles. The degree of heterogeneity 
between study results (I2) is also considered. For protection from bias, the following potential 
reasons for bias in the meta-analysis results are systematically assessed: summary OR < 1.15,
loss of significance after exclusion of first study, loss of significance after exclusion of studies 
violating HWE in control populations, evidence for publication/small-study bias using a 
modified regression test [20], and evidence for excess of statistically significant results [21]. 
These protection from bias tests are not applied to meta-analyses with a p-value < 1*10-7
after exclusion of the initial studie(s).
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AlzGene currently includes almost 1400 studies covering over 650 genes and 2900 
polymorphisms (as accessed on 5th January 2012) [17]. Meta-analysis results are available
for 320 polymorphisms.
Analysis
To investigate the p-value thresholds we used the PPV. The PPV is based on power (1-β; 
proportional to the product of effect and sample size), type 1 error (α) and prior probability 
of a true association (π). The PPV is calculated as: [3, 5].
We investigated the PPV for five different prior probabilities for association: 1*10-4, 1*10-3,
0.01, 0.10 and 0.50. The lower-bound prior probability reflects a GWAS situation in Caucasians
where 500,000 linkage disequilibrium blocks exist and are tested. Assuming that 50 of these 
blocks are truly associated with the trait of interest yields a prior probability of association 
of 1*10-4. The upper-bound prior probability of 0.50 reflects the replication of a genome-
wide significant finding or a finding that approaches genome-wide significance. The prior 
probability of 1*10-3 to 0.10 were chosen to reflect the prior probability in candidate gene
studies which may be low (1*10-3) when there is only limited prior evidence to suggest an 
association and higher (0.01-0.10) for SNPs that already show fairly compelling evidence for
association. In order to investigate the influence of the p-value on the PPV we varied the
p-value from 0.05 to 5*10-8 at a power of 0.25, 0.50, 0.80 and 0.95.
In order to evaluate the p-value threshold at which grading of formally significant genetic
association results no longer empirically changed from strong to moderate or weak 
credibility, we monitored the AlzGene top results list between 2005 and 2010 and followed
changes in the credibility assessment by the Venice criteria (see above). Meta-analyses of 
the AlzGene data and Venice grading were performed using the R programming language,
packages HardyWeinberg version 1.4, rmeta version 2.16, and a customized R code.
To determine the overlap between the top results at each time point (end of the year), we
counted the number of associations that had changed in credibility since the previous time 
point and overall. Specifically, we focused on meta-analysis results with strong credibility
that became weak or non-significant as well as results with moderate or weak credibility
that transitioned to strong credibility.
RESULTS
Investigating the influence of p-value on the PPV
Figure 1 shows the effect of varying the p-value threshold on the PPV. Figure 1A most 
closely resembles the situation in a GWAS, where the prior probability of association to the 
outcome is very low (1*10-4) and power to detect an association may vary from very low
(0.25) to high (0.95). As expected based on our experience in GWAS, “significance” defined
using p-value thresholds up until 10-5 implies a low PPV. However, the PPV rapidly increases
when using lower p-value thresholds, even if the power to detect an association is low
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(0.25). Significance defined at a p-value threshold of 1*10-7 or lower results in an excellent
PPV (> 99%) even if the study is underpowered (0.25).
For a prior probability of association of 0.10 (Figure 1D) we find that a p-value of 0.05 to
determine significance reaches a PPV of 67.9% when testing with a power of 0.95. However, 
when the prior probability of association is lower (e.g. 0.01; Figure 1C) the PPV is 16.1%.
When testing at a p-value of 1*10-5 the PPV is over 96% if the prior probability is low (1*10-3; 
Figure 1B) and to 100% if the prior probability is 0.01 to 0.50 (Figure 1C to 1E).
Figure 1 | Positive Predictive Value (PPV) of varying p-value thresholds.
Solid: power is 0.95; short dash: power is 0.80; dotted: power is 0.50; dot-dashed: power is 0.25
1A. PPV of p-value with a fixed prior probability of association of 1*10-4
1B. PPV of p-value with a fixed prior probability of association of 1*10-3
1C. PPV of p-value with a fixed prior probability of association of 0.01
1D. PPV of p-value with a fixed prior probability of association of 0.10
1E. PPV of p-value with a fixed prior probability of association of 0.50 obustness of grading over time
in AlzGene’s top list
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Supplementary table 1 displays the top results lists of the AlzGene database from 2005 
to 2010. All genes that contained at least one polymorphisms showing at least nominally
significant (p-value < 0.05) association in the AlzGene meta-analyses and that were assigned
“strong” credibility of association at any point in time between 2005 and 2010 are presented
in Table 1. In 2005, in the pre-GWAS era, five genes were graded to have strong credibility of 
association, while in 2010 only two of these five genes (40%) still showed strong credibility
of association. At that time point the meta-analysis result for one of the five genes was
no longer nominally significant, while two genes were down-graded to show only weak 
credibility of association. Of the two associations that retained their strong credibility, APOE
had a p-value of 9.27*10-120 and CST3 a p-value of 0.022. It should be noted that the meta-
analysis of the ε4-allele of APOE is not being updated in AlzGene due to its well-established 
unequivocal role in AD [17]. Accordingly, the Venice grading of APOE has not changed over
time. Regarding CST3, only two datasets have been added to the meta-analysis since 2005
making the stability of the findings on this gene difficult to interpret. Conversely, no gene
increased from weak/moderate to strong credibility grading between 2005 and 2010.
For a total of 12 out of 21 genes that had been graded to show strong credibility of 
association at any point in time between 2005 and 2010 the credibility had changed from
strong to weak or non-significance by 2010 (57%). The lowest p-value for a gene initially 
classified with strong credibility that subsequently lost its high grading was 1*10-4 (SORL1).
DISCUSSION
In this study, we found a strong association of the p-value to the PPV, implying that the lower
the p-value, the higher the probability that a finding is true. Although the p-value has for
long been ignored in epidemiology, the findings underscore its relevance in interpretation 
of the findings of a study. In line with the finding of Weitkunat et al we find that when the
prior probability of association is below 0.10, the PPV of a finding with a p-value of 0.05 is 
low even if the statistical power of the study is higher than 0.80. On the other hand, even in
an underpowered study (25%), a p-value threshold of 1*10-5 yields a high PPV (> 96%) if the 
prior probability of association is at least 1*10-3. Empirical analyses of the AlzGene database,
which uses the epidemiological approach of the Venice criteria (evidence, consistency and
bias), show that when using a p-value threshold of 0.05 as a threshold for “significance” 
upon meta-analysis of candidate genes in at least four independent datasets, still more than
half of the findings (12/21) will turn out to be false.
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The finding that a p-value threshold of 0.05 yields a low PPV when the prior probability of 
association is low corroborates findings of others [22, 23], and provides one explanation
as to why many candidate gene studies using this p-value threshold were not replicated.
This finding also extends to non-genetic studies of epidemiological risk factors. The use
of p-values in epidemiological studies has been a matter of debate for long [24]. However,
p-values are important determinants of the PPV. If the prior probability of association is 
high (e.g. 0.50) the PPV of a p-value threshold of 0.05 is nearly 90% when the power of 
the study is 0.80. A high prior probability can be anticipated for phase III clinical trials of 
new medical compounds, which are usually conducted after extensive research of the
compounds starting from cell cultures to animal models and early clinical studies in humans.
One may argue that the industry will not embark on phase III clinical trials unless the prior
probability of success is high (> 0.50). In observational studies, high prior probabilities 
could, for example, be assumed for genetic association studies that aim to replicate the
association of SNPs that were originally identified by GWAS with genome-wide significance 
(p-value < 1*10-7).
In the context of a very low prior probability of association, e.g. a GWAS that aims to discover 
novel genes with prior probabilities as low as 1*10-4 when a limited number of variants
(n = 50) determines the trait, it is clear that only very low p-values (< 1*10-7) yield a high PPV.
This corroborates the threshold of 1*10-7 or 5*10-8 that is commonly used in GWAS based on 
multiple comparison adjustment using Encode sequence data [12]. The recent finding that
most GWAS-derived associations with p-values between 1*10-7 and 5*10-8 are very often
replicated in subsequent studies also corroborates with this finding [25].
The results of our study may also be relevant for other “-omics” studies in which the general
aim is discovery without a specific hypothesis. Thousands of molecules and their ratios are
studied for which almost no prior proof of association to any trait exist. The prior probability 
for findings in these studies to be true will be very low. In this context it is interesting that 
findings from such studies have also been difficult to replicate in the past [26, 27]. It should 
be noted, that with the PPV we do not aim to determine whether a finding of association is
true or false but rather aim to give a probability that a finding is true or false. In hypothesis-
free discovery studies we are never able to discriminate between true positive and false
positive results. However, some findings are more likely to be true positives, as measured
by the PPV [3].
Though not explicitly tested, using the formula for PPV, for genome wide interaction
studies, we can extrapolate that the significance threshold needed is probably substantially 
lower as the prior probability of association is substantially lower than in classical GWAS. 
For example: if we study the main effects of 500,000 SNPs in a GWAS, in an interaction study 
(combination of 2 SNPs only) we test (500,000*500,000)/2 – 500,000 comparisons. This will
reduce the prior probability considerably. With a prior probability of 1*10-6 a PPV of 95% can 
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still be reached with a p-value threshold of 5*10-8, even when the power is low. However, if 
the prior probability is 1*10-7 a PPV of 95% is reached only with a p-value threshold of 5*10-9. 
A key issue in the estimation of PPV (or FPRP) is the need for the specification of the prior
probability of association. There will be many instances where researchers will have little
knowledge of the prior probability of association and in these situations, choosing an
appropriate p-value threshold may prove to be difficult or even impossible. This is particularly
true for candidate gene studies where genes are typically selected based on their potential
biochemical/functional implication. However, even though the biochemical involvement
may be true, genetic variations in the genes may not be relevant to pathogenesis if the
levels of the protein are predominantly determined by environmental factors. In addition,
studies that fine-map GWAS regions may fall in this category as even though the region
has been implicated it usually includes hundreds to thousands of variants, most of which
are not associated causally [28]. The prior probability that such a variant is causally related
to the disease is therefore still small, but considerably higher compared to the discovery
GWAS. Here a Bonferroni correction is often conservative, as many variants will be strongly
correlated to each other. A similar problem occurs in epidemiological research when
findings of animal studies are translated to humans [29]. The present study shows that
over a wide range of prior probabilities (1*10-3 – 0.50) and power (0.25 – 0.95), a p-value of 
1*10-5 yields a high PPV (> 96%). These conclusions are supported by meta-analysis based 
on genetic association data as posted on AlzGene. Longitudinal evaluation of the AlzGene
results by the Venice criteria also supports a more conservative p-value threshold of 1*10-5
to define “significance” for candidate associations. The lowest p-value of a marker that lost
its significance was 10-4 for SORL1.
The advantage of using a p-value threshold rather than the PPV or FPRP is that it 
is independent of a prior probability. Although one should consider the p-value as
continuous, many journals will want a threshold to determine which associations are true.
The general threshold of 1*10-5 could be used for this. However, it may be too conservative
in some instances (e.g. clinical trials or replication of GWAS) or too lenient in the case of 
gene discovery (e.g. GWAS). We therefore suggest two additional thresholds for high 
prior probability (> 0.50) and extremely low prior probability (< 1*10-4). These exploratory
suggestions for p-value thresholds are summarized in Table 2.
The low p-value thresholds needed to define “significance” imply the necessity of large 
datasets in genetics and epidemiology, in particular when the effect estimates are expected
to be small. An alternative approach in order to be able to employ less stringent significance
criteria to the initial dataset is to validate the results in a replication phase as is common
practice in GWAS designs [10]. 
We have shown that the p-value is an important determinant of the PPV, i.e. of the probability
that a finding is true. Whenever there is a high prior probability of association (> 0.50) a 
p-value threshold of 0.05 may be sufficient, while for studies with a low prior probability
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(< 1*10-4) a threshold of 1*10-7 is more appropriate. Perhaps the most important finding of 
our study is that over a wide range of prior probabilities (1*10-3 – 0.50) and power (0.25 –
0.95), a p-value of 1*10-5 yields a high PPV (> 96%). Similar to the use of the 0.05 threshold
at present, the threshold of 1*10-5 may be used for evaluating the significance of findings in
candidate gene studies. 
Table 2 | Suggestions for context specific p-value thresholds for significance.
Context High prior probability of 
association (> 0.50)
Unknown prior probability 
of association
Very low prior probability of 
association (< 1*10-4)
Example 1. Clinical trial
2. Replication of significant 
GWAS finding (1*10-7)
1. Candidate gene study
2. Translating findings from
model organisms to 
humans in epidemiology
1. GWAS
2. Other “-omics”, like
metabolomics and
lipidomics
P-value threshold 0.05 1*10-5 1*10-7
GWAS = genome wide association study
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Findings of this thesis and  
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176 | Chapter 5.2
In this thesis we aimed to identify genetic markers associated with longevity in genome-
wide association studies (GWAS) and candidate gene studies on the one hand. On the
other hand we aimed to gain a better understanding of telomere length and its relation to
longevity and mortality.
FINDINGS OF GENETIC RESEARCH IN LONGEVITY
We performed a GWAS on the longevity phenotype, yet failed to identify any new consistent 
associations (Chapter 2.1). In Table 1 we summarize the GWAS previously performed on 
longevity. The only consistent finding is APOE, originally a candidate gene [1], which was 
found to be associated with longevity at genome-wide significant level in half of the GWAS 
performed to date [2-7].
Table 1 | Summary of previous genome-wide association study findings.
Author Year Phenotype definition Sample size Main finding(s)†
Newman, AB 2010 Longevity: 90+
Comparison: died between 55-80
1,836 cases
1,955 controls
MINPP1 (6.8*10-7)
Deelen, J 2011 Longevity: 85+
Comparison: middle age
4,149 cases
7,582 controls
TOMM40** (3.4*10-17)
Nebel, A 2011 Longevity: 90+
Comparison: middle age
763 cases 
1,085 controls
APOC1** (1.8*10-10)
Malovini, A 2011 Longevity 90+
Comparison: 18-45
582 cases 
784 controls
CAMKIV (1.7*10-6)
Walter, S 2011 Survival: all-cause mortality
Follow-up: 10.6 (5.4) years
25,007 total
(8,444 deaths)
OTOL1 (1.6*10-6)
Sebastiani, P 2012 Longevity 100+
Comparison: middle age
801 cases 
914 controls
TOMM40** (2.4*10-10)
†Gene-name and p-value reported in the publication; **In high LD with APOE
In a recent and currently unpublished GWAS performed by Deelen et al in the European
Longevity Consortium the APOE region was confirmed and a new region (5q33) was found 
to be associated with longevity (personal communication). The study of Deelen et al
consisted of 5,406 longevity cases (90+) and 16,121 younger controls (< 65 years of age). We
could not replicate the newly identified variant (5q33) in our own GWAS results. Compared 
to our study in Chapter 2.1, Deelen et al had a similar number of longevity cases (6,036 
in our study) but more controls (3,757). In Chapter 2.1 we chose to only include controls
deceased before 80 years of age to increase the contrast between cases and controls. 
However, frequency distributions of suggestively associated variants in both studies across
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different age-categories reveal that the allele frequencies are stable until 85 years of age.
For example, the identified variant in FOXO3 has a minor allele frequency of 0.28 in all
age-categories below 85 years of age, while in those older than 85 years of age the allele
frequency is 0.34. This suggests that the differences in findings between Chapter 2.1 and 
Deelen et al are not explained by the differences in controls. At this point the novel finding
of Deelen et al (5q33) may be a false positive. A future joint-analysis enlarging the case 
sample will be performed to elucidate the association. The stable allele frequency until age 
85 suggests that restricting our control group to individuals who have died is not necessary.
Therefore, in order to increase our control population in the future joint-analysis our control
definition will include all individuals younger than 65 years of age at baseline, as is the case 
in the current GWAS of Deelen et al.
Despite the lack of success of GWAS in identifying genetic variants associated with 
longevity, our investigation of the total variance explained by common variants tagged by
GWAS shows that over 80% of the heritability can be explained by these variants (Chapter
2.2). This strongly suggests that very many variants all with very small effects are involved 
in longevity following the infinitesimal model of genetic contribution to common traits.
The infinitesimal model suggests that eventually nearly every gene, and also variants in 
regulatory elements, contribute to longevity, mostly with effect sizes that are so small that
it would take very large study sample sizes to detect them [8, 9]. For example, detecting an
odds ratio of 1.1 with an allele frequency ranging from 0.05 to 0.50 would require 34,906
to 175,931 longevity cases. This number will only increase as the effect size decreases. 
Increasing the sample size beyond that which was used in this thesis (6,036 cases and 3,757
controls; Chapters 2.1) may help identifying some of these variants with larger effects. 
However, another avenue may be to consider other definitions of the longevity phenotype.
It has been argued that longevity defined as 90+ is not a sufficiently extreme age for gene
discovery. Centenarians (100+) should be used instead [6]. However, our finding that over 
80% of the heritability of longevity (90+) can be explained by common variants contradicts
this. After all, in order to become a centenarian you must first reach the age of 90. Variants 
associated to centenarian status should also be associated to reaching the age of 90+.
Though studies focusing on centenarians exist, only three have genome-wide association
data allowing hypothesis-free testing of the whole genome [6, 10]. Moreover, due to the 
phenotype (100+) being rare, these studies are small (less than 1,000 cases) which hinders 
genetic discoveries as well [6, 10]. In population-based settings very few individuals
included in the study are expected to reach centenarian status, which is why the longevity
definition of 90+ is more commonly used (Table 1) [11]. For example, in the Rotterdam 
Study 1,004 individuals have reached 90 years of age since the start of the study over 20 
years ago. Of these less than 5% (46) have reached centenarian status. Additionally, it is 
known that the longevity phenotype is very heterogeneous even in centenarians, namely 
consisting of the survivors (onset of aging disease < 80 years), delayers (onset of aging 
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disease between 80 and 100 years) and escapers (onset of aging disease > 100 years) [12]. 
This heterogeneity is expected to be worse in younger age cut-offs for longevity, like 90+, 
but is present in centenarians as well. Such heterogeneity makes identifying new genetic 
associations challenging, though not impossible as variants are being found in diseases like
type 2 diabetes which is also known to be heterogenic [13, 14].
A previously suggested approach to solve the heterogeneity issue in longevity could be the 
development of novel phenotypes, such as the healthy aging index (HAI) [15]. The HAI uses
markers of 5 major organ systems that are known to predict mortality and disability. The 
systems included are vascular (carotid wall thickness), brain (white matter grade on MRI),
kidney (cystatin-c), lung (forced vital capacity) and metabolic (fasting glucose levels) [15]. 
The HAI is able to distinguish a wide risk gradient, but is most remarkable for its advantage
in identifying low risk individuals. As a single factor, the HAI prediction of mortality is similar
in magnitude to age itself. When investigated together, age remained partly independent, 
but the HAI explained 40% of the effect of age [15]. 
Another phenotype previously explored is all-cause mortality [7]. As prospective follow-
up studies with a continuous outcome are more powerful than case-control analyses, this 
might provide new insight in the phenotype. Though this design has been successfully
applied in animal models [16] and in human genetic research of blood pressure [17], no
new genome-wide significant associations were identified in the GWAS by Walter et al [7].
Another avenue to consider is further investigation of rare variants. Though most of the
heritability of longevity can be explained by common variants, the high recurrence rate of 
longevity in some families suggests the involvement of rare genetic variants in these families
[18]. Next Generation Sequencing (NGS) may help us uncover such variants [19]. However, 
we could not identify such variants in the Rotterdam Study by sequencing the exomes of 
202 longevity cases and 267 controls at an average depth of 45x. Suggestive evidence for 
the involvement of rare variants in WSCD2 in longevity was observed (Chapter 2.2). Possible 
reasons for our failure to identify rare variants are characteristics of our sample, which was
small and not pre-selected for long-lived families in which rare variants are expected to
play a larger role, and limiting sequencing to only the exome, that is about 1% of the entire
human genome. Even though rare variants are unlikely to explain the variability of the 
phenotype in the general population, such variants can give us important clues to genes 
and biological pathways involved in longevity.
HEAT SHOCK PROTEINS IN RELATION TO AGE-RELATED NEURODEGENERATIVE
DISEASES AND LONGEVITY
In animal studies the insulin pathway appears to be the key pathway determining mortality
and longevity (see Chapter 1). Studies in Caenorhabditis elegans and Drosophila melanogaster
suggest that heat shock proteins (HSPs) may play a role in lifespan [20, 21]. HSPs play in 
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particular a role in protein folding and have been implicated in neurodegenerative disorders
that are characterized by protein misfolding [22-24].
In this thesis we performed a comprehensive search for the involvement of common genetic
variation in HSPs in common age-related neurodegenerative diseases and longevity.
Previous candidate gene studies investigating HSPs only tested a limited number of SNPs 
in a limited number of genes [25-27]. First, we aimed to elucidate the association of these 
genes with Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). These are two diseases
in which protein folding is known to be involved and are therefore of interest in relation to
aging and longevity (Chapters 3.1 and 3.2). 
Pathological research has implicated several HSP families in AD including HSP70 and
prefoldin (see Chapter 3.1). In this thesis, we studied a total of 79 genes from the HSP70
family and its major co-chaperones, including HSP40 and prefoldin, in 462 patients and
5,238 controls from the Rotterdam study. We found prefoldin 2 (PFDN2) to be associated with
AD. The minor allele of rs12118313 was associated with increased AD risk, with an odds ratio 
(OR) of 1.19. Further, pathway analysis pointed to an overall involvement of the prefoldin
family of genes (p-value = 0.03; see Chapter 3.1). The findings were not replicated in the 
ongoing GWAS of AD [28, 29]. This raises the question whether the prefoldin association 
with AD as reported in Chapter 3.1 are a false or true positive. Our simulation studies in
the Chapter 5.1 may shed light on the question. The p-value for the association is as high 
as 0.003. As discussed in Chapter 5.1, findings with such a high p-value have a low positive
predictive value. For the PFDN2 finding the positive predictive value ranges between 40 and
80% depending on the prior probability of association, which is difficult to estimate. The
same argument holds for the findings of the pathway analyses which were not replicated
in the recent genome wide association studies of AD [28, 29]. Although the HSP10, HSP60,
HSP70 and HSP90 families play a key role in the pathogenesis of PD, our genetic studies of 
the genes encoding for these protein are negative. In total we studied 3,828 variants in 27 
genes in 134 patients and 5,422 controls. We could not find any statistical evidence for HSP
gene involvement (Chapter 3.2). Also in GWAS of PD HSP genes have not emerged [30].
Next we studied the relation of HSP70, small HSP (sHSP) and Heat Shock Factor (HSF) with 
all-cause mortality as a major determinant of longevity (Chapter 3.3). We chose for all-cause 
mortality as definition for longevity in this study as it has been suggested that using the 
entire age-range of deaths is a more powerful approach in gene discovery compared to a
dichotomization of the outcome as has been used previously [7]. As discussed above, this
approach allows us to maximize the statistical power of research using the information of 
all participants (N= 5,974). In total we studied 4,430 markers in 31 genes. Of these only 
HSF2 was associated with mortality at a p-value of 0.003. In the Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE) we could replicate the finding in 8 cohorts.
However in the joint analyses including 25,007 subjects we still obtained a p-value as high
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as 0.003 yielding a positive predictive value of 40 to 80% depending on the prior probability 
of association. 
Recently evidence has come to light that the mitochondrial unfolded protein response, 
which is mitigated by HSP60 and HSP70, is involved in longevity in animal models, such
as C. elegans and Mus Musculus [31]. Whether this can be translated to humans is currently
unknown. HSP complexity is increased in humans as compared to lower organisms 
[32]. However, in the mitochondria only HSP70 member HSPA9 or mortalin [33], and the
chaperonin complex (consisting of HSP60 and HSP10) [34] are expressed in both lower 
organisms as well as humans. Interestingly, mortalin has been associated with longevity in C. 
elegans previously [35]. Again we did not find any evidence for the involvement of this gene 
in longevity in humans in the GWAS (Chapter 2.1) or the HSP targeted analyses (Chapter 
3.3). Rare variants rather than common variants in these genes may be interesting as these
variants are expected to have stronger effects on the phenotypes. In our exome study
(Chapter 2.2) we identified 40 exome variants in HSPA9, 38 in HSP60 and 6 in HSP10. Burden 
test analysis did not reveal an association of these genes with longevity (p-value > 0.20).
From a methodological perspective it should be noted that difficulties of defining the
longevity phenotype as discussed earlier also hamper the findings of theses analyses and
have been recognized in the literature [11]. HSPs are emerging in GWAS of other traits 
like chronic widespread pain [36] and lean body mass (confidential). Both pain and loss
of lean mass (muscle) are associated with mortality [11]. Thus, systematic investigation of 
other traits associated with longevity may elucidate the role of HSP genes in morbidity and 
mortality.
TELOMERE LENGTH DISCOVERIES
Although the sequence of telomere length and the discovery of telomerase, the enzyme
that can rebuild telomeres, have led to the awarding of the Nobel prize (2009; Elizabeth
Blackburn, Carol Greider and Jack Szostak), little is known about the biological processes 
and environmental factors that influence telomere length. The only well-replicated
associations with telomere length in the literature are age, sex and genetic factors [37,
38]. Many other associations, including smoking, diet, body fat, leptin, adiponectin and 
blood pressure, have been proposed but never consistently associated [39-45]. Problems 
with the preferred telomere length measurement technique (gel electrophoresis Telomere
Restriction Fragment) contributed to the non-replication. This technique has a high cost
with regard to both DNA and money, resulting in small sample sizes [46] and consequently
results in false positive and false negative findings. 
With the new qPCR method to estimate (relative) telomere length based on the copy 
number of a single copy gene (usually 36B4) it has become feasible to measure telomere
length in large cohorts and at multiple time points [46]. In this thesis, we made a start
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at untangling previously suggested associations with telomere length using the qPCR
method for telomere length measurement. In our first study we determined the heritability
(Chapter 4.1). As previously reported, the heritability is high (70%; see Chapter 4.1). We
also observed a mother-offspring (0.42) and father-offspring (0.33) correlation. That this
did not differ between male and female children, suggests that this maternal effect on 
telomere length determination is not X-chromosomal in nature. In Chapter 4.1 we found 
a significant positive paternal age effect on telomere length determination, i.e., children of 
older fathers have longer telomeres. This may be related to high telomerase levels in sperm
causing telomere length to be maintained, and even lengthened, despite both mitotic and 
meiotic divisions during the proliferation and differentiation of the sperm cells [47]. This is of 
interest as increasing paternal age has an increased risk of new mutations which previously 
have been associated to autism [48].
Halaschek-Wiener et al reported a reduced variance in telomere length in the elderly 
compared to midlife controls [49]. They attributed this to the risk associated with both long 
and short telomeres, suggesting there may be an optimal telomere length that is protective 
for healthy aging. We investigated whether there is a reduced variance in telomere length in 
the elderly due to a survivor effect in telomere length, as this could explain the inconsistent 
results for the association between telomere length and mortality (Chapter 4.2). We found 
a significant reduction in telomere length variance in the population from young adulthood
to old age, which was stronger in men compared to women. Additionally we found that the 
(grand)children of the oldest-old had significantly longer telomeres compared to others in
the same age-range, which suggests that the oldest-old started life with long telomeres.
This finding is relevant when interpreting the inconsistent findings with longevity and
mortality [40, 50-59] as telomere length measured at old age is not representative for
those at the start of life. In studies conducted late in life not only the telomere length is
not representative anymore for early life but the variance is significantly reduced making it
statistically difficult to identify associations.
We also find an association of telomere length with height. A male-specific association 
has been observed in two separate animal species previously (Chapter 4.3). We also find 
a significant inverse association between telomere length and height in males (r = -0.08;
p-value = 5.8*10-4), but not in females (r = -0.02; p-value = 0.302). Results from a Mendelian 
randomization analysis are compatible with the hypothesis that differences in height cause 
differences in telomere length, as several genes involved in height are associated with 
telomere length in the inverse direction.
Finally, we investigated associations with metabolic traits and metabolome-wide data. We 
first studied adiponectin [39, 45, 60] and leptin [39, 42, 44, 45, 61, 62] for which inconsistent
associations with telomere length have been reported. We investigated the association of 
both adiponectin and leptin with telomere length in 7 studies including 11,460 participants
of the European Network for Genetic and Genomic Epidemiology (ENGAGE) consortium 
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(Chapter 4.4). We identified a highly significant association between leptin and telomere 
length (r = -0.05; p-value = 1.81*10-7), but not between adiponectin and telomere length
(r = 0.004, p-value = 0.763). A full examination of the association of 163 metabolomic traits
with telomere length is presented in Chapter 4.5. Previously a set of 22 age-associated
metabolites has been shown to explain 5% of the total telomere length variation in the
population by Menni et al [63]. We identified six metabolites that implicated the involvement
of homocysteine, lipid and thyroid metabolism in telomere length biology (Chapter 4.5). 
Menni et al used a different approach to measure metabolites, which makes a one on one
comparison between the two studies impossible. However, several lipid metabolites were
identified in the study by Menni et al [63], supporting our findings.
Recent GWAS has provided seven genetic loci to be associated with telomere length,
but the very high heritability (h2 = 70%) remains unexplained [38]. Also the intriguing
maternal aspect to telomere length inheritance we observed remains to be identified 
[37]. The investigation of mitochondrial DNA variations as well as anything expressed in
utero will be interesting to investigate in this sense. Additionally, NGS shows promise to
further unravel the high heritability of telomere length. NGS technology captures most
variations in the genome including the variants which are neither well represented on 
the regular genome-wide genotyping arrays nor can be imputed with confidence [19].
Genetic research on telomere length has been focused on common variation, following
the common trait-common variant hypothesis [64]. However, as shown in other highly
heritable traits such as height, which can be explained by the infinitesimal model of genetic 
contribution to common traits, also rare variants are expected to play a role in telomere 
length [9, 65]. Sequencing may unravel the rare/ individual specific/population specific
variants, to identify which also large samples will be required. Given the ongoing large scale 
sequencing efforts in the world and the developments of tools for the analysis and pooling 
of such data, analyzing rare variants seems to be the most logical next step.
So far, most research has focused on single measurement of telomere length. Our study
of telomere length variation presented in Chapter 4.2 suggests that this may not be 
representative. Recent studies show that telomere length changes over time might be
more informative and has an independent effect of telomere length at baseline in the 
determination of mortality and other age-related diseases [54]. Here again studies are
struggling with small sample sizes and lack of samples for replication. To truly unravel 
telomere length in an epidemiological setting, more studies with repeated telomere length
measurements are needed. Existing large follow-up studies should consider investing in
telomere length, both as an outcome and as a determinant of major age-related diseases
and longevity.
Currently, most research on telomere length is focused on older individuals with only a few
studies on adolescents and children [66, 67]. Our study on the reducing telomere length 
variation with age, suggests that telomere length is already selected on in young adulthood 
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(Chapter 4.2). A question to be answered is if such a trend starts even earlier in life. Though
we do not see a change in telomere length variation in the population between 20 and 
40 years of age, we cannot exclude that a change in telomere length variation before the 
age of 20 has occurred. Understanding telomere length dynamics at young age is vitally 
important if we want to understand the influence of these dynamics on age-related traits
and longevity. Early life events may predispose to telomere shortening. Understanding 
these dynamics will be important for future preventive studies and translation.
However there are hindrances to overcome. Maintaining telomere length is important 
for maintaining cells, however early experiments increasing telomerase levels in order
to maintain telomere length in mice resulted in high cancer rates [68]. Also in humans 
telomerase is activated in 90% of cancerous cells, maintaining telomere length despite the
large number of population doublings [69]. Finding out how this delicate balance works will 
be an important step in increasing longevity.
OMICS AND MULTIPLE TESTING
Although not a main point of this thesis, we briefly touched on metabolomics in relationship
to telomere length in Chapter 4.5. As more studies obtain metabolomics data, large scale
research into this field becomes possible, yet very challenging. Running a GWAS on 130+ 
metabolic traits is computationally challenging, although software to handle this data is in
development (http://www.genabel.org/packages/OmicABEL).
Most of the metabolites measured in metabolomics are still poorly understood. Although
genetic associations are uncovered, if we ever want to make full use of this technology it will
be vital to better understand these metabolites and what effects they have in disease and
in health [70]. Also here challenges, like the influence of medication and lifestyle, will need
to be overcome.
A final challenge with metabolomics and indeed all “-omics” is multiple testing correction. 
In Chapter 5.1 we show, based on simulations and the Alzgene database, that independent 
of power (related to sample size, frequency and effect size) and prior probability of 
association, a p-value of 1*10-7 gives an excellent posterior probability of association. In
GWAS this threshold is already commonly used. For metabolome-wide association studies 
(MWAS) the prior probability of association will also be low, leading to a strong likelihood of 
false positives. However, as these metabolites are highly correlated, we might not have to 
be as stringent as in GWAS. 
Currently, to adjust for multiple testing 3 strategies are used in literature, namely 1) 
Bonferroni correction; 2) PCA adjustment; 3) adjustment for number of independent
variables. The first strategy, where one adjusts for the exact number of metabolites tested, 
will be very conservative due to the high correlation of the metabolites. The second strategy 
is based on principal component analysis and adjusts for the number of significant principal
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components explaining a given percentage of the variance. This strategy is scientifically
not correct as you do not a priori know whether the metabolites one will deem to be
significant, are explained well by the principal components you adjust for. It might be that
the significant finding is not properly captured by the multiple testing correction. The third 
strategy, which we used in this thesis, estimates the number of independent variables to
be adjusted for based on the eigenvalues of a correlation matrix. This approach was first 
proposed for genetic associations where linkage disequilibrium creates a similar problem 
[71]. More research will be needed to come to a consensus within the metabolomics
research community to determine a strategy to adjust for multiple testing.
CONCLUDING REMARKS
In this thesis we have performed a comprehensive investigation of candidate genes (HSPs) 
as well as a GWAS to identify genetic variants associated with longevity, yet we did not
reveal any new associations. Despite this lack of success over 80% of the heritability of 
longevity can be explained by very many common variants with very small effects. Given
this lack of success it may be more fruitful to focus on telomere length as a phenotype in
the near future. Telomere length has yielded genome-wide significant results [38] and the
telomere length maintenance pathway has been shown to be associated with longevity
previously [72]. In my opinion, future research should therefore focus on telomere length
and in particular on telomere length change over time.
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SUMMARY
Longevity is usually defined as age at death or survival to an exceptional age, such as 90
years or older, or even 100 years or older in humans. The genetic contribution to longevity 
has been estimated to be up to 40%, yet no consistent genetic associations, except for
candidate genes APOE and FOXO3, have been identified. There are three well-known 
biological pathways involved in longevity in animal models, namely Insulin-like growth
factor signaling, stress resistance and senescence as mediated by telomere length.
The primary focus of this thesis was to find genetic markers associated with longevity and 
a longevity-associated trait telomere length using both genome-wide association studies
(GWAS) and candidate gene association studies. Using a candidate gene approach we 
also made an effort to identify genetic variants associated with longevity-related diseases 
including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD).
In Chapter 2.1 we investigated the genetic architecture of longevity, defined as individuals
reaching at least 90 years of age and controls defined as individuals that died between 55 
and 80 years of age, in the Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) consortium (cases = 6,036, controls = 3,757). No new genome-wide significant 
associations were discovered. Moreover none of the previously suggested longevity loci
from literature, except for APOE and FOXO3, were replicated illustrating the complexity of 
the longevity phenotype. This large scale GWAS was focused only on detecting variants that 
were common in populations and exerted small effects on longevity. A potential reason
for not finding significant associations with longevity could be the involvement of rare
genetic variants with relatively large effects on longevity, that were not captured by these 
GWAS. The only ways to identify these were to sequence or use imputed genetic variants
from the 1000 Genomes Project for analysis. We studied the rare variants using both
sequencing and 1000 Genomes imputed dataset in the Rotterdam Study to discover large
effect rare variants that might influence longevity (Chapter 2.2). However, we could not 
find significant evidence for the involvement of rare variants with large effects on longevity.
On the contrary, what we discovered was that the unidentified common variants present
on genome-wide genotyping arrays explained over 80% of the total genetic variance of 
longevity. This implies that the effect of each individual common variation is very small and
that these can be discovered by increasing the sample size in the GWAS.
Chapter 3 focusses on candidate genes involved in the stress response, namely Heat Shock 
Proteins (HSPs). We investigated the association of these genes with longevity and age-
related diseases like AD and PD, which are often identified as protein folding disorders. The
HSP families investigated included HSP10, HSP40, HSP60, HSP70, HSP90, BAG, prefoldin,
small HSP (sHSP) and Heat Shock Factors (HSFs). We investigated the association of HSPs with
AD, including 462 patients and 5,238 unaffected participants derived from the Rotterdam
Study, and sought replication in the Framingham Heart Study and Cardiovascular Health 
Study (Chapter 3.1). Adjusted for multiple testing we found a small but consistent effect 
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of rs12118313 located 32kb from PFDN2 (OR = 1.19; p-value = 0.003). In a formal pathway
analysis we found nominally significant evidence for the association of three classes of 
co-chaperones (BAG, DNAJA and prefoldin) with AD. No effect of the HSP70 family on AD 
was identified. Three genes showed evidence of association with PD, namely Chaperonin
(HSP60 + HSP10), HSPA13 and HSF5 (Chapter 3.2). None of these genes were replicated in an 
online-available GWAS on PD with p-values lower than 10-4. While three SNPs (rs12574703,
rs7797781 and rs1416733) in genes HSPA8, HSPB1 and HSF2 showed evidence for association
(p-values = 0.001, 0.002 and 0.003) with all-cause mortality replication in CHARGE was
successful for HSF2 (rs1416733, p-value = 0.003) only (Chapter 3.3). The identified SNP is 
a known cis-eQTL for HSF2, which is one of the main transcription factors influencing HSP 
transcription.
Next we focused on telomere length, which is considered as a biomarker of aging. As
telomere length is a relatively new phenotype Chapter 4 focuses on various exploratory
analyses of telomere length including heritability analysis and factors that might influence
telomere length. In Chapter 4.1 we investigated the heritability, mode of inheritance and
the influence of parental age on telomere length in six independent family-based cohorts 
including 19,713 participants. The heritability of telomere length was estimated to be 70%
(p-value = 2.31*10-111). We additionally observed a stronger mother-offspring (r = 0.42;
p-value = 3.60*10-61) than father-offspring correlation (r = 0.33; p-value = 7.01*10-5). This did 
not differ between male and female offspring, suggesting a maternal, non-X-chromosomal, 
inheritance component. We found a positive association between paternal age and 
telomere length (beta = 0.005; p-value = 7.01*10-5).
The high heritability of telomere length and the family-based structure of the ERF population
enabled us to extrapolate the telomere length of the 90+ to younger ages and also study
the so called survivor effect, i.e., the reduced variation in telomere length in the elderly 
(Chapter 4.2). Survivor effect has been cited as the reason for the inconsistent association 
between telomere length and mortality. We observed that the mean telomere length of 
the grandchildren of the oldest-old was significantly longer (p-value = 2.60*10-4) compared
to others in the same age-range. This suggests that the oldest-old started life with long
telomeres. Moreover, we observed a decreasing variability of telomere length from young 
adulthood to old age (p-value = 4.23*10-6), pointing to the presence of a survivor effect.
Average telomere length is significantly higher (p-value = 2.54*10-7) and telomere attrition 
rate lower (69.9%) in women compared to men. Differences in mean telomere length have
been attributed to differences in height between genders as larger bodies require more
cell replications which results in the reduction of telomeres. Building on this hypothesis, in
Chapter 4.3, we investigated the association of height with telomere length in humans. We
observed a significant correlation between telomere length and height in men (r = -0.08;
p-value = 5.8*10-4) but not in women (r = -0.02; p-value = 0.30). This was in line with the
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earlier findings of the studies performed in animals. Mendelian Randomization analysis
suggested that height causally influences telomere length.
Other factors influencing telomere length are oxidative stress and inflammation, which also
have an influence on the most prominent adipocyte-derived protein hormones, namely
leptin and adiponectin. In Chapter 4.4 we investigated the association of telomere length 
with these hormones. In seven independent cohorts from the ENGAGE consortium including 
11,460 participants the partial correlation between telomere length and adiponectin/leptin
was investigated adjusting for age and sex. In extended models we additionally adjusted for
body mass index (BMI) and C-reactive protein (CRP). No association between adiponectin 
and telomere length was identified. The association between telomere length and leptin 
was highly significant (r = -0.05; p-value = 1.81*10-7). Telomere length showed no association 
with BMI or CRP. Adjusting for BMI or CRP did not change the results. Sex-stratified analysis 
revealed no differences between men and women.
Finally, in an effort towards a better understanding of the biology behind the association
of telomere length with age-related diseases and mortality, we investigated the association 
between telomere length and serum metabolites in 8,192 individuals from the ENGAGE
consortium (Chapter 4.5). Partial correlation analysis identified six metabolites to be 
significantly associated with telomere length consistently across populations. These
metabolites included three phosphatidylcholines, two amino acids (methionine and
tyrosine) and one acyl-carnitine. Together these metabolites implicate the involvement of 
lipid, homocysteine and thyroid metabolism in telomere length attrition.
This thesis shows that the longevity phenotype is highly complex and resistant to finding
new genetic associations. For the biomarker telomere length we have only scratched the
surface of understanding its association with longevity. In Chapter 5 (general discussion)
the difficulty in distinguishing true from false positive findings in genomics and other -omics
studies is discussed, as well as further steps to investigate longevity and telomere length.
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SAMENVATTING
Langlevendheid wordt meestal gedefinieerd als leeftijd van overlijden of overleving tot 
extreme leeftijd, bijvoorbeeld 90 jaar en ouder of zelfs 100 jaar en ouder in mensen. De
genetische bijdrage aan langlevendheid wordt geschat op 40%, maar er zijn nog geen 
consistente genetische associaties ontdekt, behalve de kandidaatgenen APOE en FOXO3.
Er zijn drie bekende biologische processen betrokken bij langlevendheid in dierstudies,
namelijk insuline-achtige groeifactor signalering, stress resistentie en het beëindigen van
de celdeling wat gereguleerd wordt door telomeerlengte.
De primaire focus van dit proefschrift was om genetische markers te vinden die geassocieerd 
zijn met langlevendheid en telomeerlengte, gebruik makend van zowel genoom-wijde
associatie studies (GWAS) als kandidaatgen associatie studies. Gebruikmakend van
de kandidaatgen methode heb ik ook een poging gedaan om genetische varianten
geassocieerd met langlevendheid gerelateerde eigenschappen, Alzheimer(AD) en de ziekte 
van Parkinson (PD) te ontdekken.
In Hoofdstuk 2.1 hebben we de genetische architectuur van langlevendheid, gedefinieerd
als mensen die minstens 90 jaar oud zijn geworden en controles gedefinieerd als
individuen die tussen de 55 en 80 jaar oud zijn overleden, in het CHARGE consortium 
onderzocht (langlevende deelnemers = 6.036, controles = 3.757). Geen nieuwe genoom-
wijd significante associaties werden ontdekt. Bovendien werden voorheen in de literatuur
genoemde associaties niet gerepliceerd, behalve APOE en FOXO3. Dit benadrukt de
complexiteit van langlevendheid als fenotype. Deze grootschalige GWAS was gericht op het 
vinden van varianten die veelvoorkomend zijn in de populatie en een klein effect hebben op
langlevendheid. Een mogelijke reden voor het niet vinden van significante associaties met 
langlevendheid kan zijn dat zeldzame genetische varianten met grote effecten betrokken
zijn bij langlevendheid, welke niet door GWAS bestudeerd kunnen worden. De enige manier
om deze varianten te identificeren is door sequentie data te gebruiken of door de varianten
te imputeren met behulp van het 1000 Genomen Project. We bestudeerden de zeldzame
varianten gebruikmakend van zowel sequentie data als met behulp van 1000 Genomen
geïmputeerde data in de Rotterdam Study om zeldzame varianten met grote effecten te
ontdekken, die invloed op langlevendheid hebben (Hoofdstuk 2.2). We hebben echter 
geen significant bewijs gevonden voor de betrokkenheid van zeldzame varianten met grote
effecten bij langlevendheid. Daarentegen, hebben we ontdekt dat de ongeïdentificeerde
veelvoorkomende varianten aanwezig op genoom-wijde genotypering arrays meer dan
80% van de totale genetische variatie van langlevendheid bepalen. Dit suggereert dat het 
effect op langlevendheid van iedere individuele veelvoorkomende variant erg klein is en
dat deze ontdekt kunnen worden door het aantal individuen in GWAS te vergroten.
Hoofdstuk 3 richt zich op kandidaatgenen die betrokken zijn bij de stress respons, 
namelijk Heat Shock Proteins (HSPs). We onderzochten de associatie van deze genen
met langlevendheid en leeftijd-gerelateerde ziektes zoals AD en PD welke beide als
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eiwitvouwingsziektes bekent staan. De HSP families die onderzocht zijn bevatten HSP10,
HSP40, HSP60, HSP70, HSP90, BAG, prefoldin, small HSP (sHSP) en Heat Shock Factors (HSFs). 
We onderzochten de associatie van HSPs met AD. We includeerden 462 patiënten en 5.238
controles van de Rotterdam Study en zochten replicatie in de Framingham Heart Study
en Cardiovascular Health Study (Hoofdstuk 3.1). Gecorrigeerd voor meervoudig testen
vonden we een klein maar consistent effect van rs12118313, wat zich op 32kb van PDFN2
bevind (OR = 1,19; p-waarde = 0,003). In een formele netwerk analyse vonden we nominaal 
significant bewijs voor de associatie van drie groepen van co-chaperones (BAG, DNAJA
en prefoldin) met AD. Geen effect van de HSP70 familie werd geïdentificeerd. Drie genen
vertooneden bewijs van associatie met PD, namelijk Chaperonin (HSP60 en HSP10), HSPA13
en HSF5 (Hoofdstuk 3.2). Geen van deze genen werden gerepliceerd met p-waarden lager 
dan 10-4 in een online-beschikbare GWAS naar PD. Terwijl drie SNPs (rs12574703, rs7797781
en rs1416733) in de genen HSPA8, HSPB1 en HSF2 bewijs voor associatie met sterfte 
(p-waardes = 0,001, 0,002 en 0,003) vertoonden was replicatie in CHARGE alleen succesvol
voor HSF2 (rs1416733, p-waarde = 0.003, Hoofdstuk 3.3). De geïdentificeerde variant is 
een bekende cis-eQTL van HSF2, wat een van de belangrijkste transcriptiefactoren is die
transcriptie van HSPs reguleert.
Hierna concentreerden we ons op telomeerlengte, wat gezien wordt als een biomarker voor 
veroudering. Aangezien telomeerlengte een relatief nieuw fenotype is richt Hoofdstuk 4
zich op verscheidende analyses naar telomeerlengte, onder meer erfelijkheidsanalyse en
factoren die mogelijk invloed hebben op telomeerlengte. In Hoofdstuk 4.1 onderzochten
we de erfelijkheid, het overervingspatroon en de invloed van de leeftijd van de ouders
op telomeerlengte in zes onafhankelijke cohorten met in totaal 19.713 deelnemers. De
erfelijkheid van telomeerlengte werd geschat op 70% (p-waarde = 2.31*10-111). We vonden 
ook een sterkere moeder-kind (r = 0,42; p-waarde = 3,60*10-61) dan vader-kind (r = 0,33;
p-waarde = 7,01*10-5) correlatie. Dit verschilde niet tussen mannelijke en vrouwelijke kinderen 
hetgeen suggereert dat er een maternale, niet X-chromosomale, overervingscomponent is.
We vonden een positieve associatie met paternale leeftijd en telomeerlengte (beta = 0,005;
p-waarde = 7,01*10-5).
De hoge erfelijkheid van telomeerlengte en de familiestructuur van de ERF populatie stelden 
ons instaat om de telomeerlengte van de 90+ers te extrapoleren naar jongere leeftijden
en om het zogenoemde overlevingseffect, de gereduceerde variabiliteit in telomeerlengte
in ouderen, te bestuderen (Hoofdstuk 4.2). Overlevingseffect word genoemd as de reden
voor de inconsistente associaties van telomeerlengte met sterfte. We observeerden dat de 
gemiddelde telomeerlengte van de kleinkinderen van de oudste-ouden significant langer
waren (p-waarde = 2.60*10-4) dan de telomeerlengte van andere mensen van hun leeftijd. 
Dit duidt er op dat de oudste-ouden hun leven begonnen met lange telomeren. Bovendien 
observeerden we een afnemende variabiliteit van telomeerlengte van jongvolwassen 
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leeftijd tot oudere leeftijd (p-waarde = 4.23*10-6), wat duidt op de aanwezigheid van een
overlevingseffect.
Gemiddelde telomeerlengte was significant hoger (p-waarde = 2.54*10-7) en de afname-
snelheid van telomeerlengte was lager (69.9%) in vrouwen vergelijkend met mannen.
Verschillen in gemiddeld telomeerlengte worden toegeschreven aan verschillen in 
lichaamslengte tussen de geslachten aangezien grotere lichamen meer cel replicaties nodig
hebben wat resulteert in kortere telomeren. Bouwend op deze hypothese, in Hoofdstuk 
4.3, onderzochten we de associatie van lichaamslengte met telomeerlengte in mensen. 
We observeerden een significante associatie tussen telomeerlengte en lichaamslengte in 
mannen (r = -0.08; p-waarde = 5.8*10-4), maar niet in vrouwen (r = -0.02; p-waarde = 0.30). 
Dit komt overeen met eerdere bevindingen in dierstudies. Mendeliaanse Randomisatie
suggereerde dat lichaamslengte telomeerlengte causaal beïnvloed. 
Andere factoren die invloed hebben op telomeerlengte zijn oxidatieve stress en 
inflammatie, wat ook invloed heeft op de meest prominente vetcel-gemaakte eiwit
hormonen, namelijk leptine en adiponectine. In Hoofdstuk 4.4 onderzochten we de 
associatie van telomeerlengte met deze hormonen. In zeven onafhankelijke cohorten van
het ENGAGE consortium met 11.460 deelnemers onderzochten we de partiële correlatie 
tussen telomeerlengte en adiponectine/leptine, gecontroleerd voor leeftijd en geslacht.
In additionele modellen controleerden we ook voor BMI en CRP. Er werd geen associatie 
tussen adiponectine en telomeerlengte geobserveerd. De associatie tussen telomeerlengte
en leptine was zeer significant (r = -0,05; p-value = 1,81*10-7). Telomeerlengte vertoonde 
geen associatie met BMI of CRP. Corrigeren voor BMI en CRP veranderde de resultaten niet. 
Geslacht-gestratificeerde analyse liet geen verschil tussen mannen en vrouwen zien.
In een poging om de biologie achter de associatie tussen telomeerlengte en leeftijds-
gerelateerde ziektes en sterfte beter te begrijpen, onderzochten we de associatie tussen 
telomeerlengte en metabolieten gemeten in het bloed in 8.192 individuen van het ENGAGE
consortium (Hoofdstuk 4.5). Partiële correlatie analyse identificeerde zes metabolieten die
significant geassocieerd zijn met telomeerlengte. Deze metabolieten bestonden uit drie 
phosphatidylcholines, twee aminozuren (metionine en tyrosine) en een acyl-carnitine.
Samen impliceren deze metabolieten de betrokkenheid van lipide, homocysteine en 
thyroïd metabolisme in telomeerlengte bepaling.
Dit proefschrift laat zien dat langlevendheid een erg complex fenotype is en dat er
geen nieuwe consistente genetische associaties gevonden zijn. Voor de biomarker
telomeerlengte hebben we pas het topje van ijsberg ontdekt en ons begrip van de associatie
met langlevendheid is nog verre van volledig. In Hoofdstuk 5 (algemene discussie) hebben 
we de problematiek rond het onderscheiden van ware bevindingen en fout-positieve
bevindingen in genomics en andere ‘-omics’ studies beschreven, alsook verdere stappen in 
de studie naar langlevendheid en telomeerlengte beschreven.
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Appendix of published chapters (3.1, 3.2, 3.3, 4.1 and 5.1) can be found in published articles 
online.
APPENDIX CHAPTER 2.1
Methods 
Study population details
From 1991 to 1995 all inhabitants of Ommoord, a district of Rotterdam, The Netherlands,
who were 55 years or older, were invited to participate in the Rotterdam study (RS) [1, 2].
Genotyping information was available for 5,974 participants. All of the participants were
followed for incident diseases through linkage to the general practitioner data base and
record review by trained medical investigators. General practitioners’, hospital records as 
well as death certificates were used for identification of deaths and health events through 
01.01.2009.
The Study of Osteoporotic Fractures (SOF) is a prospective multicenter study of risk factors
for vertebral and non-vertebral fractures [3]. The cohort at the baseline visit is comprised of 
9704 community dwelling women 65 years old or older recruited from population-based
listings in four U.S. areas: Baltimore, Maryland; Minneapolis, Minnesota; Portland, Oregon;
and the Monongahela Valley, Pennsylvania. Women enrolled in the study were 99%
Caucasian with African American women initially excluded from the study due to their low
incidence of hip fractures. The SOF inclusion criteria were: 1) 65 years or older, (2) ability to 
walk without the assistance of another, (3) absence of bilateral hip replacements, (4) ability
to provide self-reported data, (5) residence near a clinical site for the duration of the study,
(6) absence of a medical condition that (in the judgment of the investigator) would result 
in imminent death, and (7) ability to understand and sign an informed consent. The SOF 
participants were followed up every four months by postcard or telephone to ascertain
the occurrence of falls, fractures and changes in address. To date, follow-up rates have
exceeded 95% for vital status and fractures. DNA was extracted from buffy coat or whole 
blood samples collected at visit 2 (1989-1990) or visit 6 (1997-1998) and whole-genome 
genotyping was performed at the Broad Institute using DNA from 3924 participants. After
QC, whole genome genotype data was available for 3625 SOF participants. 
The Cardiovascular Health Study (CHS) is a prospective population-based cohort study
of CVD, mortality, and other outcomes in 65+ year old Medicare-eligible adults living in
four US communities [4]. Recruitment of the initial predominantly white cohort was
completed in 1990 and 3,267 participants fulfilled the inclusion criteria of this study and had
genotyping information available. Only European or European Americans were included
in the analysis, so the CHS African Americans were excluded. Major incident health events
and deaths were identified through several methods, including: questionnaires completed
by participants at each semi-annual contact during follow-up; reports by family members;
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and periodic searches of the Medicare Utilization database, the National Death Index, and 
local newspaper obituaries through 30.06.2005. All cardiovascular events were reviewed 
and adjudicated by an events committee.
The Osteoporotic Fractures in Men Study (MrOS) is a multi-center prospective, longitudinal, 
observational study of risk factors for vertebral and all non-vertebral fractures in older men,
and of the sequelae of fractures in men [5, 6]. The MrOS study population at baseline consists 
of 5,994 community dwelling, ambulatory men aged 65 years or older from six communities 
in the United States (Birmingham, AL; Minneapolis, MN; Palo Alto, CA; Monongahela Valley 
near Pittsburgh, PA; Portland, OR; and San Diego, CA). Inclusion criteria were designed to
provide a study cohort that is representative of the broad population of older men. The
inclusion criteria were: (1) ability to walk without the assistance of another, (2) absence
of bilateral hip replacements, (3) ability to provide self-reported data, (4) residence near
a clinical site for the duration of the study, (5) absence of a medical condition that (in the 
judgment of the investigator) would result in imminent death, and (6) ability to understand
and sign an informed consent. The baseline examination was completed over a 25-month 
period from March 2000 to April 2002. During the study period, participants complete a
tri-annual questionnaire every four months that obtains information concerning the
occurrence of incident falls and fractures. Follow-up is over 99% complete. All deaths are 
centrally adjudicated using death certificates and recent hospitalization records. DNA was 
extracted from whole blood samples collected at baseline and consent for use of DNA
for genetic analysis was obtained through written consent. Whole-genome genotyping
was performed at the Broad Institute using DNA from 5506 participants. After QC, whole 
genome genotype data was available for 5151 MrOS participants.
Framingham Heart Study (FHS) was initiated to study determinants of CVD and other 
major illnesses. The original cohort was recruited in 1948 and the offspring of the Original 
cohort participants and offspring spouses were enrolled in 1971 [7-10]. DNA was obtained
for genetic studies in the 1990s from surviving Original cohort and Offspring participants.
The exam at which DNA was obtained is considered the baseline exam for these analyses. 
All participants remain under continuous surveillance and deaths that occurred through 
01.01.2009 were included.
The Health and Retirement Study (HRS) is a longitudinal survey of a representative sample
of Americans over the age of 50. The current sample includes over 26,000 persons in 17,000
households. Respondents are interviewed every two years about income and wealth, health
and use of health services, work and retirement, and family connections. DNA was extracted
from saliva collected during a face-to-face interview in the respondents’ homes. These data
represent respondents who provided DNA samples and signed consent forms in 2006 and
2008. Deaths were validated using the Social Security Administration’s Death Master File
that included reports through the end of 2010. Cause of death was determined by linking
to the National Death Index (NDI) Cause of Death file.
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The Age, Gene/Environment Susceptibility -Reykjavik Study (AGES) was initiated to 
examine potential genetic susceptibility and gene/environment interaction. Between 2002
and 2006, baseline exams were conducted in survivors from the Reykjavik Study. 3,219
AGES-Reykjavik participants were eligible for participation and with available genotype
information. Follow-up information was complete till 27.04.2009 via linkage to electronic
medical records and vital status registry.
The Religious Orders Study (ROS), started in 1994, is a longitudinal, clinical-pathologic
cohort study of common chronic conditions of aging. The study enrolls Catholic priests,
nuns, and brothers from about 40 groups in 12 states of the United States. Since January
1994, over 1,100 participants completed their baseline evaluation. The study was approved 
by the institutional review board of Rush University Medical Center. The follow-up rate of 
survivors exceeds 90%. Participants were free of known dementia at enrollment, agreed 
to annual clinical evaluations, and signed both an informed consent and an Anatomic Gift
Act form donating their brains at time of death. DNA was extracted from whole blood,
lymphocytes, or frozen postmortem brain tissue. Genotyping was performed at the Broad
Institute’s Center for Genotyping and the Translational Genomics Research Institute. 
Rush Memory and Aging Project (MAP), started in 1997, is a longitudinal, clinical-pathologic
cohort study of common chronic conditions of aging. The study enrolled older men and
women from assisted living facilities in the Chicago area with no evidence on dementia at
baseline. Since October 1997, over 1,500 participants completed their baseline evaluation. 
The study was approved by the institutional review board of Rush University Medical
Center. The follow-up rate of survivors exceeds 90%. Similar to the ROS, participants agreed 
to annual clinical evaluations and signed both an informed consent and an Anatomic Gift 
Act form donating their brains, spinal cords, and selected nerves and muscles to Rush 
investigators at the time of death. DNA was extracted from whole blood, lymphocytes, or
frozen postmortem brain tissue. Genotyping was performed at the Broad Institute’s Center
for Genotyping and the Translational Genomics Research Institute.
The Invecchiare nel Chianti (InCHIANTI) study is a population-based epidemiological study
aimed at evaluating the factors that influence mobility in the older population living in the 
Chianti region in Tuscany, Italy that was initiated in 1998. Presence of chronic diseases was
ascertained by a combination of assessments by trained geriatrician, medication use, blood
tests, and self-reported physician diagnosis. Death was determined using a death registry.
686 subjects with genotype and mortality and disease data assessed through to 06.03.2006
were used for this analysis.
The Baltimore Longitudinal Study of Ageing (BLSA) is a population-based study aimed to
evaluate contributors of healthy aging in the older population residing predominantly in
the Baltimore-Washington DC area. The study began in 1958, and follow up data through 
to 20.12.2004 for 599 subjects was used for this analysis. Participants returned for follow-up
visits every 1-2 years where presence of chronic disease was assessed by a physician during 
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the physical exam, self-report or medication use. Death was ascertained through death 
certificates or report by family members.
The NECS case-control set of 801 centenarians and 914 genetically matched controls is 
described in [11]. The study included centenarians from the NECS [12] (median survival 104
years, age range 94-119) and a combination of controls from the NECS (median age 73 years,
age range 50-93) and from the Illumina control database (iControlDB). Ages were unknown 
for the majority of Illumina controls. The algorithm for genetic matching is described in 
[13]. The data were genotyped using Illumina arrays 370, 610 and 1M, and the final list of 
281 SNPs passed stringent quality control measures, including a sample call rate > 96% 
and a SNP call rate > 98% in all array types. The NECS protocol is approved by the Boston
University Medical Campus Institutional Review Board.
The Long Life Family Study (LLFS) enrolled families enriched for longevity via 4 field centers
(Boston, New York, and Pittsburgh in the USA, and Denmark) between 2006 and 2009.
The recruitment protocol, described in [14], used the Family Longevity Selection Score
(FLoSS) [15] to identify family enriched of exceptional longevity, and enrolled 583 families
with a FLoSS > 7 consisting of 1493 probands, their siblings and 192 spouses in the older
generation, and 2437 offspring and 809 of their spouses. Genotype data for 4,567 subjects
were generated from the Illumina Omni chip 2.5 (2.5M SNPs). The genotyping protocol,
quality control and quality assessment included use of the GRR program to validate 
familial relations [16], the program Loki to validate Mendelian consistency [17], SNP call
rate > 98% and sample call rate > 97.5%. These 4,567 subjects included 1562 from the
parental generation (probands, their siblings and alive spouses, median age 93 years, range 
52-110) and 3095 from the offspring generation (offspring and their spouses, median age 
63, range 25-90). Participants underwent informed consent and the study was approved 
by the Institutional Review Boards of Boston University Medical Campus, University of 
Pittsburgh, Columbia University and Washington University St Louis, and the Ethics Board
of the University of Denmark.
The EU longevity consortium GWAS was performed in 5409 longevity cases (≥ 90 years 
of age) and 16121 controls below 65 years of age, from 13 cohorts. All individuals were of 
European descent.
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Analysis details
NECS genotype data were analyzed using allelic association tests and p-values are from
1dof c2 tests. LLFS genotype data were analyzed using a mixed effect Cox proportional
hazard regression model implemented in the coxme package in R with a random effect 
per subject to account for within family correlation [18]. The random effects were modeled
with a normal distribution with 0 mean and variance covariance matrix proportional to the
kinship matrix [19]. Kinship coefficients were estimated using the kinship2 package in R.
The EU longevity consortium performed a GWAS on longevity using the same longevity 
definition and a slightly different comparison group definition (< 65 years of age). A standard
logistic regression adjusting for sex was performed.
Significant genes were followed up using an online tool for pathway analysis: gene-networks 
(www.genenetworks.nl). We used this tool to infer biological function of newly identified 
longevity genes.
Additionally we performed look-ups in two previous longevity GWAS studies, namely
Newman et al and Sebastiani et al [11, 20]. Newman et al was the original CHARGE longevity 
GWAS publication, partly overlapping with the current study [20]. The same phenotype
description was used. Sebastiani et al concerns a recent GWAS on centenarians showing
a profile of genetic associations together determining longevity. In this study 4 different
genetic models were used [11]. We focused on those associations reaching suggestive
p-values for the additive model.
A recent genome-wide linkage analysis in longevity (90+) sibpairs identified 4 regions 
significantly linked to longevity [21]. We investigated the association of all SNPs located
under the linkage peaks. To adjust for multiple testing we corrected for the number of 
independent tests (VeffLi) [22] using an online available tool (http://gump.qimr.edu.au/
general/daleN/matSpDlite/).
Finally we performed a literature search for genetic associations of FOXO3 with longevity. 
For the SNP most commonly reported we added the literature-based associations to the 
current study in a meta-analysis.
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Supplement Table 1B | Genotyping information per replication cohort.
Study EU_longevity NECS LLFS
Array type Varies Illumina 370;610;1M Illumina 2.5
Genotyping center Varies BMC CIDR
Genotype calling Varies Illumina beadchip Illumina beadchip
Exclusion on SNPs Varies Call rate < 98% Call rate < 98%
Exclusion on  a per sample basis Varies Call rate < 98% Call rate < 98%
Data handling and statistical tests CC-assoc R R
Supplment Table 2 | Biological processes in which both GRIK2 and CADM2 are involved.
Biological process GRIK2 CADM2
neuron cell-cell adhesion 6.89*10-7 1.48*10-13
regulation of synaptic transmission. glutamatergic 2.25*10-6 7.95*10-9
homophilic cell adhesion 3.11*10-6 3.18*10-4
glutamate signaling pathway 9.26*10-6 7.22*10-15
synapse assembly 2.83*10-5 9.60*10-3
synaptic transmission. glutamatergic 1.01*10-4 6.21*10-7
response to fungicide 1.12*10-4 1.61*10-4
prepulse inhibition 2.41*10-4 2.17*10-5
detection of mechanical stimulus 3.36*10-4 2.35*10-3
gamma-aminobutyric acid signaling pathway 4.93*10-4 1.07*10-9
detection of mechanical stimulus involved in sensory perception 1.11*10-3 3.88*10-4
retina morphogenesis in camera-type eye 2.32*10-3 2.84*10-4
learning or memory 2.43*10-3 1.39*10-6
startle response 2.80*10-3 1.36*10-11
neuron-neuron synaptic transmission 2.95*10-3 5.29*10-9
cognition 2.99*10-3 7.08*10-7
neural retina development 3.61*10-3 1.46*10-3
regulation of action potential 3.74*10-3 6.61*10-6
positive regulation of amine transport 4.19*10-3 9.81*10-3
memory 4.35*10-3 1.55*10-3
regulation of synaptic transmission 7.66*10-3 1.70*10-7
cell-cell adhesion 7.73*10-3 2.76*10-3
synapse organization 8.07*10-3 4.73*10-3
neurotransmitter uptake 8.53*10-3 1.56*10-5
long-term memory 9.12*10-3 1.62*10-4
P-values for involvement in different biological processes. Only those pathways shown with a p-value < 0.01 for both CADM2
and GRIK2.
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Supplement Table 4 | Replication of the findings of Sebastiani et al, 2012.
Sebastiani Current Study
SNP Chr Gene EA OR p-additive EAF OR p-value Direction
rs2075650 19 TOMM40/APOE A 2.07 2.4*10-10 0.87 1.20 4.8*10-4 +++++?+++++
rs12629971 3 EIF4E3 T 0.62 1.9*10-6 0.14 0.93 0.118 -+-+-+--+--
rs4977756 9 NA A 0.73 8.0*10-6 0.60 0.93 0.031 -++--+---+-
rs6801173 3 EIF4E3 T 0.66 8.2*10-6 0.17 0.95 0.249 -+-+-+--+--
rs1456669 3 NA A 1.58 8.6*10-6 0.13 0.96 0.353 -++--+-++++
rs4802234 19 CEACAM16 T 0.73 9.2*10-6 0.44 0.94 0.095 ----+------
EA: effective allele; EAF: effective allele frequency; ‘+’: effective allele overrepresented in 90+ cases; ‘-’: effective allele
underrepresented in 90+ cases; ‘?’: not tested in this study
Direction: RS1, RS2, SOF, CHS, MrOS, FHS, HRS, AGES, RADC, InCHIANTI, BLSA
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Supplement Table 6 | meta-analysis of published and current results for FOXO3 (rs2802292; minor 
allele).
Study Design n_cases n_controls OR 95% CI p-value
2008_Wilcox 95+ 213 402 1.72 1.34-2.22 2.44*10-5
2009_Anselmi 100+ 281 195 1.57 1.17-2.10 0.002
2009_Li 100+ 761 1056 1.36 1.16-1.60 2.09*10-4
2010_Soerensen 95+ 313 371 1.34 1.08-1.67 0.009
RS1 90+ 899 1192 1.13 0.98-1.30 0.087
RS2 90+ 69 161 1.39 0.86-2.24 0.181
SOF 90+ 1720 124 0.95 0.72-1.25 0.710
CHS 90+ 791 560 1.13 0.96-1.33 0.135
MrOS 90+ 670 502 1.07 0.90-1.27 0.426
FHS 90+ 320 484 0.99 0.80-1.24 0.961
HRS 90+ 384 401 1.22 0.98-1.50 0.071
AGES 90+ 541 145 1.02 0.80-1.30 0.882
RADC 90+ 468 78 0.87 0.61-1.25 0.453
InCHIANTI 90+ 101 75 1.21 0.80-1.81 0.366
BLSA 90+ 73 75 1.09 0.64-1.85 0.754
meta NA 7604 5821 1.18 1.11-1.25 1.44*10-8
Design: definition of longevity cases
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FIGURES 
Supplement Figure 1 | Manhattan plot
Supplement Figure 2 | Forest plots 
A. GRIK2
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B. CADM2
C. RGS7
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D. SOX6
E. MBOAT1
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F. PFKM
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APPENDIX CHAPTER 2.2
Supplementary figures
Supplement Figure 1 | Summary results of single variant analysis
A. Manhattan plot
B. QQ plot (MAF > 0.05)
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Supplement Figure 2 | Results of gene-based sequence kernel association test (SKAT) with longevity.
Supplementary Tables
Supplement Table 1 | Single Variant analysis results of candidate gene APOE.
SNP CHR BP Gene RA EA EAF OR P
19:45411057 19 45411057 APOE G A 0.005 3.70E-10 0.9993
19:45411110 19 45411110 APOE T C 0.004 9.62E+08 0.9993
19:45411145 19 45411145 APOE G C 0.001 1.69 0.7432
19:45411147 19 45411147 APOE G T 4.26E-04 3.80E-10 0.9993
19:45411149 19 45411149 APOE A C 4.17E-04 3.71E-10 0.9993
19:45411153 19 45411153 APOE A T 4.24E-04 3.70E-10 0.9993
19:45411941 19 45411941 APOE T C 0.195 0.8995 0.8308
19:45412408 19 45412408 APOE C G 0.002 4.13E-10 0.9993
19:45412498 19 45412498 APOE C A 0.005 7.46E+08 0.9993
19:45412500 19 45412500 APOE A T 0.005 7.54E+08 0.9993
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Supplement Table 2 | PANTHER pathway analysis on SVA identified genes (GO: biological processes).
Biological Process REFLIST (20000) Observed Expected Over/Under P-value
protein transport 1724 10 2.76 + 2.46E-04
intracellular protein transport 1724 10 2.76 + 2.46E-04
transport 2984 13 4.77 + 3.80E-04
cytokinesis 228 4 0.36 + 4.71E-04
vesicle-mediated transport 1240 8 1.98 + 5.97E-04
mitosis 621 5 0.99 + 0.003
homeostatic process 185 3 0.30 + 0.003
RNA localization 81 2 0.13 + 0.008
cellular component morphogenesis 1118 6 1.79 + 0.008
anatomical structure morphogenesis 1118 6 1.79 + 0.008
cellular glucose homeostasis 84 2 0.13 + 0.008
female gamete generation 301 3 0.48 + 0.012
nuclear transport 126 2 0.20 + 0.017
localization 160 2 0.26 + 0.027
cellular component organization 1496 6 2.39 + 0.029
protein targeting 193 2 0.31 + 0.038
JAK-STAT cascade 223 2 0.36 + 0.049
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Supplement Table 4 | PANTHER pathway analysis on SKAT identified genes (GO: biological processes).
Biological Process REFLIST (20000) Observed Expected Over/Under P-value
vitamin metabolic process 80 1 0.06 + 0.062
response to toxin 99 1 0.08 + 0.076
neuromuscular synaptic transmission 121 1 0.10 + 0.093
meiosis 166 1 0.13 + 0.125
cell cycle 1602 3 1.28 + 0.132
hemopoiesis 183 1 0.15 + 0.137
cytokinesis 193 1 0.15 + 0.144
protein amino acid glycosylation 203 1 0.16 + 0.151
chromosome segregation 210 1 0.17 + 0.155
fatty acid metabolic process 227 1 0.18 + 0.167
calcium-mediated signaling 256 1 0.20 + 0.186
polysaccharide metabolic process 261 1 0.21 + 0.190
Supplement Table 5 | Burden of damaging variants.
score_cases score_controls beta Se p-value
damaging (all) 0.995 (0.0003) 0.995 (0.0003) -370.12 308.72 0.231
damaging (MAF < 0.05) 0.999 (0.0003) 0.999 (0.0003) -286.78 308.29 0.352
damaging (MAF < 0.01) 0.999 (0.0003) 0.999 (0.0003) -276.58 319.89 0.387
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Supplementary Table 1 | Association of known height SNPs with telomere length (all).
height_GIANT telo_ENGAGE
SNP Chr Gene EA beta p-value beta se p-value N
rs17081935 4 POLR2B T 0.030 4.77E-08 -0.027 0.009 0.002 37633
rs724016 3 ZBTB38 G 0.070 4.47E-52 -0.020 0.007 0.006 37323
rs2079795 17 TBX2 T 0.040 1.22E-16 0.018 0.008 0.022 37205
rs2780226 6 HMGA1 C 0.076 1.02E-18 -0.038 0.017 0.024 32536
rs634552 11 SERPINH1 T 0.039 1.35E-09 -0.026 0.012 0.026 29826
rs751543 9 PAPPA T 0.026 4.51E-08 -0.019 0.009 0.034 32272
rs6569648 6 L3MBTL3 C 0.040 8.93E-12 0.019 0.009 0.039 34469
rs6684205 1 TGFB2 G 0.028 1.97E-11 -0.016 0.008 0.043 37638
rs6439167 3 C3orf47 C 0.034 7.20E-10 0.019 0.009 0.044 34618
rs6449353 4 LCORL T 0.075 1.35E-27 0.021 0.011 0.052 37616
rs6879260 5 GFPT2 C 0.022 5.61E-10 0.015 0.009 0.075 29430
rs16942341 15 ACAN C 0.130 1.28E-17 0.057 0.033 0.083 23329
rs42235 7 CDK6 T 0.057 7.33E-28 0.015 0.009 0.088 32470
rs6473015 8 PEX2 C 0.029 1.67E-10 0.014 0.008 0.090 37658
rs2237886 11 KCNQ1 T 0.046 3.12E-08 -0.021 0.013 0.093 33710
rs9360921 6 SENP6 G 0.042 4.56E-11 0.019 0.011 0.099 37676
rs473902 9 PTCH1/FANCC T 0.065 1.70E-14 -0.030 0.018 0.108 27066
rs6457620 6 HLA_locus G 0.029 3.65E-08 -0.012 0.008 0.138 32735
rs227724 17 NOG T 0.030 1.18E-08 0.012 0.008 0.145 32509
rs12680655 8 ZFAT C 0.028 4.83E-11 -0.011 0.007 0.146 37645
rs2341459 2 C2orf34 T 0.025 3.58E-08 0.012 0.008 0.150 37587
rs9844666 3 PCCB G 0.024 3.05E-08 0.012 0.008 0.154 37669
rs7460090 8 SDR16C5 T 0.058 9.55E-16 0.015 0.011 0.158 37404
rs2154319 1 SCMH1 C 0.030 4.30E-10 0.013 0.009 0.164 32311
rs788867 4 PRKG2/BMP3 G 0.043 1.78E-15 -0.011 0.008 0.172 30251
rs2256183 6 MICA A 0.040 2.67E-14 -0.010 0.008 0.186 32639
rs11259936 15 ADAMTSL3 C 0.044 2.18E-21 -0.009 0.007 0.198 37645
rs3129109 6 OR2J3 C 0.032 3.28E-08 -0.011 0.008 0.199 32662
rs720390 3 IGF2BP2 A 0.029 1.62E-10 0.010 0.008 0.213 32280
rs2145998 10 PPIF T 0.026 2.68E-08 -0.009 0.007 0.214 37409
rs4665736 2 DNAJC27 T 0.029 1.44E-13 0.009 0.007 0.214 37339
rs7319045 13 GPC5 A 0.025 4.51E-10 -0.010 0.008 0.216 32666
rs2110001 7 TMEM176A G 0.031 9.83E-10 0.010 0.009 0.254 32299
rs422421 5 FGFR4/NSD1 C 0.031 1.43E-09 -0.012 0.011 0.260 29617
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height_GIANT telo_ENGAGE
SNP Chr Gene EA beta p-value beta se p-value N
rs17511102 2 CDC42EP3 T 0.060 1.26E-12 -0.016 0.014 0.268 34081
rs1173727 5 NPR3 T 0.034 3.97E-15 0.008 0.007 0.274 37423
rs10748128 12 FRS2 T 0.038 3.76E-11 -0.010 0.009 0.288 31074
rs9967417 18 DYM G 0.038 2.57E-16 0.008 0.008 0.291 37336
rs2665838 17 CSH1/GH1 G 0.042 2.02E-13 -0.009 0.008 0.302 37151
rs310405 6 FAM46A A 0.026 3.59E-11 0.008 0.008 0.312 34561
rs7466269 9 FUBP3 A 0.032 1.17E-14 -0.007 0.007 0.324 37404
rs2066807 12 STAT2 G 0.054 9.61E-09 -0.014 0.015 0.337 37399
rs143384 20 GDF5 G 0.063 4.94E-39 -0.008 0.008 0.349 30908
rs17780086 17 LRRC37B A 0.028 4.39E-08 -0.010 0.011 0.350 37504
rs7849585 9 QSOX2 T 0.029 3.43E-11 -0.007 0.008 0.364 35917
rs2093210 14 SIX6 C 0.032 2.30E-12 0.007 0.008 0.367 32418
rs274546 5 SLC22A5 G 0.029 8.53E-10 -0.007 0.007 0.367 37537
rs3791675 2 EFEMP1 C 0.053 2.40E-20 0.012 0.013 0.367 37455
rs3764419 17 ATAD5/RNF135 C 0.035 8.87E-16 0.007 0.008 0.370 37152
rs889014 5 BOD1 C 0.030 4.51E-10 -0.007 0.007 0.379 37436
rs1351394 12 HMGA2 T 0.060 7.78E-34 -0.006 0.007 0.386 37210
rs2871865 15 IGF1R C 0.057 1.07E-12 -0.013 0.015 0.388 29623
rs26868 16 CASKIN1 A 0.034 3.47E-08 -0.008 0.010 0.406 22771
rs11830103 12 SBNO1 G 0.035 3.79E-10 -0.008 0.010 0.410 32656
rs11684404 2 EIF2AK3 C 0.028 6.42E-09 -0.006 0.007 0.412 37478
rs10037512 5 MEF2C T 0.032 3.82E-09 -0.006 0.008 0.434 34355
rs7274811 20 ZNF341 G 0.041 6.83E-14 -0.007 0.008 0.440 37574
rs806794 6 Histone_cluster A 0.052 5.54E-26 -0.006 0.008 0.440 35315
rs4986172 17 ACBD4 C 0.032 7.12E-09 -0.006 0.008 0.446 34444
rs3782089 11 SSSCA1 C 0.058 5.89E-09 0.013 0.017 0.461 34332
rs11144688 9 PCSK5 G 0.049 1.48E-09 -0.013 0.018 0.466 16752
rs2336725 3 RTF1 C 0.027 3.52E-08 0.006 0.008 0.466 32128
rs7155279 14 TRIP11 G 0.024 8.91E-10 -0.008 0.011 0.470 37115
rs9969804 9 IPPK A 0.030 5.61E-10 -0.005 0.007 0.471 37635
rs543650 6 ESR1 G 0.034 1.36E-09 -0.006 0.009 0.476 27510
rs10152591 15 TLE3 A 0.041 3.54E-08 0.009 0.013 0.477 37495
rs526896 5 PITX1 T 0.030 1.93E-09 0.006 0.009 0.488 31009
rs8052560 16 CTU2/GALNS A 0.029 1.45E-08 -0.009 0.013 0.497 24409
rs237743 20 ZNFX1 A 0.041 7.20E-10 0.006 0.009 0.505 37654
rs1013209 8 ADAM28 C 0.025 4.51E-08 -0.005 0.008 0.515 37411
rs2145272 20 BMP2 G 0.039 5.87E-16 0.005 0.008 0.530 34480
rs3118905 13 DLEU7 G 0.056 2.99E-25 -0.007 0.013 0.578 37592
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height_GIANT telo_ENGAGE
SNP Chr Gene EA beta p-value beta se p-value N
rs11118346 1 LYPLAL1 C 0.025 2.19E-09 0.004 0.007 0.581 37593
rs10838801 11 PTPRJ/SLC39A13 G 0.027 1.76E-10 0.005 0.008 0.584 32748
rs2834442 21 KCNE2 A 0.026 7.30E-09 0.006 0.011 0.602 37420
rs7759938 6 LIN28B C 0.045 8.69E-18 -0.004 0.008 0.605 37527
rs9428104 1 SPAG17 G 0.041 8.88E-13 -0.004 0.008 0.616 37571
rs572169 3 GHSR T 0.033 9.90E-14 0.004 0.008 0.619 37300
rs3812163 6 BMP6 T 0.036 6.66E-16 -0.003 0.008 0.644 37363
rs2629046 2 SERPINE2 T 0.024 2.17E-08 0.003 0.007 0.661 37333
rs7763064 6 GPR126 G 0.048 6.41E-19 -0.003 0.008 0.690 37316
rs9472414 6 SUPT3H/RUNX2 T 0.026 2.43E-08 0.003 0.009 0.707 37640
rs6457821 6 PPARD/FANCE C 0.104 1.82E-11 0.014 0.037 0.715 22813
rs12982744 19 DOT1L G 0.030 2.79E-12 -0.003 0.007 0.727 37444
rs1741344 20 SMOX C 0.023 3.52E-08 -0.003 0.008 0.755 33811
rs10799445 1 JMJD4 A 0.032 1.18E-08 -0.003 0.009 0.756 37473
rs6470764 8 GSDMC C 0.050 5.88E-17 -0.003 0.009 0.758 37498
rs4282339 5 SLIT3 G 0.036 3.38E-10 0.003 0.009 0.768 37537
rs1046934 1 TSEN15 C 0.044 6.43E-22 -0.002 0.007 0.776 37587
rs11205277 1 SF3B4 G 0.046 1.20E-18 0.002 0.009 0.787 25438
rs2856321 12 ETV6 G 0.029 1.48E-10 -0.002 0.008 0.798 37517
rs12470505 2 CCDC108/IHH T 0.041 1.29E-10 0.003 0.012 0.799 37635
rs798489 7 GNA12 C 0.048 8.47E-25 -0.002 0.008 0.818 37076
rs11107116 12 SOCS2 T 0.052 1.75E-23 0.002 0.009 0.823 37626
rs7689420 4 HHIP C 0.073 1.38E-29 0.002 0.010 0.823 34731
rs4800452 18 CABLES1 T 0.051 2.36E-17 0.002 0.009 0.824 32684
rs4965598 15 ADAMTS17 C 0.028 1.36E-13 -0.002 0.008 0.830 34140
rs2284746 1 MFAP2 G 0.040 5.64E-15 -0.002 0.008 0.847 32347
rs11958779 5 SLC38A9 G 0.027 8.04E-09 0.002 0.012 0.855 32735
rs1325598 1 PAPPA2 G 0.022 1.61E-08 -0.001 0.007 0.856 37571
rs1582931 5 CEP120 G 0.023 2.08E-08 0.001 0.008 0.869 32425
rs5742915 15 PML C 0.031 2.99E-10 -0.001 0.008 0.878 32227
rs1490384 6 C6orf173 T 0.034 3.22E-16 0.001 0.007 0.879 37406
rs4470914 7 TWISTNB T 0.029 3.78E-08 0.001 0.010 0.899 37266
rs17318596 19 ATP5SL A 0.032 3.01E-09 -0.001 0.008 0.903 34797
rs12153391 5 FBXW11 C 0.030 8.75E-10 -0.001 0.009 0.910 32573
rs7027110 9 ZNF462 A 0.031 1.34E-10 0.001 0.009 0.918 37657
rs10770705 12 SLCO1C1 A 0.033 4.62E-11 -0.001 0.008 0.920 37391
rs1950500 14 NFATC4 T 0.034 3.94E-11 0.000 0.008 0.954 37608
rs17346452 1 DNM3 C 0.040 3.28E-14 0.000 0.008 0.962 37439
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height_GIANT telo_ENGAGE
SNP Chr Gene EA beta p-value beta se p-value N
rs9863706 3 RYBP C 0.031 1.47E-08 0.000 0.009 0.966 37213
rs2580816 2 NPPC C 0.045 1.78E-12 0.000 0.010 0.968 35820
rs2638953 12 CCDC91 C 0.032 8.45E-14 0.000 0.008 0.970 36180
rs4821083 22 SYN3 T 0.031 4.79E-08 0.000 0.011 0.990 34613
rs1708299 7 JAZF1 A 0.040 1.48E-17 0.000 0.008 0.994 37519
OVERALL 0.000 0.001 0.925
EA = Effective allele
Telo_ENGAGE = look up of known height SNPs in telomere length GWAS
Height_GIANT = genome-wide significant results from published height GWAS
229Appendices (supplementary material) |
7
APPENDIX CHAPTER 4.4
Supplementary methods
Telomere length
ERF; KORA; LLS; TwinsUK
Mean leucocyte telomere length was measured established and validated quantitative PCR-
based technique. This method expresses telomere length as a ratio (T/S) of telomere repeat
length (T) to copy number of a single copy gene, 36B4(S), within each sample. DNA samples 
were run in duplicate in 25μL reactions containing 1x SensiMix NoRef SYBR Green master mix
(Quantace, UK), 300nM of Tel1b (5’ CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT 
3’), 300nM Tel2b (5’ GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT 3’)primers and
30ng of template DNA. For the 36b4 PCR the above was performed, substituting the Tel 
primers for 300nM 36b4U (5’ CAGCAAGTGGGAAGGTGTAATCC 3’) and 500nM of 36B4D (5’ 
CCCATTCTATCATCAACGGGTACAA 3’).
All reactions were set up using a Qiagility liquid handling system (Qiagen, UK) and run on a 
Rotorgene-Q Real Time Thermal Cycler (Qiagen, UK). Alongside the samples each run also 
contained a Calibrator sample (genomic DNA from the K562 cell line) in duplicate and a no 
template control. Cycling conditions were 950C incubation for 10mins followed by either
20 cycles (telomere) or 30 cycles (36B4) of 95C for 15 sec and 58C for 1min. Dilution series
(100-1.56ng in two-fold dilutions) were run for both telomere and 36B4 assays to establish 
the linear range. Good linearity was observed across this range (r2 > 0.99) and the input 
amount of 30ng was subsequently set. Any samples found to run outside this range were 
diluted and run again.
Analysis of the PCR output was performed using Comparative Quantitation (Corbett Life 
Science Rotorgene analysis software version 1.7, Corbett Life Science, UK) as previously 
described.15 A takeoff value was produced for each sample based on the second derivative of 
the amplification plot, which represents the start of the exponential phase. The amplification 
efficiency for each sample and subsequently the mean amplification across the run was 
calculated. The relative concentration of the sample was then calculated relative to the
calibrator sample using the takeoff value and amplification efficiency. This was performed 
for both the telomere (T) and 36B4 (S) assays and telomere length expressed as the ratio of 
these (T/S). For quality control all samples were checked for concordance between duplicate 
values. Samples showing a difference between the duplicate measurements of greater than
0.2 cycles in the takeoff value were excluded and re-run. Mean inter-run coefficients of 
variation for the cohorts measured with this technique ranged from 2.7-3.6%.
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SAPHIR
Genomic DNA was extracted from blood samples with the Qiagen EZ1®DNA Blood 200 μl
Kit using the Qiagen EZ1 advanced Biorobot. DNA concentrations were quantified with the 
Tecan NanoQuant infinite M200. Samples were normalized in 96-well microtiter plates.
Samples were ascertained in a singleplex, quadruplicate approach to measure the T/S-
ratios. These T/S-ratios are proportional to individual relative telomere length (RTL). 
RTL was measured with some modifications by using a quantitative real-time polymerase
chain reaction (qPCR) assay, which was first described by Cawthon [1] and we modified as 
described below.
Each qPCR was carried out in 384-well format which was vertically segmented in two
parts: telomere (T) and housekeeping gene 36B4 (S).Telomere (T) and housekeeping gene
(S) PCRs were identical composed except for the primers. DNA samples were run in 15μl
reactions containing 1x QuantifastTM SYBR® Green PCR mastermix (Qiagen), 10 ng of DNA,
1μM of telomere primer and 250nm of housekeeping gene 36B4 primer, respectively. The
primer sequences (5’o3’) were:
tel1b CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT;
tel2b GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT; 
36B4u CAGCAAGTGGGAAGGTGTAATCC;
36B4d CCCATTCTATCATCAACGGGTACAA [2].
Each 384-well plate contained the standard DNA, a positive control (commercially available 
DNA-Human Genomic DNA, Roche) and a non template control (NTC) in quadruplicate.
All sample transfers and dilution steps were performed with a Tecan robotic workstation.
Relative qPCR was carried out on an Applied Biosystems Taqman Fast Real-Time PCR 7900HT 
System. The thermal cycling began with the initial polymerase activation step (10 min at
95°C) and was followed by 40 cycles of 95°C for 15 s, 60°C for 1 min. A melting curve analysis 
to verify the specificity and identity of the products was performed.
The relative quantities were determined by the efficiency correction method [3], which
does not need calibration curves and includes the individual real-time PCR efficiencies. This
mathematical model calculates the ratio of a target gene (telomere) from the efficiencies 
and Ct-value of an experimental sample versus a standard in comparison to a reference
gene (housekeeping gene). To calculate PCR efficiencies of both the reference gene and
the target gene PCR raw data were imported into the program LinRegPCR (version 12.5.0) 
[4]. Efficiencies were computed for all replicates of each sample. To check PCR data for
outliers, the coefficients of variation (intra-assay CVs) were assessed for the Ct-values and 
the efficiency-values of each sample in each gene. All single outlying values (CV > 5%) were
removed from further analyses. In the case of the housekeeping gene 36B4, less than 1%
and in case of telomere, about 3% were removed. For further mathematical analysis, the
mean value of all efficiency-values of each gene on each plate and the mean Ct-value of the 
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four replicates for each gene and each sample were used. Relative T/S-ratios reflect relative
telomere length differences of the samples.
To test the reproducibility of RTL measurement, the inter-assay CV of T/S-ratios was 
calculated according to the following formula
6.8% of all samples were analyzed in duplicate. Duplicate samples were never positioned 
on the same plate or at the same plate position. Inter-assay CV of T/S-ratios was 6%. As 
second RTL measurement quality control, we analyzed the relative telomere length of a
commercially available DNA, which was positioned on each 384-well plate (a total of 39 
plates). Inter-assay CV of T/S-ratios of this 39 times analyzed sample was 7.7%.
Finnish Twins
Leukocyte telomere length was measured from DNA extracted from peripheral blood. We
used a qPCR-based method [1], as described previously [5]. We used β-hemoglobin (Hgb) 
as a single copy reference gene. Separate reactions for telomere and Hgb reaction were 
carried out in paired 384-well plates in which matched sample well positions were used.
Ten nanograms of DNA were used for each reaction, performed in triplicate. Every plate
included a 7-point standard curve, which was used to create a standard curve and to perform
absolute quantification of each sample. Samples and standard dilutions were transferred
into the plates using a DNA Hydra 96 robot and dried overnight at +37oC. Specific reaction 
mix for telomere reaction included 270 nM tel1b primer (5´-CGGTTT(GTTTGG)5GTT-3´) 
and 900 nM tel2b primer (5´-GGCTTG(CCTTAC)5CCT-3´), 150 nM ROX (Invitrogen), 0.2X 
SYBR Green I (Invitrogen), 5 mM DTT (Sigma-Aldrich), 1% DMSO (Sigma-Aldrich), 0.2
mM of each dNTP (Fermentas), and 1.25 U AmpliTaq Gold DNA polymerase (Applied 
Biosystems) in a total volume of 15 μl AmpliTaq Gold Buffer I. Hgb reaction mix included
300 nM Hgb1 primer (5´-GCTTCTGACACAACTGTGTTCACTAGC-3´) and Hgb2 primer
(5´-CACCAACTTCATCCACGTTCACC-3´) in a total volume of 15 μl of iQ SyBrGreen supermix 
(BioRad). The cycling conditions for telomere amplification were: 10 minutes at 95°C
followed by 25 cycles at 95°C for 15 s and 54°C for 2 min with signal acquisition. The cycling 
conditions for Hgb amplification were: 95 °C for 10 min followed by 35 cycles at 95°C for 15
s, 58°C for 20 s, 72°C for 20 s with signal acquisition. Reactions were performed with CFX384 
Real-Time PCR Detection System (Bio-Rad). Melt-curve analysis was carried out in the end of 
the run to ensure specific primer binding. 
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We used the Bio-Rad CFX Manager software to perform quality control, and samples with 
standard deviation of > 0.5 between triplicates were omitted from the analysis. Plate effect 
was taken into account by analyzing five genomic DNA control samples on every plate. We 
normalized the telomere and Hgb signal values separately to the mean of these control
samples before taking the T/S ratio. The control samples were used for calculating the 
coefficient of variation (CV) values, which was 2.8% for the telomere reaction, 6.4% for the
Hgb reaction, and 8.2% for their ratio (T/S).
Adiponectin/leptin/CRP
ERF
Blood from participants was obtained in a fasted state. Total plasma adiponectin
measurements were analyzed with a human adiponectin RIA kit (Linco Research). Plasma
leptin was determined using a custom made duplex assay (cat.#: N45ZA-1) of Meso Scale
Discovery (MSD). The Leptin/Resistin duplex assay was analyzed using a sector 2400 imager. 
Total plasma CRP measurements were analyzed with the US C-reactive protein ELISA (cat.#
DSL-10-42100) of Diagnostic Systems Laboratories, Inc. All measurements were performed 
conform the manufactures protocol.
KORA F3 and F4
In the KORA F3 and F4 studies, non-fasting and fasting venous blood samples stored at 
-80°C were used to measure blood markers. Concentrations of CRP were measured by
nephelometry using a BNII and the test kit from Siemens (Erlangen, Germany). CRP 
concentrations were approximately lognormal distributed and therefore log-transformed if 
used as a continuous variable. Serum leptin concentrations were determined using ELISAs 
from Mercodia, Stockholm, Sweden. The intra- and inter- assay coefficients of variation for
leptin were < 10.0%.
In KORA F3, adiponectin levels were measured by an ELISA assay from Mercodia as described 
recently [6]. The quality of the measurements was monitored by 4 controls samples on each
microtitre plate. The intra-assay and inter-assay coefficient of variation for adiponectin was 
3.78% and < 10%, respectively. In KORA-F4, serum adiponectin levels were measured using 
the Quantikine ELISA kit from R&D Systems (Wiesbaden, Germany). The intra- and inter-
assay coefficients of variation were 3.8% and 8.0%, respectively.
LLS
In the LLS all standard serum measurements were performed using fully automated 
equipment. Adiponectin levels were determined with the DuoSet ELISA kit (R&D Systems
Europe Ltd, Abingdon, United Kingdom) according to manufacturer’s instructions. The 
lower and upper detection limits of the assay were respectively 62.5 and 4000 pg/ml. Serum
leptin was measured using ‘two-step’ sandwich ELISA kit (Diagnostics Biochem Canada Inc.,
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Dorchester, Ontario,  Canada) according to manufacturer’s instructions. Assay sensitivity
was 0.5 ng/ml. High-sensitivity C-reactive protein (hsCRP) was measured using the Hitachi
Modular P800 (Roche, Almere, the Netherlands) [7]. Since the adiponectin, leptin and hsCRP 
levels were not normally distributed the log transformed values were used for analysis. For
all serum parameters, measurements with a deviation from the mean > 3 SD were removed.
TwinsUK
Fasting morning serum total adiponectin levels were measured with a two-site DELFIA
assay using antibodies and standards from R&D Systems (Minneapolis, MN). The day-to-
day coefficient of variation (CV) for adiponectin was 9.9% at a concentration of 3.2 ng/ml, 
7.8% at 8.5 ng/ml, and 5.2% at 14.7 ng/ml. Serum leptin concentration was determined
after an overnight fast using a RIA (Linco Research, St Louis, MO). CRP concentrations from
serum were measured with the Human Cardiovascular Disease (CVD) Panel 2 (acute-phase
proteins) LINCOplex Kit (HCVD2-67BK) from Linco (Millipore) and with the Extracellular
Protein Buffer Reagent Kit (LHB0001) from Invitrogen. CRP concentrations were expected
to be very high and a dilution step was required prior to analysis. The optimal dilution
which was not specified in the assay procedure was set at 1:2000. Sample analyses were 
performed according to the manufacturers’ protocol and assayed in duplicate. Data was 
collected using the Luminex-100 system (Qiagen LiquiChip).
SAPHIR
Venous blood (EDTA) was collected after an overnight fast and full blood as well as serum/
plasma was stored at -80°C. Serum adiponectin levels were measured using the human
adiponectin ELISA kit (BioCat GmbH Heidelberg, Germany). hsCRP was measured by 
applying the Tina-quant Cardiac C-reactive Protein (Latex) High Sensitivity kit as described 
by the manufacturer (Roche) and analyzed by the Hitachi 911.
Finnish Twins
Venous blood samples for plasma leptin and adiponectin were obtained between 07:30 AM
and 08:30 AM after an overnight fast. Leptin and adiponectin were analysed by enzyme-
linked immunosorbent assay (ELISA) by using DuoSet ELISA, R&D Systems Europe Ltd,
Abindgon, UK. Serum hsCRP was measured by particle-enhanced immunoturbidimetric
assay (Cobas CRP(Latex)HS, Roche Diagnostics) on Modular automatic analyzer (Hitachi Ltd, 
Tokyo, Japan).
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APPENDIX CHAPTER 4.5
Methods
Cohort descriptions 
The KORA (Cooperative Health Research in the Region of Augsburg) study is a series
of independent population-based epidemiological surveys and follow-up studies of 
participants living in the region of Augsburg, Southern Germany [1]. All survey participants
are of German nationality, identified through the registration office. Informed consent has
been given by all participants. The present study includes data of the KORA F4 (2006-2008) 
study which is a follow-up study of the KORA S4 survey (1999-2001).
The Netherlands Twin Register (NTR: http://www.tweelingenregister.org/) recruits twins 
and their family members to study the causes of individual differences in health, behavior 
and lifestyle. Participants are followed longitudinally; details about the cohort have been
published previously [2]. A subsample of unselected twins and their family members has
taken part in the NTR-Biobank [3] in which biological samples, including DNA and RNA,
were collected in a standardized manner after overnight fasting. Study protocols were
approved by the medical ethics board of the VUMC Amsterdam, the Netherlands.
The Estonian Genome Center, University of Tartu (EGCUT) is a population-based biobank of 
the Estonian Genome Project of University of Tartu (www.biobank.ee) [4]. The current cohort
size is over 51,515, from 18 years of age and up, which reflects closely the age distribution in
the adult Estonian population. The samples included in this study form a random subset of 
the cohort, with the exception of 500 female individuals aged 83+ which were specifically
selected according to age and sex. Subjects are recruited by the general practitioners (GP)
and physicians in the hospitals. Each participant filled out a Computer Assisted Personal 
interview, including personal data (place of birth, place(s) of living, nationality etc.), 
genealogical data (family history, three generations), educational and occupational history 
and lifestyle data (physical activity, dietary habits, smoking, alcohol consumption, women’s
health, quality of life). Anthropometric and physiological measurements were also taken.
The TwinsUK cohort (www.twinsuk.ac.uk) is an adult twin British registry shown to be 
representative of singleton populations and the United Kingdom population [5]. A total
of 6,038 twins with RTL measurement were included in the analysis. The age range of the
TwinsUK cohort was 16-99 years. Ethical approval was obtained from the Guy’s and St.
Thomas’ Hospital Ethics Committee. Written informed consent was obtained from every 
participant in the study.
The Erasmus Rucphen Family (ERF) study is a cross-sectional cohort including 3,000 living 
descendants of 22 couples who had at least 6 children baptized in the community church
around 1850-1900. The participants are not selected on any disease or other outcome.
Details about the genealogy of the population have been described elsewhere [6, 7]. The 
study protocol was approved by the medical ethics board of the Erasmus MC Rotterdam, 
the Netherlands.
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For the Leiden Longevity Study (LLS), long-lived siblings of Dutch descent were recruited
together with their offspring and the partners of thereof. Families were included if at least
two long-lived siblings were alive and fulfilled the age criterion of 89 years or older for males 
and 91 years or older for females, representing less than 0.5% of the Dutch population in 
2001 [8]. In total, 944 long-lived proband siblings from 421 families with a mean age of 94 
years (range, 89-104), 1,671 offspring (61 years, 39-81), and 744 partners (60 years, 36-79)
were included in the study. DNA from the LLS was extracted from samples at baseline using
conventional methods [9]. For the current analysis only the offspring and their partners
were used.
The Queensland Institute of Medical Research (QIMR) adolescent study comprised twins
and their non-twin siblings living in south-east Queensland, Australia [10]. Most (98% by 
self-report) are of mixed European ancestry, mainly from the British Isles. The participants
are not selected on the basis of any disease or other outcome. Blood samples were collected 
at the end of testing sessions from participants and, if possible, from their parents. Pedigree
relationships and zygosity were confirmed by genotype data. Further details are provided
elsewhere [11].
Telomere length measurements
All samples from all studies were measured in the same laboratory under standard
conditions. Mean leukocyte telomere length was measured by quantitative PCR-based 
technique as previously described [12, 13]. This method expresses telomere length as a 
ratio (T/S) of telomere repeat length (T) to copy number of a single copy gene, 36B4(S),
within each sample. Samples were quantified relative to a calibrator sample used on each
run (DNA from the K562 cell line) [13]. Mean inter-run coefficient of variations (CVs) were 
calculated for all study cohorts and these were less than 5% in all.
Metabolite measurements
Targeted metabolite profiling by electrospray ionization (ESI) tandem mass spectrometry
(MS/MS) was performed on a fee-for-service basis on a quantitative metabolomics platform
at Biocrates Life Sciences AG, Austria. The company had no access to genotype or phenotype 
information that would have permitted any data pre-filtering other than objective quality
control for measurement errors based on internal controls and duplicates. The experimental 
metabolomics measurement technique is described in detail by patent US 2007/0004044 
(accessible online at http://www.freepatentsonline.com/20070004044.html). A summary 
of the method can be found in [14, 15] and a comprehensive overview of the field and
the related technologies is given in the review paper by Wenk [16]. Briefly, a targeted
profiling scheme is used to quantitatively screen for known small molecule metabolites
using multiple reaction monitoring, neutral loss and precursor ion scans. Quantification of 
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the metabolites of the biological sample is achieved by reference to appropriate internal 
standards.
Metabolite QC
Metabolite profile quality control was performed both for metabolites (variables) and 
samples (individuals).
Metabolite quality control
For each cohort, metabolite profile measurements for all included individuals were
performed on multiple plates. For each metabolite i and plate j, the coefficient of variation
(CVi,j ) was calculated as
where the standard deviation (sd) and mean were calculated over all reference measurements
per plate j (five per plate). A metabolite was excluded from further analyses if the mean CVi
over all plates exceeded 25%. Furthermore, metabolites for which the concentration data 
contained more than 5% missing values were excluded from further analysis.
Summary statistics for the metabolite concentration data for each cohort were compared
with measurement detection limit specifications as reported by the manufacturer of the
AbsoluteIDQ p150 kit (Biocrates AG, Innsbruck, Austria). For metabolites reported as absolute
concentrations (μM), a metabolite was excluded from further analysis for that cohort if its 
median was below the lower limit of quantification (LLOQ) as reported by Biocrates AG.
In the case of semiquantitatively determined metabolites (relative to a suitable internal
standard), such metabolites were excluded for a given cohort if their median measurement
values were below the limit of detection (LOD).
Assessment of sample quality
To assess whether individual study samples should be excluded from further analyses, we
applied the following procedure. First, outlying data points per metabolite were defined
as those deviating more than five SDs from the mean value for that metabolite calculated
over all individuals in which this metabolite was detected. Outlying data points were set
to missing. Outlying data points per metabolite were considered independent if they were 
located in a metabolite for which the correlations with all other metabolites containing 
outliers (for a given individual) were less than 70%. Samples containing more than three
independent outlying data points were excluded from further analysis.
241Appendices (supplementary material) |
7
Imputation of missing values
Missing values in the remaining metabolite concentration data were imputed using a 
multiple imputation procedure as implemented in the ‘mice’ package in the statistical
language and environment “R” [17].
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Tables
Supplement Table 1 | Exclusion reasons per cohort for each metabolite.
KORA NTR EGCUT TwinsUK ERF LLS QIMR
Mtb C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3
C0 + + + + + + + + + + + + + + + + + + + + +
C10 + + + + + - - + - + + - + + + + + - + + -
C10:1 + + + + + + - + - + + + + + + + + + + + -
C10:2 + + + + + + - + - + + + + + + + + + + + -
C12 + + - + + - - + - + + - + + - + + - + + -
C12-DC + + - + + - - + - + + - + + - + + - + + -
C12:1 + + + + + + + + + + + + + + + + + + + + +
C14 + + - + + - - + - + + - + + - + + - + + -
C14:1 + + + + + + + + + + + + + + + + + + + + +
C14:1-OH + + - + + - - + - + + + + + - + + + + + -
C14:2 + + + + + + - + - + + + + + + + + + + + -
C14:2-OH + + - + + - - + - + + - + + - + + - + + -
C16 + + - + + - + + - + + - + + - + + - + + -
C16-OH - + - - + - - + - - + - + + - + + - + + -
C16:1 + + - + + - - + - + + - + + - + + - + + -
C16:1-OH + + - - + - - + - + + - + + - + + - + + -
C16:2 - + - - + - - + - - + + + + + + + - + + -
C16:2-OH + + - - + - - + - + + - - + - + + - + + -
C18 + + - + + - - + - + + - + + - + + - + + -
C18:1 + + + + + + + + - + + + + + + + + + + + +
C18:1-OH - + - - + - - + - - + - + + - + + - + + -
C18:2 + + + + + + + + + + + + + + + + + + + + +
C2 + + + + + + + + + + + + + + + + + + + + +
C3 + + - + + - + + - + + - + + + + + + + + -
C3-DC (C4-OH) + + - + + - - + - + + - + + - + + - + + -
C3-OH - + - - + - - + - - + - + + + + + + + + -
C3:1 - + - - + - - + - - + - + + - + + - + + -
C4 + + - + + - + + - + + - + + - + + - + + -
C4:1 - + - + + - - + - - + - + + - + + - + + -
C5 + + - + + - + + - + + - + + - + + - + + -
C5-DC (C6-OH) + + - + + - - + - + + - + + - + + - + + -
C5-M-DC + + - + + - - + - + + - + + - + + - + + -
C5-OH (C3-DC-M) + + - + + - - + - + + - + + - + + - + + -
C5:1 + + - + + - - + - + + - + + - + + - + + -
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KORA NTR EGCUT TwinsUK ERF LLS QIMR
Mtb C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3
C5:1-DC + + - + + + - + - + + - + + + + + - + + -
C6 (C4:1-DC) + + - + + - - + - + + - + + - + + - + + -
C6:1 + + - + + - - + - + + - + + - + + - + + -
C7-DC + + + + + + - + - + + + + + + + + + + + -
C8 + + + + + - - + - + + - + + + + + - + + -
C8:1 + + + + + + + + + + + + + + + + + + + + +
C9 + + + + + - - + - + + + + + + + + + + + -
Arg + + + + + + + + - + + + + + + + + + + + -
Gln + + + + + + + + + + + + + + + + + + + + +
Gly + + + + + + + + + + + + + + + + + + + + +
His + + + + + + + + + + + + + + + + + + + + +
Met + + + + + + + + + + + + + + + + + + + + +
Orn + + + + + + + + + + + + + + + + + + + + +
Phe + + + + + + + + + + + + + + + + + + + + +
Pro + + + + + + + + + + + + + + + + + + + + +
Ser + + + + + + + + + + + + + + + + + + + + +
Thr + + + + + + + + - + + + - + + + + + + + +
Trp + + + + + + + + - + + + - + + + + + + + +
Tyr + + + + + + + + + + + + - + + + + + + + +
Val + + + + + + + + + + + + - + + + + + + + +
xLeu + + + + + + + + + + + + - + + + + + + + +
PC aa C24:0 + + + - + + - + - + + + + + - + + - + + +
PC aa C26:0 + + - + + - - + - + + - + + - + + - + + -
PC aa C28:1 + + + + + + + + + + + + + + + + + + + + +
PC aa C30:0 + + + + + + + + + + + + + + + + + + + + +
PC aa C30:2 - + - - - - - - + - + + - - - - + - + - +
PC aa C32:0 + + + + + + + + + + + + + + + + + + + + +
PC aa C32:1 + + + + + + + + + + + + + + + + + + + + +
PC aa C32:2 + + + + + + + + + + + + + + + + + + + + +
PC aa C32:3 + + + + + + + + + + + + + + + + + + + + +
PC aa C34:1 + + + + + + + + + + + + + + + + + + + + +
PC aa C34:2 + + + + + + + + + + + + + + + + + + + + +
PC aa C34:3 + + + + + + + + + + + + + + + + + + + + +
PC aa C34:4 + + + + + + + + + + + + + + + + + + + + +
PC aa C36:0 + + + + + + + + + + + + + + + + + + + + +
PC aa C36:1 + + + + + + + + + + + + + + + + + + + + +
PC aa C36:2 + + + + + + + + + + + + + + + + + + + + +
PC aa C36:3 + + + + + + + + + + + + + + + + + + + + +
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KORA NTR EGCUT TwinsUK ERF LLS QIMR
Mtb C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3
PC aa C36:4 + + + + + + + + + + + + + + + + + + + + +
PC aa C36:5 + + + + + + + + + + + + + + + + + + + + +
PC aa C36:6 + + + + + + + + + + + + + + + + + + + + +
PC aa C38:0 + + + + + + + + + + + + + + + + + + + + +
PC aa C38:1 - + - - + + - + + - + + - + + + + + + + +
PC aa C38:3 + + + + + + + + + + + + + + + + + + + + +
PC aa C38:4 + + + + + + + + + + + + + + + + + + + + +
PC aa C38:5 + + + + + + + + + + + + + + + + + + + + +
PC aa C38:6 + + + + + + + + + + + + + + + + + + + + +
PC aa C40:1 + + + + + + + + - + + + + + - + + + + + -
PC aa C40:2 + + + + + + + + + + + + + + + + + + + + +
PC aa C40:3 + + + + + + + + + + + + + + + + + + + + +
PC aa C40:4 + + + + + + + + + + + + + + + + + + + + +
PC aa C40:5 + + + + + + + + + + + + + + + + + + + + +
PC aa C40:6 + + + + + + + + + + + + + + + + + + + + +
PC aa C42:0 + + + + + + + + + + + + + + + + + + + + +
PC aa C42:1 + + + + + + + + + + + + + + + + + + + + +
PC aa C42:2 + + + + + + + + + + + + + + + + + + + + +
PC aa C42:4 + + + + + + + + + + + + + + + + + + + + +
PC aa C42:5 + + + + + + + + + + + + + + + + + + + + +
PC aa C42:6 + + + + + + + + - + + + + + + + + + + + +
PC ae C30:0 + + + + + + + + - + + + + + + + + + + + +
PC ae C30:1 - + - - + + - - + - + + - - + - + - + - +
PC ae C30:2 + + - + + - - + - + + - + + - + + - + + -
PC ae C32:1 + + + + + + + + + + + + + + + + + + + + +
PC ae C32:2 + + + + + + + + + + + + + + + + + + + + +
PC ae C34:0 + + + + + + + + + + + + + + + + + + + + +
PC ae C34:1 + + + + + + + + + + + + + + + + + + + + +
PC ae C34:2 + + + + + + + + + + + + + + + + + + + + +
PC ae C34:3 + + + + + + + + + + + + + + + + + + + + +
PC ae C36:0 + + + + + + + + + + + + + + + + + + + + +
PC ae C36:1 + + + + + + + + + + + + + + + + + + + + +
PC ae C36:2 + + + + + + + + + + + + + + + + + + + + +
PC ae C36:3 + + + + + + + + + + + + + + + + + + + + +
PC ae C36:4 + + + + + + + + + + + + + + + + + + + + +
PC ae C36:5 + + + + + + + + + + + + + + + + + + + + +
PC ae C38:0 + + + + + + + + + + + + + + + + + + + + +
PC ae C38:1 + + + + + + + + + + + + - + + + + + + + +
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KORA NTR EGCUT TwinsUK ERF LLS QIMR
Mtb C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3
PC ae C38:2 + + + + + + + + + + + + + + + + + + + + +
PC ae C38:3 + + + + + + + + + + + + + + + + + + + + +
PC ae C38:4 + + + + + + + + + + + + + + + + + + + + +
PC ae C38:5 + + + + + + + + + + + + + + + + + + + + +
PC ae C38:6 + + + + + + + + + + + + + + + + + + + + +
PC ae C40:0 + + - + + - - + - + + - + + - + + - + + -
PC ae C40:1 + + + + + + + + + + + + + + + + + + + + +
PC ae C40:2 + + + + + + + + + + + + + + + + + + + + +
PC ae C40:3 + + + + + + + + + + + + + + + + + + + + +
PC ae C40:4 + + + + + + + + + + + + + + + + + + + + +
PC ae C40:5 + + + + + + + + + + + + + + + + + + + + +
PC ae C40:6 + + + + + + + + + + + + + + + + + + + + +
PC ae C42:0 + + + + + + + + - + + + + + + + + + + + +
PC ae C42:1 + + + + + + + + + + + + + + + + + + + + +
PC ae C42:2 + + + + + + + + + + + + + + + + + + + + +
PC ae C42:3 + + + + + + + + + + + + + + + + + + + + +
PC ae C42:4 + + + + + + + + + + + + + + + + + + + + +
PC ae C42:5 + + + + + + + + - + + + + + + + + + + + +
PC ae C44:3 + + + + + + + + + + + + + + + + + + + + +
PC ae C44:4 + + + + + + + + + + + + + + + + + + + + +
PC ae C44:5 + + + + + + + + + + + + + + + + + + + + +
PC ae C44:6 + + + + + + + + + + + + + + + + + + + + +
lysoPC a C14:0 + + - + + - - + - + + - + + - + + - + + -
lysoPC a C16:0 + + + + + + + + + + + + + + + + + + + + +
lysoPC a C16:1 + + + + + + + + + + + + + + + + + + + + +
lysoPC a C17:0 + + + + + + + + + + + + + + + + + + + + +
lysoPC a C18:0 + + + + + + + + + + + + + + + + + + + + +
lysoPC a C18:1 + + + + + + + + + + + + + + + + + + + + +
lysoPC a C18:2 + + + + + + + + + + + + + + + + + + + + +
lysoPC a C20:3 + + + + + + + + + + + + + + + + + + + + +
lysoPC a C20:4 + + + + + + + + + + + + + + + + + + + + +
lysoPC a C24:0 + + - + + - - + - + + - + + - + + - + + -
lysoPC a C26:0 - + - + + + - + - - + - + + - + + - + + -
lysoPC a C26:1 + + - + + - - + - + + - + + - + + - + + -
lysoPC a C28:0 + + + + + + + + - + + + + + + + + + + + +
lysoPC a C28:1 + + + + + + + + + + + + + + + + + + + + +
lysoPC a C6:0 - + - - + - - - - - + - - - - - + - + - -
SM (OH) C14:1 + + + + + + + + + + + + + + + + + + + + +
247Appendices (supplementary material) |
7
KORA NTR EGCUT TwinsUK ERF LLS QIMR
Mtb C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3 C1 C2 C3
SM (OH) C16:1 + + + + + + + + + + + + - + + + + + + + +
SM (OH) C22:1 + + + + + + + + + + + + - + + + + + + + +
SM (OH) C22:2 + + + + + + + + + + + + - + + + + + + + +
SM (OH) C24:1 + + + + + + + + + + + + - + + + + + + + +
SM C16:0 + + + + + + + + + + + + + + + + + + + + +
SM C16:1 + + + + + + + + + + + + + + + + + + + + +
SM C18:0 + + + + + + + + + + + + + + + + + + + + +
SM C18:1 + + + + + + + + + + + + + + + + + + + + +
SM C20:2 + + + + + + + + + + + + + + + + + + + + +
SM C22:3 - + - - - - - - - - + + - - - - + - + - -
SM C24:0 + + + + + + + + + + + + + + + + + + + + +
SM C24:1 + + + + + + + + + + + + + + + + + + + + +
SM C26:0 + + + + + + - + + + + + + + + + + + + + +
SM C26:1 + + + + + + + + + + + + + + + + + + + + +
H1 + + + + + + + + + + + + + + + + + + + + +
C1: Median(Concentration) > LOD, where LOD is limit of detection specified by Biocrates
C2: Excluded based on local QC of the metabolomics data.
C3: f(0) < 5%, where f(0)=N(0)/Samplesize. For the Biocrates data set a value of exactly 0 is considered a missing value.
‘+’: passed QC for this criterion; ‘-‘: failed QC for this criterion
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